<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006897.pub4" GROUP_ID="AIRWAYS" ID="300607032711502516" MERGED_FROM="" MODIFIED="2018-03-05 09:29:26 +0000" MODIFIED_BY="Emma Dennett" NOTES="&lt;p&gt;&lt;b&gt;JW 19/12/17 DATES UPDATED-SEARCH 11/03/17, NEXT STAGE 11/03/19. &lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Changes checked and accepted. Check in for ME&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;DT 1/12/17 &lt;/b&gt;&amp;#8203;WHO + clinicaltrails.gov databases searched for on-going studies (up to March 17): 1 identified.&lt;/p&gt;&lt;p&gt;(Another by Leuppi: 3 days vs 5 days, recruiting). Added to on-going trials + text updated.&lt;br&gt;Updated text on supplementary searches performed in March 17&lt;br&gt;New PRISMA diagram added using Liz's format&lt;br&gt;Excluded studies + reasons for exclusion added to references / text - total 23 excluded - 1 study added as multiple citations to Leuppi 2013.&lt;/p&gt;&lt;p&gt;&lt;b&gt;JW/DT TO &lt;/b&gt;make the following changes requested by ME CAG&lt;br&gt;&lt;br&gt;- Check you are happy with the edits (all in tracked changes) and make any further edits required&lt;br&gt;- Confirm if you checked clincaltrials.gov and the WHO. If not, please can you run those searches and incorporate into the review.&lt;br&gt;- In the previous version, you ran supplementary searches &amp;#8211; did you do this? If not, this will need reflecting in the text&lt;br&gt;- The PRISMA will need updating. We suggest to delete the old PRISMA diagram and add a new one using the approach described in Liz&amp;#8217;s paper &amp;#8211; https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/2046-4053-3-54 just look at figure 1 - However if you prefer to merge the new search to the old PRISMA diagram, this is fine too.&lt;br&gt;- Add the excluded studies (excluded based on full text screen) and reasons for exclusion.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Liz 21/11/2017&lt;/b&gt;&lt;/p&gt;&lt;p&gt;-Appendix 3 (results of 2011 searches) deleted &amp;#8211; not needed for this review version&lt;/p&gt;&lt;p&gt;-Updated the search methods text with new standard text to comply with updated Cochrane Style Manual&lt;/p&gt;&lt;p&gt;-Updated the Airways Register search strategy in appendix 2 to the CRS Web search strategy format (CRS Web not available at time of previous search updates in 2011+2014)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;17/11/17 added text in whats new:&lt;br&gt;New literature search run. 1st March 2017&lt;br&gt;&amp;#8220;417 references, 13 duplicates. 390 irrelevant on title/abstract; 14 assessed, 13 excluded (7 Wrong intervention, 4 Wrong comparator, 2 Wrong study design),&lt;br&gt;1 included study 3rd citation Leuppi 2013.&amp;#8221;&lt;/p&gt;&lt;p&gt;&lt;br&gt;Added the citation for Schuetz P, Leuppi J D, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Prospective analysis of adrenal function in patients with acute exacerbations of COPD: the Reduction in the Use of Corticosteroids in Exacerbated COPD (REDUCE) trial. 2015;173(1):19-27.&lt;/p&gt;&lt;p&gt;&lt;b&gt;DT 4/04/17 RAN&lt;/b&gt; the Pubmed and CENTRAL searches: duplicates removed- 142 refs for screening (Pubmed + Central searches minus duplicates)&lt;br&gt;&lt;br&gt;Pubmed: 171&lt;br&gt;Central: 93 added to covidence.&lt;/p&gt;&lt;p&gt;JW &amp;amp; DT SCREENED&lt;/p&gt;&lt;p&gt;&lt;b&gt;JW 27/03/17 emailed authors regarding availblity for update work. To ask Liz to rerun search. NB same strategy for EXA COP&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2014-11-18 11:41:18 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt;We do not have enough information to prove that shorter-duration corticosteroid is equivalent to longer-duration of treatment, or that shorter-duration is associated with less side effects&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2014-11-10 12:07:00 +0000&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;&lt;b&gt;&lt;u&gt;CJC editing 10/11&lt;/u&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2014-11-10 12:07:00 +0000&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;&lt;b&gt;&lt;u&gt;I have added some details of the new study to what's new and changed the wording of the conclusions following feedback from &lt;/u&gt;&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;u&gt;&lt;span modified=&quot;2014-11-10 12:08:00 +0000&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;an external reviewer. I hope this is ok with the authors and happy to discuss further. Otherwise ready for copy editing.&lt;/span&gt;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2014-11-10 12:08:00 +0000&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;&lt;b&gt;&lt;u&gt;Thanks, Chris&lt;/u&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2014-10-14 11:24:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;&lt;b&gt;&lt;u&gt;CJC notes 14/10&lt;/u&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2014-10-14 11:53:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;&lt;b&gt;&lt;u&gt;I think that footnote 6 in &lt;/u&gt;&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;u&gt;&lt;span modified=&quot;2014-10-14 11:54:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;the SoF table does not match the results, so maybe this one should be moderate rather than low?&lt;/span&gt;&lt;/u&gt;&lt;/b&gt;&lt;span modified=&quot;2014-10-14 11:54:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt; Otherwise checking all the data entry I was unable to find any mistakes!&lt;/span&gt;&lt;span modified=&quot;2014-10-14 11:55:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt; Wonderful.&lt;/span&gt;&lt;span modified=&quot;2014-10-14 11:57:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt; It is also really helpful to have the GRADE assessments alongside the results w&lt;/span&gt;&lt;span modified=&quot;2014-10-14 11:58:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;inserted&quot;&gt;hen they are reported in the main text. I have tweaked the abstract wording to avoid the possibility of readers thinking that equivalence has been demonstrated (if they just look at the abstract text)&lt;/span&gt;&lt;span modified=&quot;2014-10-14 11:58:00 +0100&quot; modified_by=&quot;Christopher J Cates&quot; class=&quot;insertedmarker&quot;&gt;.&lt;/span&gt;&lt;span class=&quot;marker&quot;&gt; &lt;/span&gt;&lt;span modified=&quot;2014-10-16 09:16:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;insertedmarker&quot;&gt;JW I think this &lt;/span&gt;&lt;span modified=&quot;2014-10-16 11:08:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;insertedmarker&quot;&gt;entry in SOF &lt;/span&gt;&lt;span modified=&quot;2014-10-16 09:16:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;insertedmarker&quot;&gt;got duplicated with 1 somehow, I have remo&lt;/span&gt;&lt;span modified=&quot;2014-10-16 09:20:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;insertedmarker&quot;&gt;v&lt;/span&gt;&lt;span modified=&quot;2014-10-16 09:16:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;insertedmarker&quot;&gt;ed and graded &lt;/span&gt;&lt;span modified=&quot;2014-10-16 09:20:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;insertedmarker&quot;&gt;&amp;quot;&lt;/span&gt;&lt;span modified=&quot;2014-10-16 09:16:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;insertedmarker&quot;&gt;moderate&amp;quot;&lt;/span&gt;&lt;span modified=&quot;2014-10-16 09:20:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;insertedmarker&quot;&gt;, changed summary text in discussion to Moderate for QOL outcome.&lt;/span&gt;&lt;span modified=&quot;2014-10-16 11:08:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;insertedmarker&quot;&gt; I am happy with your text in Abstract.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;&lt;u&gt;Liz notes 08/10/2014&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;The search methods section needs a bit of clarification. For the searches of additional databases done to supplement the CAGR search, please provide the platform (e.g. Ovid) and the dates covered by the search. The table of search strategies in the appendix needs checking too please: there is no strategy for Medline included and the CENTRAL strategy is duplicated.&lt;span modified=&quot;2014-10-16 09:45:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt; MEdline strategy&lt;/span&gt;&lt;span modified=&quot;2014-10-16 09:52:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt; added&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The total number of refs identified by the CAGR search plus the supplementary searches you ran need to go in PRISMA diagram and in text (Results of search section). Thanks!&lt;span modified=&quot;2014-10-16 09:45:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt; d&lt;/span&gt;&lt;span modified=&quot;2014-10-16 09:52:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt;one&lt;/span&gt;&lt;span modified=&quot;2014-10-16 09:45:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt; &lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;&lt;u&gt;Emma W comments 03/10/2014&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Thanks Julia and team - I made some minor changes in the text, please check you are happy with them and accept.&lt;/p&gt;&lt;p&gt;Prisma added, but numbers don't seem to follow, please check &lt;span modified=&quot;2014-10-16 11:00:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;insertedmarker&quot;&gt;Checked updated PRIS&lt;/span&gt;&lt;span modified=&quot;2014-10-16 11:08:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;insertedmarker&quot;&gt;MA&lt;/span&gt;&lt;span modified=&quot;2014-10-16 11:00:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;insertedmarker&quot;&gt;- numbers add up JW&lt;/span&gt;&lt;/p&gt;&lt;p&gt;conclusions - the statement on patient reported outcomes - do you mean the EXACT tool? Please can you rephrase to be more specific?&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2014-10-17 13:01:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt;added to background &amp;quot;&lt;/span&gt;&lt;span modified=&quot;2014-10-17 13:01:58 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt;More recently, a standardized measure for assessing the frequency, severity, and duration of exacerbations of COPD using patient reported outcomes has been developed for use in clinical studies, the EXACT diary with 14 items (&lt;/span&gt;&lt;a link_type=&quot;REFERENCE&quot; href=&quot;Leidy 2010&quot; protected=&quot;true&quot;&gt;Leidy 2010&lt;/a&gt;&lt;span modified=&quot;2014-10-17 13:01:58 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt;: &lt;/span&gt;&lt;a link_type=&quot;REFERENCE&quot; href=&quot;Leidy 2011&quot; protected=&quot;true&quot;&gt;Leidy 2011&lt;/a&gt;&lt;i&gt;&lt;span modified=&quot;2014-10-17 13:01:58 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt;)&lt;/span&gt;&lt;/i&gt;&lt;span modified=&quot;2014-10-17 13:01:58 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt;.&lt;/span&gt;&lt;span modified=&quot;2014-10-17 13:02:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt;&amp;quot;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2014-10-17 13:02:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt;added in conclusions &amp;quot;&lt;/span&gt;&lt;span modified=&quot;2014-10-17 13:02:49 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt; Studies should use validated patient reported exacerbation outcomes (&lt;/span&gt;&lt;a link_type=&quot;REFERENCE&quot; href=&quot;Jones 2014&quot; protected=&quot;true&quot;&gt;Jones 2014&lt;/a&gt;&lt;span modified=&quot;2014-10-17 13:02:49 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt;; &lt;/span&gt;&lt;a link_type=&quot;REFERENCE&quot; href=&quot;Leidy 2014&quot; protected=&quot;true&quot;&gt;Leidy 2014&lt;/a&gt;&lt;span modified=&quot;2014-10-17 13:02:49 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt;), &lt;/span&gt;&lt;span modified=&quot;2014-10-17 13:02:00 +1100&quot; modified_by=&quot;Julia A.E. Walters&quot; class=&quot;inserted&quot;&gt;&amp;quot;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;---------------------------------------------------------------&lt;/p&gt;&lt;p&gt;JW updated text. Reviewed RWB, DT, changes incorporated. spell check done, validation corrections made. submit to RG 25/09/14.&lt;/p&gt;&lt;p&gt;&lt;b&gt;05/06/14 Search update from CAG 222 refs&lt;/b&gt;- CW/DT check titles, abstracts- CW/DT screened the results of the CAG search and we identified 2 studies, both of which have already been included&lt;/p&gt;&lt;p&gt;&lt;b&gt;Leuppi&lt;/b&gt; &amp;#8211;(Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, Miedinger D, Muller B, Scherr A, Schindler C, Stoeckli R, Viatte S, Von Garnier C, Tamm M, Rutishauser J. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: The REDUCE randomised clinical trial. JAMA 2013; 309: 2223-31.) &lt;b&gt;OGT in first version. Moved to included studies&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Abdullah Al Mamun&lt;/b&gt; (Abdullah Al Mamun SM, Rahman S. Role of 7-day and 14-day courses of oral prednisolone treatment in acute exacerbation of COPD [Abstract]. Thorax 2011; 66: A172 [P258}).&lt;b&gt;This abstract is verbatim identical to Rahman 2004&lt;/b&gt; (Rahman M, Abdullah A, Mamun SM, Haque MDA. Role of 7-day and 14-day courses of oral prednisolone treatment in acute exacerbation of COPD [Abstract]. Chest 2004;126(4 Suppl):839S-a.) &lt;b&gt;Entered as second citation.&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;DT double checked the study characteristics and data entry for Leuppi. date in excel file, DT check data entry&lt;/p&gt;&lt;p&gt;- Length of hospitalisation: Table 3 mean, median, IQR given. Handbook 7.7.3.5. When sample sizes are large and the distribution of the outcome is similar to the normal distribution, the width of the interquartile range will be approximately 1.35. standard deviations derived SD 5d and 14 d 4.4444 , 5.9259&lt;/p&gt;&lt;p&gt;- FEV1, figure 4 JAMA mean 95% CI, , day 6 using plot digitizer software.&lt;/p&gt;&lt;p&gt;&lt;b&gt;from JAMA Supplementary Online Content pdf. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term versus conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the &amp;#8220;REDUCE&amp;#8221; randomised clinical trial. JAMA. doi: 10.1001/jama.2013.5023 eFigure 1. Secondary end points&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Panel A: MRC dyspnoea scale&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Panel B: Quality of life score&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;21/08/12 OS copd search found2 possible studies:&lt;/p&gt;&lt;p&gt;1.Abdullah Al Mamun SM, &lt;span class=&quot;marker&quot;&gt;Rahman &lt;/span&gt;S. Role of 7-day and 14-day courses of oral prednisolone treatment in acute exacerbation of COPD [Abstract]. Thorax. 2011;66:A172 [P258}. &lt;span class=&quot;marker&quot;&gt;Second citation,&lt;/span&gt; few results but email found Sher-e-Bangla Medical College (SBMC), medical college in Barisal, Bangladesh&amp;#160;&amp;#160;&lt;/p&gt;&lt;p&gt;Dr. Md.Siddiqur Rahman &amp;#160; Assistant Professor &amp;#160;dr.siddik34821@gmail.com&lt;/p&gt;&lt;p&gt;Dr. S.M. Abdullah Al Mamun &amp;#160; Assistant Professor &amp;#160; mamundr@dhaka.net&lt;/p&gt;&lt;p&gt;&lt;br&gt;2.Aggarwal P, Wig N, Bhoi S. Efficacy of two corticosteroid regimens in acute exacerbation of chronic obstructive pulmonary disease. International journal of tuberculosis and lung disease. 2011;15:687-692. compares intravenous (IV) methylprednisolone (MP) followed by oral MP with IV hydrocortisone (HC) followed by oral prednisolone in patients with AECOPD 2 weeks each- &lt;span class=&quot;marker&quot;&gt;exclude&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;marker&quot;&gt;also second citation for de Jong 2005 excluded: main article&lt;/span&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;CJC graph labels corrected and minus signs put back into the text.&lt;/p&gt;&lt;p&gt;The results in the abstract had not all be updated perhaps, but now all match the forest plots and main text&lt;/p&gt;&lt;p&gt;Minus signs have been restored to point estimates and CI of all results!&lt;/p&gt;&lt;p&gt;++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++&lt;/p&gt;&lt;p&gt;CJC Post peer changes (Sorry did not notice this was deliberate but Chen change from baseline now removed)&lt;/p&gt;&lt;p&gt;Thanks for responding with changes following Peer review. I have noticed that FEV1 had one study (Chen 2005 change from baseline) unchecked in REvMan so have corrected this and the pooled end of study FEV1 is therefore altered in the abstract and results.&lt;/p&gt;&lt;p&gt;Otherwise fine to go for copy editing.&lt;/p&gt;&lt;p&gt;Chris&lt;/p&gt;&lt;p&gt;++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++&lt;/p&gt;&lt;p&gt;CJC ready for Peer review.&lt;/p&gt;&lt;p&gt;JW- changes made. Chen full publication data available so included in review. See response to reviewers document. 18/07/11&lt;/p&gt;&lt;p&gt;Agree this is too strong. hVE REMOVED REFERENCE QOUN 2008. Have ammended &amp;quot;The healthcare costs associated with COPD are principally due to hospital admissions for acute exacerbations of COPD (&lt;a link_type=&quot;REFERENCE&quot; href=&quot;Wouters 2003&quot; protected=&quot;true&quot;&gt;Wouters 2003&lt;/a&gt;) but in this review only one study reported on length of stay and found no significant difference.&amp;quot;&lt;/p&gt;&lt;p&gt;Conclusions rephrased&lt;/p&gt;&lt;p&gt;&amp;quot; The result of this review, that there is no significant increase in treatment failure with shorter systemic corticosteroid treatment for 7 days for acute exacerbations of COPD, is potentially important and further data are required for confirmation, despite the acknowledged difficulties in recruiting participants in many countries.&lt;/p&gt;&lt;p&gt;CJC 13th May&lt;/p&gt;&lt;p&gt;&amp;quot;Given the prevalence of patients presenting to hospital with acute exacerbations of COPD, reducing the length of corticosteroid treatment will save a significant amount of resources (Quon 2008).&amp;quot;&lt;/p&gt;&lt;p&gt;HOW?&lt;/p&gt;&lt;p&gt;The conclusions are too strong for the wide Confidence intervals so I have toned them down.&lt;/p&gt;&lt;p&gt;&amp;quot;The result of this review indicating equivalence for up to 7 days corticosteroid treatment with longer treatment are important &amp;quot; This is not correct as you cannot suggest equivalence with such wide confidence intervals. Please rephrase!&lt;/p&gt;&lt;p&gt;JW 13th May 2011&lt;/p&gt;&lt;p&gt;embase search found new study- paper requested locally MRIT. Aggarwal P, Wig N, Bhoi S. Efficacy of two corticosteroid regimens in acute exacerbation of chronic obstructive pulmonary disease. International Journal of Tuberculosis and Lung Disease. 2011;15(5):687-92. REference added to &amp;quot;awaiting classification&amp;quot;.&lt;/p&gt;&lt;p&gt;Revisions- based on EW comments completed.&lt;/p&gt;&lt;p&gt;Abstract:&lt;/p&gt;&lt;p&gt;Objectives...acute exacerbations of COPD in adults&lt;/p&gt;&lt;p&gt;Main results... Risk of bias for allocation and blinding was assessed as low for studies included in meta-analyses.&lt;/p&gt;&lt;p&gt;Excluded studies -have deleted description&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;Emma comments 21st April 2011&lt;/p&gt;&lt;p&gt;Abstarct&lt;/p&gt;&lt;p&gt;Objectives. Please define type of people and setting if appropriate - it seems about strange to say adults though, in patients with COPD as I guess you have to be an adult to have COPD almost by definition?&lt;/p&gt;&lt;p&gt;Main results. Please add a sentence about the risk of bias of included studies&lt;/p&gt;&lt;p&gt;Excluded studies - suggest deleting description that is repetition from the results of search&lt;/p&gt;&lt;p&gt;Results - see tracked changes. I also changed the formatting of the analysis results.&lt;/p&gt;&lt;p&gt;Conclusion&lt;/p&gt;&lt;p&gt;suggest changing &amp;quot;This review has found that there is no additional benefit for patients with acute exacerbations of COPD to receiving corticosteroid therapy for more than 7 days.&amp;quot; to &amp;quot;This review showed no additional benefit for patients with acute exacerbations of COPD to receiving corticosteroid therapy for more than 7 days.&amp;quot;&lt;/p&gt;&lt;p&gt;The totals in the forest plots have been turned off where there is only one study in that meta-analysis.&lt;/p&gt;&lt;p&gt;--------------------------------------------&lt;/p&gt;&lt;p&gt;2 REMINDER EMAILS TO PRATTER ereSalam data, no response so presume data unavailable.&lt;/p&gt;&lt;p&gt;20/10/10 email Salam data promised by Pratter, email Bangladesh CC for contacts Gomaa- no response&lt;/p&gt;&lt;p&gt;22/06/10 Letters to 4 abstract authors- Salam,&lt;/p&gt;&lt;p&gt;12/05/10&lt;/p&gt;&lt;p&gt;chen 2005- authors aupplied data&lt;/p&gt;&lt;p&gt;Gooma 2008- abstract- needs letter&lt;/p&gt;&lt;p&gt;Rahman 2004- abstract- needs letter&lt;/p&gt;&lt;p&gt;Salam 1998- abstract- needs letter&lt;/p&gt;&lt;p&gt;Sayiner 2001- full paper&lt;/p&gt;&lt;p&gt;Sirichana 2008- abstract- needs letter&lt;/p&gt;&lt;p&gt;Woodbaker 1997- abstract- needs letter&lt;/p&gt;&lt;p&gt;seraches Embase, cinnahl done&lt;/p&gt;&lt;p&gt;Need ongoing studies searches- Soltani?&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Hi Toby,&lt;br&gt;Any chance of rapid peer review for this so we can get it on the module?&lt;br&gt;Chris&lt;/p&gt;&lt;p&gt;~~~~~~~~~~~~~~~~~~~~~~&lt;br&gt;Editing by CJC Oct 29&lt;/p&gt;&lt;p&gt;Reviewers Contributions: fine&lt;/p&gt;&lt;p&gt;References: fine&lt;/p&gt;&lt;p&gt;Background: fine&lt;/p&gt;&lt;p&gt;Objectives: see minor changes in red. When are you interested in FEV1&lt;/p&gt;&lt;p&gt;Methods : Fine&lt;/p&gt;&lt;p&gt;Contentious issues; Just clarification when you think outcomes should be measured in relation to the course of treatment would be useful&lt;/p&gt;&lt;p&gt;Next action: Back to authors for response to the above and this may then go on for the current submission.&lt;/p&gt;&lt;p&gt;1.11.07 Authors response: JW If data on lung function or other continuous outcomes such as symptom scores are available at multiple time points, these outcomes will be divided into early (0-72 hours) and late (the latest measurement occurring after 72 hours) time points.&lt;/p&gt;&lt;p&gt;1.11.07 Authors response: MJS typo error noted and changed already under &amp;quot;types of intervention&amp;quot;&lt;/p&gt;" NOTES_MODIFIED="2017-12-22 15:36:36 +1100" NOTES_MODIFIED_BY="Julia Walters" REVIEW_NO="DUR-COP" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0"><COVER_SHEET MODIFIED="2018-03-05 09:29:19 +0000" MODIFIED_BY="Emma Dennett"><TITLE>Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease</TITLE><CONTACT MODIFIED="2018-03-05 09:29:19 +0000" MODIFIED_BY="Emma Dennett"><PERSON ID="12527" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Julia</FIRST_NAME><MIDDLE_INITIALS>AE</MIDDLE_INITIALS><LAST_NAME>Walters</LAST_NAME><EMAIL_1>Julia.Walters@utas.edu.au</EMAIL_1><ADDRESS><ORGANISATION>La Trobe University</ORGANISATION><ADDRESS_1>55 Commercial Rd</ADDRESS_1><ADDRESS_2>Alfred Health Clinical School</ADDRESS_2><CITY>Melbourne</CITY><ZIP>3004</ZIP><REGION>Victoria</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 422 266 158</PHONE_1><PHONE_2>+61 394285960</PHONE_2></ADDRESS></PERSON></CONTACT><CREATORS MODIFIED="2018-03-05 09:29:19 +0000" MODIFIED_BY="Emma Dennett"><PERSON ID="12527" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Julia</FIRST_NAME><MIDDLE_INITIALS>AE</MIDDLE_INITIALS><LAST_NAME>Walters</LAST_NAME><EMAIL_1>Julia.Walters@utas.edu.au</EMAIL_1><ADDRESS><ORGANISATION>La Trobe University</ORGANISATION><ADDRESS_1>55 Commercial Rd</ADDRESS_1><ADDRESS_2>Alfred Health Clinical School</ADDRESS_2><CITY>Melbourne</CITY><ZIP>3004</ZIP><REGION>Victoria</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 422 266 158</PHONE_1><PHONE_2>+61 394285960</PHONE_2></ADDRESS></PERSON><PERSON ID="z1305141514585849521955509509908" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Daniel</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Tan</LAST_NAME><POSITION>5th Year Medical Student</POSITION><EMAIL_1>dtan1@postoffice.utas.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of Tasmania</ORGANISATION><CITY>Hobart</CITY><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="z1305141510544590685970942900195" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Clinton</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>White</LAST_NAME><POSITION>5th Year Medical Student</POSITION><EMAIL_1>cjwhite@utas.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of Tasmania</ORGANISATION><ADDRESS_1>MS1, 17 Liverpool Street</ADDRESS_1><ADDRESS_2>PO Box 23</ADDRESS_2><CITY>Hobart</CITY><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="12536" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><LAST_NAME>Wood-Baker</LAST_NAME><POSITION>Clinical Professor</POSITION><EMAIL_1>Richard.WoodBaker@utas.edu.au</EMAIL_1><MOBILE_PHONE>0407641077</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of Tasmania</ORGANISATION><CITY>Hobart</CITY><ZIP>7001</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 3 6226 4805</PHONE_1><PHONE_2>0407 641 077</PHONE_2></ADDRESS></PERSON></CREATORS><DATES MODIFIED="2017-12-19 11:57:14 +1100" MODIFIED_BY="[Empty name]"><UP_TO_DATE><DATE DAY="11" MONTH="3" YEAR="2017"/></UP_TO_DATE><LAST_SEARCH><DATE DAY="11" MONTH="3" YEAR="2017"/></LAST_SEARCH><NEXT_STAGE><DATE DAY="11" MONTH="3" YEAR="2019"/></NEXT_STAGE><PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/><REVIEW_PUBLISHED ISSUE="10" YEAR="2011"/><LAST_CITATION_ISSUE ISSUE="3" YEAR="2018"/></DATES><WHATS_NEW MODIFIED="2017-12-20 02:53:39 +1100" MODIFIED_BY="Emma J Dennett"><WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-12-20 02:53:39 +1100" MODIFIED_BY="Emma J Dennett"><DATE DAY="11" MONTH="3" YEAR="2017"/><DESCRIPTION><P>No new studies identified. The only change was to add the search results.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-12-20 02:49:41 +1100" MODIFIED_BY="Emma J Dennett"><DATE DAY="11" MONTH="3" YEAR="2017"/><DESCRIPTION><P>417 references, 13 duplicates. 390 irrelevant on title/abstract; 13 excluded. 1 citation for an already included study (Leuppi 2013). 1 ongoing study identified (Leuppi 2017). No new studies included, no change to conclusions.</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW><HISTORY MODIFIED="2017-12-19 12:23:31 +1100" MODIFIED_BY="[Empty name]"><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-12-19 12:23:31 +1100" MODIFIED_BY="[Empty name]"><DATE DAY="11" MONTH="3" YEAR="2017"/><DESCRIPTION><P>New literature search run.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-03-02 01:02:44 +1100" MODIFIED_BY="Emma J Dennett"><DATE DAY="5" MONTH="6" YEAR="2014"/><DESCRIPTION><P>New literature search run</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-03-02 01:02:41 +1100" MODIFIED_BY="Emma J Dennett"><DATE DAY="5" MONTH="6" YEAR="2014"/><DESCRIPTION><P>One new study (<LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>) with 314 participants added, conclusions redrafted. Background and PLS redrafted and 'Summary of findings' table added. Methods amended to bring them up-to-date, but no substantial alterations in how we conducted the review. See 'Differences between protocol and review' for a description</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-12-08 21:32:55 +1100" MODIFIED_BY="Julia A.E. Walters"><DATE DAY="14" MONTH="2" YEAR="2012"/><DESCRIPTION><P>Review republished to rectify copyediting error. Corrections made to signs of treatment effects and confidence intervals in the abstract and in the main text</P></DESCRIPTION></WHATS_NEW_ENTRY></HISTORY><SOURCES_OF_SUPPORT MODIFIED="2014-12-08 21:30:39 +1100" MODIFIED_BY="Julia A.E. Walters"><INTERNAL_SOURCES MODIFIED="2014-12-08 21:30:39 +1100" MODIFIED_BY="Julia A.E. Walters"><SOURCE MODIFIED="2014-12-08 21:30:39 +1100" MODIFIED_BY="Julia A.E. Walters"><NAME>Breathe Well Centre of Research Excellence, University of Tasmania</NAME><COUNTRY CODE="AU">Australia</COUNTRY><DESCRIPTION><P>Logistical support</P></DESCRIPTION></SOURCE></INTERNAL_SOURCES><EXTERNAL_SOURCES MODIFIED="2014-12-08 21:28:54 +1100" MODIFIED_BY="Julia A.E. Walters"><SOURCE MODIFIED="2014-12-08 21:28:54 +1100" MODIFIED_BY="Julia A.E. Walters"><NAME>NHMRC</NAME><COUNTRY CODE="AU">Australia</COUNTRY><DESCRIPTION><P>Funding support for the Australian Satellite of the Cochrane Airways Group</P></DESCRIPTION></SOURCE></EXTERNAL_SOURCES></SOURCES_OF_SUPPORT><MESH_TERMS VERIFIED="NO"/><KEYWORDS/></COVER_SHEET><MAIN_TEXT MODIFIED="2017-12-19 12:17:04 +1100" MODIFIED_BY="[Empty name]"><SUMMARY MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><TITLE MODIFIED="2014-12-08 20:49:21 +1100" MODIFIED_BY="Julia A.E. Walters">Are shorter courses of systemic steroids as effective as conventional longer courses in the treatment of patients with flare-ups of COPD?</TITLE><SUMMARY_BODY MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><P><B>Why is this question important?</B></P><P>Chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, is a long-term lung condition that is commonly associated with smoking. Patients with COPD may experience flare-ups (exacerbations), often precipitated by infection, in which symptoms such as breathlessness, cough and phlegm become markedly worse, and extra treatment or admission to hospital is required.</P><P>Systemic (i.e. not inhaled) corticosteroids, such as prednisolone, prednisone and cortisone, are commonly used in the treatment of patients with these flare-ups (exacerbations). We wanted to assess whether a shorter course (seven or fewer days) of this treatment was as good as a course of usual length (longer than seven days) and caused fewer side effects.</P><P><B>How did we answer the question?</B></P><P>We looked for all studies that compared oral or injected corticosteroid treatment given for seven or fewer days versus treatment given for longer than seven days in people with acute exacerbations of COPD.</P><P><B>What did we find?</B></P><P>We found eight studies that included 582 people with COPD who experienced a flare-up that required extra treatment in hospital. These studies compared oral or injected corticosteroid treatment given for seven or fewer days versus treatment for longer than seven days. Most of the people in these studies were in their late sixties and had severe or very severe symptoms of COPD; more men than women took part. The last search for studies to be included in the review was conducted in March 2017.</P><P>No differences were observed between shorter and longer courses of treatment. People treated for seven or fewer days did not have a higher rate of treatment failure or longer time to their next exacerbation; the number of people who avoided treatment failure ranged from 51 fewer to 34 more per 1000 treated (average 22 fewer people per 1000). Time in hospital and lung function (blowing tests) at the end of treatment were not different. No differences in side effects or death were noted between treatments. Information on quality of life, which is an important outcome for people with COPD, is limited, as only one study measured it.</P><P>The eight studies included in this review were generally well designed, and the quality of the evidence was rated as moderate because of imprecision in results; more research, especially involving people with less severe COPD, is needed.</P></SUMMARY_BODY></SUMMARY><ABSTRACT MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><ABS_BACKGROUND MODIFIED="2014-12-08 20:48:49 +1100" MODIFIED_BY="Julia A.E. Walters"><P>Current guidelines recommend that patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) should be treated with systemic corticosteroid for seven to 14 days. Intermittent systemic corticosteroid use is cumulatively associated with adverse effects such as osteoporosis, hyperglycaemia and muscle weakness. Shorter treatment could reduce adverse effects.</P></ABS_BACKGROUND><ABS_OBJECTIVES MODIFIED="2014-12-08 20:48:48 +1100" MODIFIED_BY="Julia A.E. Walters"><P>To compare the efficacy of short-duration (seven or fewer days) and conventional longer-duration (longer than seven days) systemic corticosteroid treatment of adults with acute exacerbations of COPD.</P></ABS_OBJECTIVES><ABS_SEARCH_STRATEGY MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><P>Searches were carried out using the Cochrane Airways Group Specialised Register of Trials, MEDLINE and CENTRAL (Cochrane Central Register of Controlled Trials) and ongoing trials registers up to March 2017.</P></ABS_SEARCH_STRATEGY><ABS_SELECTION_CRITERIA MODIFIED="2014-12-03 01:13:49 +1100" MODIFIED_BY="Emma J Welsh"><P>Randomised controlled trials comparing different durations of systemic corticosteroid defined as short (i.e. seven or fewer days) or longer (i.e. longer than seven days). Other interventions&#8212;bronchodilators and antibiotics&#8212;were standardised. Studies with participants requiring assisted ventilation were excluded.</P></ABS_SELECTION_CRITERIA><ABS_DATA_COLLECTION MODIFIED="2014-12-03 01:13:54 +1100" MODIFIED_BY="Emma J Welsh"><P>We used standard methodological procedures as expected by The Cochrane Collaboration.</P></ABS_DATA_COLLECTION><ABS_RESULTS MODIFIED="2014-12-08 20:49:11 +1100" MODIFIED_BY="Julia A.E. Walters"><P>Eight studies with 582 participants met the inclusion criteria, of which five studies conducted in hospitals with 519 participants (range 28 to 296) contributed to the meta-analysis. Mean ages of study participants were 65 to 73 years, the proportion of male participants varied (58% to 84%) and COPD was classified as severe or very severe. Corticosteroid treatment was given at equivalent daily doses for three to seven days for short-duration treatment and for 10 to 15 days for longer-duration treatment. Five studies administered oral prednisolone (30 mg in four, tapered in one), and two studies provided intravenous corticosteroid treatment. Studies contributing to the meta-analysis were at low risk of selection, performance, detection and attrition bias. In four studies we did not find a difference in risk of treatment failure between short-duration and longer-duration systemic corticosteroid treatment (n = 457; odds ratio (OR) 0.72, 95% confidence interval (CI) 0.36 to 1.46)), which was equivalent to 22 fewer per 1000 for short-duration treatment (95% CI 51 fewer to 34 more). No difference in risk of relapse (a new event) was observed between short-duration and longer-duration systemic corticosteroid treatment (n = 457; OR 1.04, 95% CI 0.70 to 1.56), which was equivalent to nine fewer per 1000 for short-duration treatment (95% CI 68 fewer to 100 more). Time to the next COPD exacerbation did not differ in one large study that was powered to detect non-inferiority and compared five days versus 14 days of systemic corticosteroid treatment (n = 311; hazard ratio 0.95, 95% CI 0.66 to 1.37). In five studies no difference in the likelihood of an adverse event was found between short-duration and longer-duration systemic corticosteroid treatment (n = 503; OR 0.89, 95% CI 0.46 to 1.69, or nine fewer per 1000 (95% CI 44 fewer to 51 more)). Length of hospital stay (n = 421; mean difference (MD) -0.61 days, 95% CI -1.51 to 0.28) and lung function at the end of treatment (n = 185; MD FEV1 -0.04 L; 95% CI -0.19 to 0.10) did not differ between short-duration and longer-duration treatment.</P></ABS_RESULTS><ABS_CONCLUSIONS MODIFIED="2014-12-03 01:16:10 +1100" MODIFIED_BY="Emma J Welsh"><P>Information from a new large study has increased our confidence that five days of oral corticosteroids is likely to be sufficient for treatment of adults with acute exacerbations of COPD, and this review suggests that the likelihood is low that shorter courses of systemic corticosteroids (of around five days) lead to worse outcomes than are seen with longer (10 to 14 days) courses. We graded most available evidence as moderate in quality because of imprecision; further research may have an important impact on our confidence in the estimates of effect or may change the estimates. The studies in this review did not include people with mild or moderate COPD; further studies comparing short-duration systemic corticosteroid versus conventional longer-duration systemic corticosteroid for treatment of adults with acute exacerbations of COPD are required.</P></ABS_CONCLUSIONS></ABSTRACT><BODY MODIFIED="2017-12-19 12:17:04 +1100" MODIFIED_BY="[Empty name]"><BACKGROUND MODIFIED="2014-12-05 01:44:41 +1100" MODIFIED_BY="Emma J Welsh"><CONDITION MODIFIED="2014-12-05 01:44:41 +1100" MODIFIED_BY="Emma J Welsh"><P>Chronic obstructive pulmonary disease (COPD) is characterised by persistent airflow limitation that is usually progressive and is associated with an enhanced chronic inflammatory response to noxious particles or gases in the airways and the lung (<LINK REF="REF-GOLD-2014" TYPE="REFERENCE">GOLD 2014</LINK>). A diagnosis of COPD is considered on a clinical basis in the presence of symptoms such as dyspnoea, chronic cough or sputum production and exposure to known risk factors. Confirmation of COPD diagnosis is based on demonstration of persistent airflow limitation with spirometry, according to the criterion of postbronchodilator forced expiratory volume in one second (FEV<SUB>1</SUB>)/forced vital capacity (FVC) ratio less than 0.7, as specified in guidelines included in GOLD (Global Strategy for Diagnosis, Management, and Prevention of COPD) (<LINK REF="REF-GOLD-2014" TYPE="REFERENCE">GOLD 2014</LINK>). However, heterogeneity (<LINK REF="REF-Agusti-2010" TYPE="REFERENCE">Agusti 2010</LINK>) and phenotypical variation in COPD (<LINK REF="REF-Weatherall-2009" TYPE="REFERENCE">Weatherall 2009</LINK>) are increasingly recognised. COPD and asthma overlap syndrome are known to have a higher prevalence in older individuals and are associated with more frequent exacerbations (<LINK REF="REF-Hardin-2014" TYPE="REFERENCE">Hardin 2014</LINK>).</P><P>COPD is an important and increasing cause of mortality; it was estimated to be the fifth leading cause of death in the year 2000 and was responsible for 2.75 million deaths (<LINK REF="REF-Lopez-2006" TYPE="REFERENCE">Lopez 2006</LINK>). Worldwide mortality due to COPD is projected to rise to 4.5 million deaths in 2020, becoming the third leading cause (<LINK REF="REF-Murray-1997" TYPE="REFERENCE">Murray 1997</LINK>). Worldwide COPD resulted in 16.5 million years of life lost in 2000, almost 10 million years lived with disability and 26.5 million disability-adjusted life-years (<LINK REF="REF-Lopez-2006" TYPE="REFERENCE">Lopez 2006</LINK>).</P><P>The Burden of Lung Disease (BOLD) study (<LINK REF="REF-Buist-2007" TYPE="REFERENCE">Buist 2007</LINK>) reported a worldwide prevalence of stage II or greater severity (FEV<SUB>1</SUB> &lt; 80% predicted) of 10.1% (standard error (SE) 4.8) overall, 11.8% (SE 7.9) for men and 8.5% (SE 5.8) for women. International variation in the prevalence and severity of COPD is partially explained by variation in smoking prevalence and other risk factors (<LINK REF="REF-Buist-2007" TYPE="REFERENCE">Buist 2007</LINK><I>)</I>.</P><P>Exacerbations and co-morbidities contribute to the varying natural history of COPD in individual patients (<LINK REF="REF-GOLD-2014" TYPE="REFERENCE">GOLD 2014</LINK>)<I>.</I> Exacerbations contribute to long-term decline in lung function (<LINK REF="REF-Donaldson-2002" TYPE="REFERENCE">Donaldson 2002</LINK>) and reduced physical activity (<LINK REF="REF-Donaldson-2005" TYPE="REFERENCE">Donaldson 2005</LINK><I>)</I> and are associated with increased risk of death (<LINK REF="REF-Soler_x002d_Cataluna-2005" TYPE="REFERENCE">Soler-Cataluna 2005</LINK>). They also have a profound and long-lasting effect on quality of life (<LINK REF="REF-Groenewegen-2001" TYPE="REFERENCE">Groenewegen 2001</LINK>; <LINK REF="REF-Wilkinson-2004" TYPE="REFERENCE">Wilkinson 2004</LINK>); in 10% of exacerbations, pre-exacerbation quality of life was not recovered after three months (<LINK REF="REF-Seemungal-2000" TYPE="REFERENCE">Seemungal 2000</LINK>).</P><P>Exacerbations of COPD are a frequent cause of hospitalisation (<LINK REF="REF-Donaldson-2006" TYPE="REFERENCE">Donaldson 2006</LINK>), although exacerbations with less severe symptoms and signs are often managed on an outpatient basis (<LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>). Hospital-at-home or early discharge services, if available, may be used as an alternative way of caring for patients with exacerbations of COPD who otherwise would need to be admitted or to remain in hospital (<LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>). Treatment of patients with exacerbations is a large contributor to the economic burden of COPD (<LINK REF="REF-Schermer-2002" TYPE="REFERENCE">Schermer 2002</LINK>; <LINK REF="REF-Sullivan-2000" TYPE="REFERENCE">Sullivan 2000</LINK>), and a high proportion of costs is due to hospitalisation (<LINK REF="REF-Oostenbrink-2004" TYPE="REFERENCE">Oostenbrink 2004</LINK>).</P><P>Studies on the frequency of exacerbations usually use an &#8220;event-based&#8221; definition based on healthcare utilization (<LINK REF="REF-Effing-2009" TYPE="REFERENCE">Effing 2009</LINK>), and different events may be a proxy for severity, with unscheduled clinic or emergency room visits rated &#8220;moderate,&#8221; and those requiring hospitalisation labelled &#8220;severe&#8221; (<LINK REF="REF-Rodriguez_x002d_Roisin-2000" TYPE="REFERENCE">Rodriguez-Roisin 2000</LINK>). However, the clinical onset of an acute exacerbation is defined according to symptoms, although no universally agreed upon definition is known (<LINK REF="REF-Rodriguez_x002d_Roisin-2000" TYPE="REFERENCE">Rodriguez-Roisin 2000</LINK>). Type 1 exacerbations were originally defined by Anthonisen on the basis of three major symptoms: increased dyspnoea, sputum volume and sputum purulence; type 2 exacerbations were associated with only two of the major symptoms, and type 3 exacerbations involved one major symptom plus cough, wheeze or symptoms of an upper respiratory tract infection (<LINK REF="REF-Anthonisen-1987" TYPE="REFERENCE">Anthonisen 1987</LINK>). A later definition required an increase in two of the "major symptoms" of dyspnoea&#8212;sputum volume or sputum purulence&#8212;or in one major symptom and one "minor symptom" (wheeze, sore throat, cough or common cold symptoms) for two days (<LINK REF="REF-Seemungal-2000" TYPE="REFERENCE">Seemungal 2000</LINK>). More recently, a standardised measure for assessing frequency, severity and duration of exacerbations of COPD using patient-reported outcomes has been developed for use in clinical studies: the EXACT (exacerbations of chronic pulmonary disease tool) diary, which consists of 14 items (<LINK REF="REF-Leidy-2010" TYPE="REFERENCE">Leidy 2010</LINK>; <LINK REF="REF-Leidy-2011" TYPE="REFERENCE">Leidy 2011</LINK>).</P><P>The inflammatory mechanisms underlying the onset and development of COPD exacerbations are complex (<LINK REF="REF-Bathoorn-2008" TYPE="REFERENCE">Bathoorn 2008</LINK>), and exacerbations can be precipitated by several factors, and the most common causes are infective (<LINK REF="REF-Papi-2006" TYPE="REFERENCE">Papi 2006</LINK>); bacterial pathogens are identified in just over 50% of cases, and viral causes in around 25% (<LINK REF="REF-Sethi-2002" TYPE="REFERENCE">Sethi 2002</LINK>; <LINK REF="REF-Sherk-2000" TYPE="REFERENCE">Sherk 2000</LINK>). Non-infective causes such as air pollution and other environmental conditions that increase airway inflammation may account for 15% to 20% of exacerbations (<LINK REF="REF-Sethi-2008" TYPE="REFERENCE">Sethi 2008</LINK>). Exacerbations become more frequent and more severe as the severity of COPD increases (<LINK REF="REF-Suissa-2012" TYPE="REFERENCE">Suissa 2012</LINK>), although the rate at which they occur may reflect an independent susceptibility phenotype&#8212;the &#8220;frequent exacerbator&#8221; (<LINK REF="REF-Hurst-2010" TYPE="REFERENCE">Hurst 2010</LINK>).</P></CONDITION><INTERVENTION MODIFIED="2014-12-03 01:20:36 +1100" MODIFIED_BY="Emma J Welsh"><P>The acute inflammatory response to airway infection is influenced by both pathogenic and host factors, resulting in increased airway and systemic inflammation (<LINK REF="REF-Sethi-2008" TYPE="REFERENCE">Sethi 2008</LINK>). Airway inflammation is significantly increased during exacerbations of COPD, and evidence of increased numbers of neutrophils, lymphocytes and eosinophils is seen in airways and in sputum (<LINK REF="REF-Falk-2008" TYPE="REFERENCE">Falk 2008</LINK>; <LINK REF="REF-Papi-2006" TYPE="REFERENCE">Papi 2006</LINK>). Systemic inflammation is also present in COPD; many circulating inflammatory mediators are elevated, both in stable COPD and during exacerbations. C-reactive protein (CRP) is a known marker of systemic inflammation whose levels are elevated during exacerbations; it is a likely participant in the inflammatory cascade (<LINK REF="REF-Falk-2008" TYPE="REFERENCE">Falk 2008</LINK>). Theoretical mechanisms for clinical improvement in lung function among patients treated with corticosteroids during exacerbations may include reduction in airway inflammation or a decrease in airway oedema (<LINK REF="REF-Wedzicha-2000" TYPE="REFERENCE">Wedzicha 2000</LINK>)<I>.</I></P></INTERVENTION><IMPORTANCE MODIFIED="2014-12-03 01:21:25 +1100" MODIFIED_BY="Emma J Welsh"><P>Systemic corticosteroid use in COPD is associated with potential adverse drug effects, including fluid retention, hypertension, diabetes mellitus, adrenal suppression and osteoporosis (<LINK REF="REF-McEvoy-1996" TYPE="REFERENCE">McEvoy 1996</LINK>). Fracture risk is increased (<LINK REF="REF-De-Vries-2007" TYPE="REFERENCE">De Vries 2007</LINK>; <LINK REF="REF-Vestergaard-2007" TYPE="REFERENCE">Vestergaard 2007</LINK>); this is potentially important, as the rate of existing vertebral compression fractures in the COPD population experiencing acute exacerbations, especially among older people with longer duration of disease, is high (<LINK REF="REF-Majumdar-2010" TYPE="REFERENCE">Majumdar 2010</LINK>). Short-term use of systemic corticosteroids in the treatment of patients with exacerbations of COPD also has adverse effects on respiratory and peripheral muscle strength (<LINK REF="REF-Decramer-1994" TYPE="REFERENCE">Decramer 1994</LINK>). The risk of adverse drug effects of systemic corticosteroids in COPD rises with increasing frequency of high-dose systemic corticosteroid use and with increasing cumulative exposure (more than 1 g) (<LINK REF="REF-De-Vries-2007" TYPE="REFERENCE">De Vries 2007</LINK>).</P><P>Systemic corticosteroid treatment of patients with acute exacerbations of COPD decreases treatment failure and is associated with early improvement in lung function, breathlessness and arterial hypoxaemia and reduced length of hospital stay (<LINK REF="REF-Walters-2014" TYPE="REFERENCE">Walters 2014</LINK>), although in this Cochrane review, the duration of systemic corticosteroid treatment varied, usually described as between three days and 15 days. Guidelines for the management of COPD specify a duration of treatment ranging from seven days to 10 days (<LINK REF="REF-GOLD-2014" TYPE="REFERENCE">GOLD 2014</LINK>), from seven days to 14 days (<LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>) and from 10 days to 14 days (<LINK REF="REF-McKenzie-2003" TYPE="REFERENCE">McKenzie 2003</LINK>). Thus, it is important to define the optimum duration of corticosteroid treatment and to take into account limiting potential adverse effects.</P></IMPORTANCE></BACKGROUND><OBJECTIVES MODIFIED="2014-12-03 01:21:32 +1100" MODIFIED_BY="Emma J Welsh"><P>To compare the efficacy of short-duration (seven or fewer days) and conventional longer-duration (longer than seven days) systemic corticosteroid treatment of adults with acute exacerbations of COPD.</P></OBJECTIVES><METHODS MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><SELECTION_CRITERIA MODIFIED="2014-12-03 01:22:36 +1100" MODIFIED_BY="Emma J Welsh"><CRIT_STUDIES MODIFIED="2014-12-03 01:21:46 +1100" MODIFIED_BY="Emma J Welsh"><P>Randomised controlled trials (RCTs) comparing short-duration systemic corticosteroid treatment (seven or fewer days) versus conventional, longer-duration treatment (longer than seven days).</P></CRIT_STUDIES><CRIT_PARTICIPANTS MODIFIED="2014-12-03 01:21:51 +1100" MODIFIED_BY="Emma J Welsh"><P>Adults with an acute exacerbation of COPD. The definition of an acute exacerbation could include any combination of an increase in breathlessness, sputum volume, sputum purulence, cough or wheeze. We excluded studies that included patients with asthma and other lung diseases (e.g. interstitial lung disease, bronchiectasis), unless separate data on participants with COPD alone were available.</P></CRIT_PARTICIPANTS><CRIT_INTERVENTIONS MODIFIED="2014-12-03 01:21:59 +1100" MODIFIED_BY="Emma J Welsh"><P>Systemic corticosteroid (SCS) given for a period of seven or fewer days (SCS &#8804; 7) versus systemic corticosteroid given for longer than seven days (SCS &gt; 7). Co-interventions were required to be standardised across groups. We excluded studies in which participants received assisted ventilation (invasive or non-invasive).</P></CRIT_INTERVENTIONS><CRIT_OUTCOMES MODIFIED="2014-12-03 01:22:36 +1100" MODIFIED_BY="Emma J Welsh"><CRIT_OUTCOMES_PRIMARY MODIFIED="2014-12-03 01:22:12 +1100" MODIFIED_BY="Emma J Welsh"><OL><LI>Treatment failure (e.g. the need for additional treatment, hospital admission/re-admission for index episode, return to emergency department, unscheduled physician visit for the index episode).</LI><LI>Relapse after treatment (e.g. treatment for new acute exacerbation, re-admission or hospitalisation for COPD).</LI><LI>Adverse drug effects.</LI></OL></CRIT_OUTCOMES_PRIMARY><CRIT_OUTCOMES_SECONDARY MODIFIED="2014-12-03 01:22:36 +1100" MODIFIED_BY="Emma J Welsh"><OL><LI>Mortality.</LI><LI>Lung function.</LI><LI>Length of hospital stay.</LI><LI>Arterial blood gases.</LI><LI>Symptom scores.</LI><LI>Quality of life.</LI></OL><P>Time period for assessment of continuous outcomes: Early response was measured on or before day seven of treatment, and end of treatment response measurements were made at the time point equivalent to the end of the longer treatment period.</P></CRIT_OUTCOMES_SECONDARY></CRIT_OUTCOMES></SELECTION_CRITERIA><SEARCH_METHODS MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><ELECTRONIC_SEARCHES MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><P>We identified trials from the Cochrane Airways Trials Register, which is maintained by the Information Specialist for the Group. The Cochrane Airways Trials Register contains studies identified from several sources:</P><OL><LI>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), through the Cochrane Register of Studies Online (crso.cochrane.org);</LI><LI>Weekly searches of MEDLINE Ovid SP 1946 to date;</LI><LI>Weekly searches of Embase Ovid SP 1974 to date;</LI><LI>Monthly searches of PsycINFO Ovid SP 1967 to date;</LI><LI>Monthly searches of CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature) 1937 to date;</LI><LI>Monthly searches of AMED EBSCO (Allied and Complementary Medicine);</LI><LI>Handsearches of the proceedings of major respiratory conferences.</LI></OL><P>Studies contained in the Trials Register are identified through search strategies based on the scope of Cochrane Airways. Details of these strategies, as well as a list of handsearched conference proceedings are in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P><P>We conducted additional supplementary searches of MEDLINE (PubMed platform, dates covered 1950 to March 2017) and CENTRAL (2017, Issue 3). EMBASE (Embase.com platform, dates covered 1947 to July 2014) searches were conducted in previous versions of this review.. Search strategies used in the Cochrane Airways Register of Trials and other databases are shown in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P><P>For this review update, searches were conducted in the Cochrane Airways Group Register of Trials, and in the other databases in March 2017.</P></ELECTRONIC_SEARCHES><OTHER_SEARCHES MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><P>Bibliographies of RCTs and review articles identified for inclusion were searched for additional papers. Registers of ongoing trials at Clinicaltrials.gov and the WHO trial portal were searched in March 2017.</P></OTHER_SEARCHES></SEARCH_METHODS><DATA_COLLECTION MODIFIED="2014-12-04 22:32:11 +1100" MODIFIED_BY="Emma J Welsh"><STUDY_SELECTION MODIFIED="2014-12-04 22:27:11 +1100" MODIFIED_BY="Emma J Welsh"><P>All potentially relevant trials were assessed for relevance by at least two review authors (DT, CW), who screened the full text to independently select trials for inclusion and to identify and record reasons for exclusion of ineligible studies. We resolved disagreements through discussion or, if required, we consulted a third person (JW). We identified and excluded duplicates and collated multiple reports of the same study, so that each study (rather than each report) was the unit of interest in the review. We recorded the selection process as a PRISMA flow diagram and in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P><P>We initially screened all studies using the following criteria.</P><OL><LI>Acute exacerbation of COPD?</LI><LI>Systemic corticosteroids as intervention?</LI><LI>Comparison of short-duration (seven or fewer days) versus longer-duration (longer than seven days) corticosteroid therapy?</LI><LI>Randomised controlled trial?</LI></OL><P>We noted other arms and reasons for study exclusion when appropriate. We determined exclusion using the criteria listed above and categorised the following as applicable.</P><OL><LI>Not different durations of steroids.</LI><LI>Not exacerbations of COPD.</LI><LI>Not treatment with systemic corticosteroids.</LI><LI>Review or other type of article.</LI></OL><P>We also assessed each study for accuracy of the diagnosis of COPD using the following criteria (<LINK REF="REF-GOLD-2014" TYPE="REFERENCE">GOLD 2014</LINK>).</P><OL><LI>Did the patient have dyspnoea, chronic cough or sputum production?</LI><LI>Was there a history of exposure to risk factors including tobacco smoke; occupational dusts and chemicals; and smoke from home cooking and heating fuel?</LI><LI>Was a spirometry measurement of the FEV<SUB>1</SUB>/FVC ratio less than 0.7 post bronchodilator?</LI></OL></STUDY_SELECTION><DATA_EXTRACTION MODIFIED="2014-12-03 01:24:53 +1100" MODIFIED_BY="Emma J Welsh"><P>We used a data collection form to document study characteristics and outcome data. Two review authors (DT, CW) extracted the following study characteristics from included studies.</P><OL><LI>Methods: study design, total duration of study, number of study centres and locations, study setting, withdrawals and date of study.</LI><LI>Participants: N, mean age, age range, gender, COPD diagnostic criteria, diagnostic criteria for exacerbation, baseline lung function, smoking history, inclusion criteria and exclusion criteria.</LI><LI>Interventions: systemic corticosteroid treatment dose/schedule, concomitant medications and excluded medications.</LI><LI>Outcomes: primary and secondary outcomes specified and collected and time points reported.</LI><LI>Notes: funding for trial and notable conflicts of interest of trial authors.</LI></OL><P>Two review authors (two of JW, DT, CW) independently extracted outcome data from included studies. Results presented in graphical form were extracted using the software Plot Digitizer. When results were available as means with interquartile ranges, standard deviation was based on the width of the interquartile range&#8212;approximately 1.35. standard deviations.</P><P>Data were entered into Review Manager (by JW, DT, CW) and were double-checked by a second review author. We checked that data were entered correctly by comparing data presented in the systematic review against data provided in the study reports.</P></DATA_EXTRACTION><QUALITY_ASSESSMENT MODIFIED="2014-12-04 22:32:11 +1100" MODIFIED_BY="Emma J Welsh"><P>Two review authors (of JW, CW, DT) independently assessed the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved disagreements by discussion or by involving another review author. We assessed risk of bias according to the following domains.</P><OL><LI>Random sequence generation.</LI><LI>Allocation concealment.</LI><LI>Blinding of participants and personnel.</LI><LI>Blinding of outcome assessment.</LI><LI>Incomplete outcome data.</LI><LI>Selective outcome reporting.</LI><LI>Presence of other bias(es).</LI></OL><P>We graded each potential source of bias as high, low or unclear, and provided a quote from the study report, together with a justification for our judgement, in the 'Risk of bias' table. We summarised risk of bias judgements across different studies for each of the domains listed. When information on risk of bias was related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table.</P><P>When considering treatment effects, we took into account the risk of bias for studies that contributed to this outcome.</P></QUALITY_ASSESSMENT><EFFECT_MEASURES MODIFIED="2014-12-03 01:25:52 +1100" MODIFIED_BY="Emma J Welsh"><P>For continuous variables, data were analysed as mean differences (MDs) with 95% confidence intervals (CIs). Standardised mean differences (SMDs) with 95% CIs were used when different scales of measurement had been used for an outcome. The SMD is a statistic that expresses the difference in means between treatment groups in units of the pooled standard deviation. Dichotomous outcomes were analysed using Mantel-Haenszel odds ratios with 95% CIs. When events were rare, we employed the Peto odds ratio. Scale data were entered with a consistent direction of effect.</P><P>We undertook meta-analyses only when these were meaningful&#8212;when treatments, participants and the underlying clinical question were similar. When data were skewed, we described them narratively.</P><P>For 'time-to-event' outcomes such as log hazard ratios, the fixed-effect generic inverse variance outcome was used to combine results. This method provides a weighted average of the effect estimates of separate studies (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Number needed to treat for an additional beneficial outcome was calculated from the pooled odds ratio and its confidence interval, using baseline risk in the control group.</P></EFFECT_MEASURES><UNIT_OF_ANALYSIS MODIFIED="2014-12-03 01:25:54 +1100" MODIFIED_BY="Emma J Welsh"><P>We analysed dichotomous data using participants as the unit of analysis. For continuous data, the MD based on change from baseline was preferred over the MD based on absolute values when both were available.</P></UNIT_OF_ANALYSIS><MISSING_DATA MODIFIED="2014-12-03 01:26:04 +1100" MODIFIED_BY="Emma J Welsh"><P>We contacted investigators to obtain missing numerical outcome data when possible (e.g. when a study was reported as an abstract only). When this was not possible, and when missing data were thought to introduce serious bias, we performed a sensitivity analysis to explore the impact of including such studies in the overall assessment of results.</P></MISSING_DATA><HETEROGENEITY_ASSESSMENT MODIFIED="2014-12-03 01:26:21 +1100" MODIFIED_BY="Emma J Welsh"><P>An assessment of possible heterogeneity, when the null hypothesis is that all studies are evaluating the same effect, was carried out for pooled effects using a Breslow-Day test of heterogeneity; the Chi<SUP>2</SUP> test measures the deviation of observed effect sizes from an underlying overall effect. This test has low power for detecting true heterogeneity when studies have small sample size or are few in number, hence we used a P value of 0.10 (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>). In addition, the I<SUP>2</SUP> statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), was used. Statistical heterogeneity was interpreted as follows: 0% to 40% might not be important, 30% to 60% may represent moderate heterogeneity and 50% to 90% may represent substantial heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P><P>We assessed clinical and methodological heterogeneity by recording differences in study design and participant characteristics between individual studies. When we found substantial heterogeneity, we reported this and explored possible causes by performing prespecified subgroup analysis.</P></HETEROGENEITY_ASSESSMENT><BIAS_ASSESSMENT MODIFIED="2014-12-03 01:26:33 +1100" MODIFIED_BY="Emma J Welsh"><P>We tried to minimise reporting bias from non-publication of studies or selective outcome reporting by using a broad search strategy. We checked references of included studies and relevant systematic reviews, and we contacted study authors to request additional outcome data. To assess the presence of publication bias, we visually inspected funnel plots when 10 or more studies contributed to the analysis for a specified outcome.</P></BIAS_ASSESSMENT><DATA_SYNTHESIS MODIFIED="2014-12-03 01:27:10 +1100" MODIFIED_BY="Emma J Welsh"><P>Data were pooled using Review Manager 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We used a fixed-effect model, and when heterogeneity could not be explained, we performed a sensitivity analysis using a random-effects model. We presented the findings of our primary outcomes in a 'Summary of findings' table according to recommendations provided in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (generated with the use of GradePro software).</P></DATA_SYNTHESIS><SUBGROUP_ANALYSIS MODIFIED="2014-12-03 01:27:47 +1100" MODIFIED_BY="Emma J Welsh"><P>When we detected statistically significant heterogeneity (P value &lt; 0.10), several options were available. We explored the clinical diversity of studies through prespecified subgroup analyses by comparing the following factors.<BR/></P><OL><LI>Definition of COPD.</LI><LI>Aspects of study quality (e.g. concealment of allocation).</LI><LI>Characteristics of participants.</LI></OL><P>We considered random-effects analysis methods (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) when heterogeneity was unexplained and study sizes were large, or when study findings were not pooled.</P><P>We performed subgroup analyses, stratified by the following variables, when possible.</P><OL><LI>Inpatient versus outpatient.</LI><LI>Studies that included participants previously treated with corticosteroids (inhaled and systemic).</LI></OL></SUBGROUP_ANALYSIS><SENSITIVITY_ANALYSIS MODIFIED="2014-12-03 01:28:13 +1100" MODIFIED_BY="Emma J Welsh"><P>In assessment of heterogeneity, possible causes arising from details of study design were considered. Sensitivity analyses were performed using a random-effects model versus a fixed-effect model for risk of bias and other potential confounders.</P></SENSITIVITY_ANALYSIS></DATA_COLLECTION></METHODS><RESULTS MODIFIED="2017-12-19 12:17:04 +1100" MODIFIED_BY="[Empty name]"><STUDY_DESCRIPTION MODIFIED="2017-12-19 12:17:04 +1100" MODIFIED_BY="[Empty name]"><SEARCH_RESULTS MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><P>Of 644 unique records obtained in the 2011 searches (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), seven studies met the inclusion criteria, of which four reported data and contributed to the original meta-analysis (<LINK REF="REF-Walters-2011" TYPE="REFERENCE">Walters 2011</LINK>). One ongoing study (<LINK REF="STD-Reid-2010" TYPE="STUDY">Reid 2010</LINK>) suspended recruitment in 2010, but no data are available. Searches from 2011 to 2014 yielded 284 results in the Cochrane Airways Group Register of Trials, 39 results in CINAHL, 168 in EMBASE and 102 in CENTRAL. When the inclusion criteria were applied, one new study was identified for inclusion (<LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>), which was listed as an ongoing trial in 2011. </P><P>In March 2017, we ran an update search. This returned 417 references of which 13 were duplicate, 390 were judged as irrelevant based on title and abstract alone. 14 full text articles were assessed, 13 excluded (<B>7</B> Wrong intervention, <B>4</B> Wrong comparator, <B>2</B> Wrong study design), 1 citation belonged to an already included study (Leuppi 2013). </P><P>One on-going study was identified as of March 2017 (Leuppi 2017). </P></SEARCH_RESULTS><INCLUDED_STUDIES_DESCR MODIFIED="2014-12-03 01:32:03 +1100" MODIFIED_BY="Emma J Welsh"><P>We have provided details of the eight included studies in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table and a comparison of their main inclusion criteria and characteristics in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P><P>All eight studies with a total of 582 participants were parallel-group RCTs comparing systemic corticosteroid treatment for seven or fewer days versus treatment for longer than seven days in people with an acute exacerbation of COPD; all were conducted in hospital settings. These studies were published between 1997 and 2013. Two studies reported the definition for COPD diagnosis (<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>; <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>), and two studies specified the inclusion of participants with an FEV<SUB>1</SUB> below 50% predicted (<LINK REF="STD-Gomaa-2008" TYPE="STUDY">Gomaa 2008</LINK>; <LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>) or below 35% predicted (<LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK>). Two studies (<LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>; <LINK REF="STD-Sirichana-2008" TYPE="STUDY">Sirichana 2008</LINK>) provided a specific symptom-based definition of an acute exacerbation.</P><P>Studies varied in size from 21 to 314 participants; the mean age of participants was between 65 and 73 years, and the proportion of female participants ranged from 6% to 42% (in four studies that reported these data). Participants had severe to very severe COPD; in two studies baseline mean FEV<SUB>1</SUB> ranged from 0.5 to 0.8 litres, and in two other studies baseline mean FEV<SUB>1</SUB> ranged from 25% to 33% predicted.</P><P>Five studies used only oral prednisolone (<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>; <LINK REF="STD-Gomaa-2008" TYPE="STUDY">Gomaa 2008</LINK>; <LINK REF="STD-Rahman-2004" TYPE="STUDY">Rahman 2004</LINK>; <LINK REF="STD-Sirichana-2008" TYPE="STUDY">Sirichana 2008</LINK>; <LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>) at a dose of 30 mg daily, except <LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>, which provided oral prednisolone 2.5 mg/kg in the short-duration arm and a tapered dose (0.6 mg/kg/d for seven days followed by 0.3 mg/kg/d for seven days) in the longer-duration arm. Three studies used intravenous corticosteroid initially in both arms for 24 or 72 hours: methylprednisolone in <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK> and <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK>, and an unspecified intravenous corticosteroid in <LINK REF="STD-Salam-1998" TYPE="STUDY">Salam 1998</LINK>. Participants then received systemic corticosteroids intravenously for seven days in <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK> and orally for seven days in <LINK REF="STD-Salam-1998" TYPE="STUDY">Salam 1998</LINK> in the longer-duration arm. All participants in <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK> received oral prednisone from day 2 onwards for the appropriate treatment duration.</P><P>Duration of treatment in the short-course arm was three days in <LINK REF="STD-Salam-1998" TYPE="STUDY">Salam 1998</LINK>, <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK> and <LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>; five days in <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK> and <LINK REF="STD-Sirichana-2008" TYPE="STUDY">Sirichana 2008</LINK>; and seven days in <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>, <LINK REF="STD-Gomaa-2008" TYPE="STUDY">Gomaa 2008</LINK> and <LINK REF="STD-Rahman-2004" TYPE="STUDY">Rahman 2004</LINK>. The duration of longer-course treatment was 10 days in <LINK REF="STD-Salam-1998" TYPE="STUDY">Salam 1998</LINK>, <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK> and <LINK REF="STD-Sirichana-2008" TYPE="STUDY">Sirichana 2008</LINK>; 14 days in <LINK REF="STD-Gomaa-2008" TYPE="STUDY">Gomaa 2008</LINK>, <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>, <LINK REF="STD-Rahman-2004" TYPE="STUDY">Rahman 2004</LINK> and <LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>; and 15 days in <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>.</P><P>Three studies were published as full papers (<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>; <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>; <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK>), and additional data were supplied by the study author for <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>. Of five studies published only as abstracts in conference proceedings, data were supplied by authors for <LINK REF="STD-Sirichana-2008" TYPE="STUDY">Sirichana 2008</LINK> and <LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>. Despite at least two requests, no data were made available for <LINK REF="STD-Gomaa-2008" TYPE="STUDY">Gomaa 2008</LINK>, <LINK REF="STD-Rahman-2004" TYPE="STUDY">Rahman 2004</LINK> and <LINK REF="STD-Salam-1998" TYPE="STUDY">Salam 1998</LINK>.</P></INCLUDED_STUDIES_DESCR><EXCLUDED_STUDIES_DESCR MODIFIED="2017-12-19 12:17:04 +1100" MODIFIED_BY="[Empty name]"><P>A total of 23 studies with reasons for exclusion are listed in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P></EXCLUDED_STUDIES_DESCR></STUDY_DESCRIPTION><STUDY_QUALITY MODIFIED="2014-12-03 01:32:45 +1100" MODIFIED_BY="Emma J Welsh"><P>The methodological quality of the published included trials was good; they were determined to have low risk of selection, performance, detection and attrition bias. Risk of bias was unclear in studies available only as abstracts (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P><ALLOCATION MODIFIED="2014-12-03 01:32:34 +1100" MODIFIED_BY="Emma J Welsh"><P>In four studies (<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>; <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>; <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK>; <LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>) the randomisation procedure was adequate, but sequence generation was unclear. Allocation concealment was adequate in four studies (<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>; <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>; <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK>; <LINK REF="STD-Sirichana-2008" TYPE="STUDY">Sirichana 2008</LINK>) but was not described in four studies.</P></ALLOCATION><BLINDING MODIFIED="2014-12-03 01:32:39 +1100" MODIFIED_BY="Emma J Welsh"><P>Four studies were double blind (<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>; <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>; <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK>; <LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>). One study (<LINK REF="STD-Sirichana-2008" TYPE="STUDY">Sirichana 2008</LINK>) was not blinded to participants or investigators. Blinding was unclear in the three other studies, although one study (<LINK REF="STD-Gomaa-2008" TYPE="STUDY">Gomaa 2008</LINK>) stated that the study was single blinded but provided no further details.</P></BLINDING><EXCLUSIONS MODIFIED="2014-12-03 01:32:42 +1100" MODIFIED_BY="Emma J Welsh"><P>Incomplete data were adequately addressed in four studies (<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>; <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>; <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK>; <LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>), but risk of bias was judged high in <LINK REF="STD-Sirichana-2008" TYPE="STUDY">Sirichana 2008</LINK> and was unclear in three studies.</P></EXCLUSIONS><SELECTIVE_REPORTING MODIFIED="2014-12-03 01:32:45 +1100" MODIFIED_BY="Emma J Welsh"><P>Three studies were assessed as free of selective reporting (<LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>; <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK>; <LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>), but risk of bias was unclear in five studies.</P></SELECTIVE_REPORTING></STUDY_QUALITY><INTERVENTION_EFFECTS MODIFIED="2014-12-03 02:37:28 +1100" MODIFIED_BY="Emma J Welsh"><SUBSECTION><HEADING LEVEL="3">Primary outcomes</HEADING><SUBSECTION><HEADING LEVEL="5">1.1 Treatment failure</HEADING><P>Four studies reported treatment failure that occurred during the index exacerbation, and the definition was provided in three studies (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). No significant difference was noted in the likelihood of treatment failure between systemic corticosteroid for seven or fewer days and longer than seven days (n = 457; odds ratio (OR) 0.72, 95% confidence interval (CI) 0.36 to 1.46; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), and no statistical heterogeneity was observed. This result is equivalent to 22 fewer treatment failures per 1000 (95% CI 51 fewer to 34 more). The outcome was downgraded for imprecision and was rated as having moderate quality because the confidence intervals for the pooled effect included important benefit and potential harm.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">1.2 Relapse</HEADING><P>Relapse was measured as a new acute exacerbation or hospital admission for COPD in four studies: <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK> (follow-up period not stated), <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK> and <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK> (six-month follow-up) and <LINK REF="STD-Sirichana-2008" TYPE="STUDY">Sirichana 2008</LINK> (30-day follow-up). No significant difference was reported between systemic corticosteroid use for seven or fewer days and for longer than seven days (n = 478; OR 1.04, 95% CI 0.7 to 1.56; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>), and no statistical heterogeneity was observed. The outcome was downgraded for imprecision and was rated as having moderate quality because the confidence intervals for the pooled effect included important benefit and potential harm.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">1.3 Time to re-exacerbation</HEADING><P>Time to next COPD exacerbation, defined as "acute-onset worsening of the patient&#8217;s condition beyond day-to-day variations requiring interaction with a healthcare provider which could occur during the index exacerbation or during follow-up," over six months of follow-up was reported in one study (<LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>). This study adopted an a priori non-inferiority definition, by which the proportion of participants with re-exacerbation during follow-up should be no more than 65% compared with 50% for standard treatment for an exacerbation, yielding a critical hazard ratio of 1.515. Time to the next exacerbation did not differ in this one large study, which was powered to detect non-inferiority and compared five days versus 14 days of systemic corticosteroid treatment (n = 311; hazard ratio (HR) 0.95, 95% CI 0.66 to 1.37; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">1.4 to 1.6 Adverse effects</HEADING><P><U>1.4</U> Hyperglycaemia: In two studies (<LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>; <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK>) no difference was noted in the likelihood of hyperglycaemia between systemic corticosteroid for seven or fewer days and longer than seven days (n = 345; OR 0.99, 95% CI 0.64 to 1.53; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), and no heterogeneity was observed. The outcome was downgraded for imprecision and was rated as having moderate quality because the confidence intervals for the pooled effect included important benefit and potential harm.</P><P><U>1.5</U> Hypertension: In one trial (<LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>)no difference was noted in the likelihood of hypertension between systemic corticosteroid for seven or fewer days and longer than seven days (n = 311; OR 0.61, 95% CI 0.31 to 1.22; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P><P><U>1.6</U> Other adverse effects were reported in five studies and included gastrointestinal tract bleeding, symptomatic gastrointestinal reflux, symptoms of congestive heart failure or ischaemic heart disease, sleep disturbance, fractures and depression. No difference was noted in the likelihood of another adverse event between systemic corticosteroids for seven or fewer days and longer than seven days (n = 503; OR 0.89, 95% CI 0.46 to 1.69; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). The outcome was downgraded for imprecision and was rated as having moderate quality because the confidence intervals for the pooled effect included important benefit and potential harm.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Secondary outcomes</HEADING><SUBSECTION><HEADING LEVEL="5">1.7 Mortality</HEADING><P>In two studies the likelihood of mortality did not differ between systemic corticosteroid for seven or fewer days and longer than seven days (n = 336; OR 0.91, 95% CI 0.40 to 2.06; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). The outcome was downgraded for imprecision and was rated as having moderate quality because the confidence intervals for the pooled effect included important benefit and potential harm.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">1.8 Length of hospitalisation</HEADING><P>In three studies no difference was noted in length of hospital stay between systemic corticosteroid for seven or fewer days and longer than seven days (n = 421; mean difference (MD) -0.61 days, 95% CI -1.51 to 0.28; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). The outcome was downgraded for imprecision and was rated as having moderate quality because the confidence intervals for the pooled effect included important benefit and potential harm.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">1.9 to 1.14 Lung function</HEADING><P>In three studies no difference was noted in absolute FEV<SUB>1</SUB> measured within seven days between systemic corticosteroid for seven or fewer days and longer than seven days (n = 96; MD -0.07 litres, 95% CI -0.19 to 0.05; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>), and no heterogeneity was observed. <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK> reported lung function as FEV<SUB>1</SUB> percentage predicted and noted no difference between systemic corticosteroid for seven or fewer days and longer than seven days (n = 289; MD 0.76%, 95% CI -3.15 to 4.66; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). In three studies no difference was noted in early response of FVC between systemic corticosteroid for seven or fewer days and longer than seven days (n = 97; MD 0.01 L, 95% CI -0.20 to 0.22; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>), and no statistical heterogeneity was observed.</P><P>For lung function measured at the end of treatment in four studies, no difference was noted in FEV<SUB>1</SUB> between systemic corticosteroid for seven or fewer days and longer than seven days (n = 187; MD -0.04 litres, 95% CI -0.19 to 0.10; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>); important heterogeneity was observed (Chi² = 7.17, df = 3 (P value 0.07), I² = 58%). The outcome was rated as having very low quality and was downgraded for imprecision because the confidence intervals for the pooled effect included important benefit and potential harm, and risk of attrition bias and inconsistency were due to unexplained heterogeneity. In <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>, no difference was noted in FEV<SUB>1</SUB> percentage predicted at 30 days between systemic corticosteroid for seven or fewer days and more than seven days (n = 289; MD 1.29%, 95% CI -3.35 to 5.93; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). In three studies no difference was noted in FVC at the end of treatment between systemic corticosteroid for seven or fewer days and longer than seven days (n = 99; MD -0.12, 95% CI -0.33 to 0.09; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>), and no heterogeneity was observed.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">1.15 to 1.17 Arterial blood gases</HEADING><P><LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK> reported partial pressure of oxygen in arterial blood (PaO<SUB>2</SUB>) before seven days (n = 34). No difference was noted between treatment with systemic corticosteroid for seven or fewer days and longer than seven days (MD -0.20 mmHg; 95% CI -9.21 to 8.81; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P><P>In two studies (n = 121) at completion of treatment, no difference was noted in PaO<SUB>2</SUB> after 10 to 14 days of follow-up between systemic corticosteroid for seven or fewer days and longer than seven days (MD -1.38 mmHg; 95% CI -4.96 to 2.21; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P><P>In <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK> (n = 34) no difference was noted in partial pressure of carbon dioxide in arterial blood (PaCO<SUB>2</SUB>) after three days (MD -1.80 mmHg, 95% CI -11.14 to 7.54) or after 10 days (MD 1.50 mmHg, 95% CI -5.20 to 8.20) between treatment with systemic corticosteroid for seven or fewer days and longer than seven days (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">1.18 to 1.19 Symptom scores</HEADING><P>In two studies no differences were noted in dyspnoea scores when measured before seven days between systemic corticosteroid for seven or fewer days and longer than seven days (n = 320; standardised mean difference (SMD) -0.08, 95% CI -0.29 to 0.14; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>), and no statistical heterogeneity was observed. When expressed on the Medical Research Council (MRC) scale (1 to 5), this would equate to 0.1 units better (95% CI 0.4 better to 0.2 worse).</P><P>In four studies at the end of treatment, no difference was noted in dyspnoea scores between systemic corticosteroid for seven or fewer days and longer than seven days (n = 404; SMD 0.16, 95% CI -0.03 to 0.36; <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>),and moderate heterogeneity was observed (Chi² = 5.89, df = 3 (P value 0.12), I² = 49%). When expressed on the MRC scale (1 to 5), this would equate to 0.2 units worse (95% CI 0.04 better to 0.45 worse).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">1.20 to 1.21 Quality of life</HEADING><P>Health-related quality of life was assessed in <LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK> by using the acute bronchitis health-related quality-of-life interview, which measures changes in health-related quality of life among patients treated for chronic lung disease; it consists of 22 items in four domains: activity-related limitations (six items); effects of symptoms (eight items); fatigue (four items); and emotional functioning (four items). Each item is rated on a 7-point scale, and a difference of 0·5 points is taken to be the smallest important difference (<LINK REF="REF-Evans-2002" TYPE="REFERENCE">Evans 2002</LINK>). No difference was reported in overall score between systemic corticosteroid for seven or fewer days and longer than seven days when measured before seven days (n = 290; MD 0.03, 95% CI -0.15 to 0.21; <LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>) or after 30 days (n = 263; MD 0.07, 95% CI -0.11 to 0.25; <LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>).</P></SUBSECTION></SUBSECTION></INTERVENTION_EFFECTS></RESULTS><DISCUSSION MODIFIED="2014-12-04 22:33:42 +1100" MODIFIED_BY="Emma J Welsh"><SUMMARY_OF_RESULTS MODIFIED="2014-12-03 02:37:45 +1100" MODIFIED_BY="Emma J Welsh"><SUBSECTION><HEADING LEVEL="2">SCS treatment for seven or fewer days compared with SCS treatment for longer than seven days for acute exacerbations of COPD</HEADING><P>Please see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P><P>The likelihood of treatment failure did not differ between treatment with systemic corticosteroids for seven or fewer days and longer than seven days over 10 to 14 days of follow-up in four studies, although wide confidence intervals around the estimate were reported (457 participants; odds ratio (OR) 0.72, 95% confidence interval (CI) 0.36 to 1.46). This difference equates to 22 fewer people experiencing treatment failure per 1000 (95% CI 51 fewer to 34 more) for short-duration corticosteroid treatment. Similarly, no difference was noted for re-exacerbation over 14 to 180 days of follow-up in four studies (478 participants; OR 1.04, 95% CI 0.7 to 1.56); this equates to nine fewer people with re-exacerbation per 1000 (95% CI 68 fewer to 100 more) for longer-duration corticosteroid treatment. Time to the next COPD exacerbation did not differ in one large study, which was powered to detect non-inferiority and compared five days versus 14 days of systemic corticosteroid treatment (n = 311; hazard ratio 0.95, 95% CI 0.66 to 1.37).</P><P>The likelihood of adverse drug effects when systemic corticosteroids given for seven or fewer days were compared with systemic corticosteroids given for longer than seven days did not differ for hyperglycaemia in two studies with data of moderate quality (n = 345; OR 0.99, 95% CI 0.64 to 1.53), nor for a range of other drug effects in five studies with data of low quality (n = 503; OR 0.88, 95% CI 0.46 to 1.69). Mortality during follow-up of between 14 days and 180 days did not differ in two studies (n = 336; OR 0.91, 95% CI 0.40 to 2.06) with data of moderate quality.</P><P>No differences in length of hospitalisation were noted in three studies (n = 421; MD -0.61 days, 95% CI -1.51 to 0.28) with data of moderate quality, and no differences in lung function at the end of treatment were reported in four studies (n = 187; mean difference (MD) in forced expiratory volume in one second (FEV<SUB>1</SUB>) -0.04 L, 95% CI -0.19 to 0.10) with data of very low quality. No difference in health-related quality of life was observed in one study with data of moderate quality.</P></SUBSECTION></SUMMARY_OF_RESULTS><APPLICABILITY_OF_FINDINGS MODIFIED="2014-12-03 02:38:01 +1100" MODIFIED_BY="Emma J Welsh"><P>Five of the eight included studies were not published as full articles. Meta-analyses were limited by the need to omit three studies for which no data could be extracted from abstracts, or for which no data were supplied by study authors (<LINK REF="STD-Gomaa-2008" TYPE="STUDY">Gomaa 2008</LINK>; <LINK REF="STD-Rahman-2004" TYPE="STUDY">Rahman 2004</LINK>; <LINK REF="STD-Salam-1998" TYPE="STUDY">Salam 1998</LINK>). The small number of trials meant that no subgroup analyses were performed.</P><P>One study (<LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>) closed prematurely because of the difficulty of recruiting participants who met the inclusion criterion stating that participants should not have commenced oral steroid treatment before recruitment. This stipulation also caused low recruitment for the ongoing study (<LINK REF="STD-Reid-2010" TYPE="STUDY">Reid 2010</LINK>). In many countries this is likely to be a barrier to conducting inpatient studies comparing corticosteroid treatment of shorter duration versus conventional duration of up to 14 days, as guidelines and action plans recommend early initiation of therapy.</P><P>As this review excluded studies in which participants received assisted ventilation (invasive or non-invasive), the findings are not generalisable to people on assisted ventilation. Doses of systemic corticosteroid given to patients admitted to an intensive care unit (ICU) who may require assisted ventilation usually are much higher than those given in the studies included in this review (<LINK REF="REF-Kiser-2014" TYPE="REFERENCE">Kiser 2014</LINK>). An observational study evaluating corticosteroid use in patients admitted to the ICU with an exacerbation of chronic obstructive pulmonary disease (COPD) concluded that fewer deaths and shorter stays in hospital occurred among people treated with systemic corticosteroid at doses equivalent to less than 240 mg per day of methylprednisolone. An observational study involving patients admitted to a non-intensive care setting with an exacerbation of COPD who received systemic corticosteroids did not assess duration of treatment; this study found that low-dose corticosteroids (20 to 80 mg/d prednisone equivalent) administered orally were not associated with worse outcomes than were seen with high-dose intravenous therapy (120 to 800 mg/d prednisone equivalent) during the first two hospital days (<LINK REF="REF-Lindenauer-2010" TYPE="REFERENCE">Lindenauer 2010</LINK>).</P></APPLICABILITY_OF_FINDINGS><QUALITY_OF_EVIDENCE MODIFIED="2014-12-03 02:38:08 +1100" MODIFIED_BY="Emma J Welsh"><P>Studies that contributed to the meta-analysis were at low risk of selection bias, although one study was at high risk of performance and detection bias from lack of blinding. Some heterogeneity between studies was observed with regard to the inclusion criteria. Many studies did not provide details of their inclusion criteria, including their definition of an acute exacerbation of COPD. Only three studies specified the severity of COPD in participants based on their lung function reading (FEV<SUB>1</SUB>) upon admission. Thresholds to define severity included FEV<SUB>1</SUB> less than 50% predicted in <LINK REF="STD-Gomaa-2008" TYPE="STUDY">Gomaa 2008</LINK> and <LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>, and less than 35% predicted in <LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK>. Variation in the systemic corticosteroid used in the included studies was reported: Five used oral prednisolone, one at high then tapering dose (<LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>), and two used intravenous corticosteroid. However, oral and intravenous corticosteroids have been shown to have equal efficacy and should not, therefore, contribute to any heterogeneity (<LINK REF="REF-Therapeutic-Guidelines-2009" TYPE="REFERENCE">Therapeutic Guidelines 2009</LINK>). Sensitivity analyses according to risks of bias due to lack of blinding or route of corticosteroid administration had no significant effects on pooled results (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Duration of follow-up varied between studies and was not stated in four studies. Follow-up periods may have been too short to allow detection of potential differences in relapse, mortality and readmission. Lack of data for pooling limited the analysis of some outcomes that are important to patients, such as quality of life.</P></QUALITY_OF_EVIDENCE><POTENTIAL_BIASES MODIFIED="2014-12-04 22:33:42 +1100" MODIFIED_BY="Emma J Welsh"><P>The review authors made every effort to identify all relevant published and unpublished studies by using additional methods to identify studies that might not have been found during the main electronic search (e.g. searching drug company databases and clinical trial registration sites, checking reference lists). We did not routinely contact individual trial authors for additional data unless outcomes were clearly selectively reported. All review authors adhered to the most recent best practice guidelines in terms of study selection, resolution of disagreements, data extraction and analysis to reduce bias and error. We included all data obtained from the included studies, even those from studies at higher risk of bias with regard to participant withdrawals, such as <LINK REF="STD-Sirichana-2008" TYPE="STUDY">Sirichana 2008</LINK>, but we performed sensitivity analysis to check whether omitting the study changed the results. We obtained data for one study (<LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK>) from an author from this review team; however, data extraction and analysis were performed in the same way as for the other studies.</P></POTENTIAL_BIASES></DISCUSSION><CONCLUSIONS MODIFIED="2014-12-03 02:38:28 +1100" MODIFIED_BY="Emma J Welsh"><IMPLICATIONS_PRACTICE MODIFIED="2014-12-03 02:38:28 +1100" MODIFIED_BY="Emma J Welsh"><P>We have obtained information from one new large study that has increased our confidence that five days of oral corticosteroids is likely to be sufficient for treatment of patients with exacerbations of COPD, and this review suggests that the likelihood that shorter courses of systemic corticosteroids (of around five days) lead to worse outcomes compared with longer (10 to 14 days) courses is low. Most evidence was graded as having moderate quality as the result of imprecision; further research may have an important impact on our confidence in the estimates of effect or may change these estimates.</P></IMPLICATIONS_PRACTICE><IMPLICATIONS_RESEARCH MODIFIED="2014-12-03 02:38:28 +1100" MODIFIED_BY="Emma J Welsh"><P>The studies in this review did not include people with mild or moderate COPD, and further studies are required to compare short-duration systemic corticosteroid versus conventional, longer-duration treatment for people with acute exacerbations in this group. Studies should use validated patient-reported exacerbation outcomes (<LINK REF="REF-Jones-2014" TYPE="REFERENCE">Jones 2014</LINK>; <LINK REF="REF-Leidy-2014" TYPE="REFERENCE">Leidy 2014</LINK>), and this review reinforces the need for researchers to publish results of all completed clinical trials. However, difficulties are associated with recruiting participants to studies with this clinical question in many countries in which early treatment in the community is promoted.</P></IMPLICATIONS_RESEARCH></CONCLUSIONS></BODY><ACKNOWLEDGEMENTS MODIFIED="2014-12-03 02:38:40 +1100" MODIFIED_BY="Emma J Welsh"><P>We acknowledge the work of Wendy Wang, Carla Morley and Amir Soltani, as authors of the previous version of this review, published in 2011.</P><P>We acknowledge the assistance of the following individuals.</P><UL><LI>Dr Worawan Sirichana, Department of Medicine, Chulalongkorn University, Bangkok, Thailand, who kindly supplied study information and data.</LI></UL><UL><LI>Dr C Xie and Dr G Chen, Department of Respiratory Medicine, First Affiliated Hospital of Zhongshan University, Guangzhou, China, who kindly supplied study information and data.</LI></UL><UL><LI>Dr Abdullah Sayiner of Ege University, Ismir, Turkey, who kindly supplied study information.</LI></UL><UL><LI>Dr W Chou and Dr M Sung, who wrote the first draft of the protocol, and Yi Foong, who provided translation from Mandarin.</LI></UL><P>Chris Cates was the Editor for this review and commented critically on the review.</P><P>TheBackground and Methods sections of this protocol/review are based on a standard template used by the Cochrane Airways Group.</P></ACKNOWLEDGEMENTS><CONFLICT_OF_INTEREST MODIFIED="2014-12-03 02:41:09 +1100" MODIFIED_BY="Emma J Welsh"><P>R Wood-Baker was chief investigator in a study contributing data to this review. Data from this study were verified and analysed by JAE Walters.</P></CONFLICT_OF_INTEREST><CONTRIBUTIONS MODIFIED="2014-12-03 02:41:09 +1100" MODIFIED_BY="Emma J Welsh"><P>JAE Walters contributed to searches and study selection, data extraction, data entry and analysis and interpretation of results. D Tan and C White contributed to searches and study selection, data extraction, data entry and analysis and interpretation of results. This review was drafted and revised by JAE Walters, and D Tan, C White and R Wood-Baker contributed to revisions.<BR/></P></CONTRIBUTIONS><PRO_REV_DIFF MODIFIED="2014-12-03 02:41:09 +1100" MODIFIED_BY="Emma J Welsh"><P>Adverse events were included as a primary outcome, and the order of the secondary outcomes was changed. Methods were updated to apply the latest intervention methods, as required for a Cochrane review, and a 'Summary of findings' table was included.<BR/></P></PRO_REV_DIFF><PUBLIC_NOTES/></MAIN_TEXT><STUDIES_AND_REFERENCES MODIFIED="2018-03-05 09:29:26 +0000" MODIFIED_BY="Emma Dennett">
<STUDIES MODIFIED="2017-12-20 02:51:47 +1100" MODIFIED_BY="Emma J Dennett">
<INCLUDED_STUDIES MODIFIED="2017-12-19 12:26:40 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Chen-2005" MODIFIED="2014-09-25 20:07:30 +1000" MODIFIED_BY="Emma Jackson" NAME="Chen 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-27 17:05:19 +1000" MODIFIED_BY="Julia AE Walters" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen G, Xie C</AU>
<TI>The efficacy and treatment length of oral corticosteroids in patients with acute exacerbations of chronic obstructive pulmonary disease [Abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>Suppl 49</NO>
<PG>Abstract No. 1966</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923538"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-25 20:07:30 +1000" MODIFIED_BY="Emma Jackson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chen G, Xie CM, Luo YF</AU>
<TI>[The effects and therapeutic duration of oral corticosteroids in patients with acute exacerbation of chronic obstructive pulmonary diseases]. [Chinese]</TI>
<SO>Chinese Journal of Tuberculosis and Respiratory Diseases [Chung-Hua Chieh Ho Ho Hu Hsi Tsa Chih]</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>8</NO>
<PG>577-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923539"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923537"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Gomaa-2008" MODIFIED="2017-12-19 12:26:40 +1100" MODIFIED_BY="[Empty name]" NAME="Gomaa 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-12-19 12:26:40 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gomaa M, Faramawy M, Ibrahim H</AU>
<TI>Duration of systemic corticosteroids treatment in COPD exacerbations [Abstract]</TI>
<SO>European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin</SO>
<YR>2008</YR>
<PG>[P3601]</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923541"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923540"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leuppi-2013" MODIFIED="2017-12-19 12:25:58 +1100" MODIFIED_BY="[Empty name]" NAME="Leuppi 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-11-16 15:12:32 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher et al</AU>
<TI>Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial</TI>
<SO>JAMA</SO>
<YR>2013</YR>
<VL>309</VL>
<NO>21</NO>
<PG>2223-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7743984"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-12-19 12:25:58 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuetz P, Leuppi JD, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, Miedinger D, Mueller B, Scherr A, Schindler C, Stoeckli R, Viatte S, von Garnier C, Tamm M, Rutishauser J</AU>
<TI>Prospective analysis of adrenal function in patients with acute exacerbations of COPD: the Reduction in the Use of Corticosteroids in Exacerbated COPD (REDUCE) trial</TI>
<SO>Eur J Endocrinol</SO>
<YR>2015</YR>
<VL>173</VL>
<NO>1</NO>
<PG>19-27</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7743985"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-16 15:12:43 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuetz P, Leuppi JD, Tamm M, Briel M, Bingisser R, Dürring U et al</AU>
<TI>Short versus conventional term glucocorticoid therapy in acute exacerbation of chronic obstructive pulmonary disease&#8212;the "REDUCE" trial</TI>
<SO>Swiss Medical Weekly</SO>
<YR>2011</YR>
<VL>140</VL>
<NO>18 October 2010</NO>
<PG>w13109</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923544"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923542"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Rahman-2004" MODIFIED="2014-12-08 21:12:13 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Rahman 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-12-08 21:12:13 +1100" MODIFIED_BY="Julia A.E. Walters" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdullah Al Mamun SM, Rahman S</AU>
<TI>Role of 7-day and 14-day courses of oral prednisolone treatment in acute exacerbation of COPD [Abstract]</TI>
<SO>Thorax</SO>
<YR>2011</YR>
<VL>66</VL>
<NO>Suppl 4</NO>
<PG>A172</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923546"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-25 20:35:30 +1000" MODIFIED_BY="Emma Jackson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rahman M, Abdullah A, Mamun SM, Haque MD</AU>
<TI>Role of 7-day and 14-day courses of oral prednisolone treatment in acute exacerbation of COPD [Abstract]</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>4 Suppl</NO>
<PG>839S-a</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923547"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923545"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Salam-1998" MODIFIED="2014-09-25 20:43:00 +1000" MODIFIED_BY="Emma Jackson" NAME="Salam 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-09-25 20:43:00 +1000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salam T, Akers SM, Lotano R, Arnold GK, Bartter T, Pratter MR et al</AU>
<TI>Optimal duration of corticosteroid therapy in the treatment of exacerbations of chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>3 Suppl</NO>
<PG>A801</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923549"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923548"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sayiner-2001" MODIFIED="2014-08-07 17:56:30 +1000" MODIFIED_BY="Julia A.E. Walters" NAME="Sayiner 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-04-27 17:05:19 +1000" MODIFIED_BY="Julia AE Walters" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sayiner A, Aytemur ZA, Cirit M, Unsal I</AU>
<TI>Systemic glucocorticoids in severe exacerbations of COPD</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<NO>3</NO>
<PG>726-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923551"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923550"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sirichana-2008" MODIFIED="2011-06-26 15:46:10 +1000" MODIFIED_BY="Julia A.E. Walters" NAME="Sirichana 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-06-26 15:45:53 +1000" MODIFIED_BY="Julia A.E. Walters" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sirichana W, Sittipunt C, Kawkitinarong K, Wongtim S</AU>
<TI>Comparison between 5 days and 10 days of prednisolone in treatment of acute exacerbation of chronic obstructive pulmonary disease [Abstract]</TI>
<SO>Respirology</SO>
<YR>2008</YR>
<VL>13</VL>
<NO>Suppl 5</NO>
<PG>A120 [012-01]</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923553"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923552"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wood_x002d_Baker-1997" MODIFIED="2010-04-27 17:15:49 +1000" MODIFIED_BY="Julia AE Walters" NAME="Wood-Baker 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-04-27 17:15:49 +1000" MODIFIED_BY="Julia AE Walters" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wood-Baker R, Wilkinson J, Pearce M, Ryan G</AU>
<TI>A double-blind, randomised, placebo-controlled trial of corticosteroids for acute exacerbations of chronic obstructive pulmonary disease [Abstract]</TI>
<SO>Australian &amp; New Zealand Journal of Medicine</SO>
<YR>1998</YR>
<VL>28</VL>
<PG>262</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923555"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923554"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-12-20 02:51:26 +1100" MODIFIED_BY="Emma J Dennett">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Aaron-2003" MODIFIED="2014-12-08 21:12:50 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Aaron 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-12-08 21:12:50 +1100" MODIFIED_BY="Julia A.E. Walters" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J et al</AU>
<TI>Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease [comment]</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<NO>26</NO>
<PG>2618-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923557"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923556"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abroug-2014" MODIFIED="2017-12-19 12:31:12 +1100" MODIFIED_BY="[Empty name]" NAME="Abroug 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-12-19 12:31:12 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abroug F, Ouanes-Besbes L, Fkih-Hassen M, Ouanes I, Ayed S, Dachraoui F, Brochard L, Elatrous S</AU>
<TI>Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation</TI>
<SO>Eur Respir J</SO>
<YR>2014</YR>
<VL>43</VL>
<NO>3</NO>
<PG>717-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7743987"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-11-24 15:40:54 +1100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7743986"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albert-1980" MODIFIED="2011-09-01 11:46:29 +1000" MODIFIED_BY="[Empty name]" NAME="Albert 1980" YEAR="1980">
<REFERENCE MODIFIED="2011-09-01 11:46:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albert RK, Martin TR, Lewis SW</AU>
<TI>Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1980</YR>
<VL>92</VL>
<NO>6</NO>
<PG>753-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923559"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923558"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albert-2008" MODIFIED="2011-09-01 11:46:40 +1000" MODIFIED_BY="[Empty name]" NAME="Albert 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-09-01 11:46:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albert P, Calverley P</AU>
<TI>A PEACE-ful solution to COPD exacerbations? [comment]</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<NO>9629</NO>
<PG>1975-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923561"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923560"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ardestani-2017" MODIFIED="2017-12-19 12:31:27 +1100" MODIFIED_BY="[Empty name]" NAME="Ardestani 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-12-19 12:31:27 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ardestani E, Kalantary E, Samaiy, Taherian K</AU>
<TI>Methyl prednisolone vs dexamethasone in management of COPD exacerbation; a randomized clinical trial</TI>
<SO>Emergency</SO>
<YR>2017</YR>
<VL>5</VL>
<NO>1</NO>
<PG>195-200</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7743989"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7743988"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brusse_x002d_Keizer-2014" MODIFIED="2017-12-19 12:27:27 +1100" MODIFIED_BY="[Empty name]" NAME="Brusse-Keizer 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-12-19 12:27:27 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brusse-Keizer M, VanderValk P, Hendrix R, Kerstjens H, van der Palen J</AU>
<TI>Necessity of amoxicillin clavulanic acid in addition to prednisolone in mild-to-moderate COPD exacerbations</TI>
<SO>BMJ open respiratory research</SO>
<YR>2014</YR>
<VL>1</VL>
<NO>1</NO>
<PG>e000052</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7743991"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7743990"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ceviker-2014" MODIFIED="2017-12-19 12:31:58 +1100" MODIFIED_BY="[Empty name]" NAME="Ceviker 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-12-19 12:31:58 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ceviker Y, Sayiner A</AU>
<TI>Comparison of two systemic steroid regimens for the treatment of COPD exacerbations</TI>
<SO>Pulm Pharmacol Ther Apr</SO>
<YR>2014</YR>
<VL>27</VL>
<NO>2</NO>
<PG>179-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7743993"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7743992"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cordero-1996" MODIFIED="2014-12-08 21:14:04 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Cordero 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-12-08 21:13:19 +1100" MODIFIED_BY="Julia A.E. Walters" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cordero PJ, Benlloch E, Solè A, Morales P, Menèndez R, Cebri·NJ</AU>
<TI>Corticosteroid therapy for COPD exacerbations at inpatient settings: a controlled-randomized study</TI>
<SO>Archivos de Bronconeumologia</SO>
<YR>1996</YR>
<VL>32</VL>
<NO>Suppl 2</NO>
<PG>17</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923563"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-08 21:14:04 +1100" MODIFIED_BY="Julia A.E. Walters" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cordero PJ, Solè A, Benlloch E, Morales P, Vallterra J, Menèndez R et al</AU>
<TI>A randomized controlled study of prednisone in outpatients with acute exacerbation of COPD</TI>
<SO>European Respiratory Journal Supplement</SO>
<YR>1996</YR>
<VL>9 Suppl 23</VL>
<PG>110s-1s</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923564"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923562"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Courtney-2003" MODIFIED="2011-09-01 11:48:26 +1000" MODIFIED_BY="[Empty name]" NAME="Courtney 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-09-01 11:48:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Courtney AU</AU>
<TI>Oral prednisone prevents relapse in COPD exacerbations</TI>
<SO>Journal of Family Practice</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>10</NO>
<PG>762-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923566"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923565"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davies-1999" MODIFIED="2011-09-01 11:48:47 +1000" MODIFIED_BY="[Empty name]" NAME="Davies 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-09-01 11:48:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies L, Angus R, Mand Calverley PMA</AU>
<TI>A prospective, randomised, double-blind, placebo controlled study of oral corticosteroids in patients admitted with normocapnic acute exacerbations of chronic obstructive pulmonary disease (COPD)</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>Suppl 6</NO>
<PG>A5 S18</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923568"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-09-01 11:48:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davies L, Angus RM, Calverley PM</AU>
<TI>Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9177</NO>
<PG>456-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923569"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923567"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Jong-2007" MODIFIED="2011-09-01 11:49:27 +1000" MODIFIED_BY="[Empty name]" NAME="De Jong 2007" YEAR="2004">
<REFERENCE MODIFIED="2011-09-01 11:49:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Jong YP, Uil M, Grotjohan P, Postma S, Kerstjens M, Van den Berg JWK</AU>
<TI>A comparison of intravenous versus oral administration of corticosteroids in the treatment of patients admitted to the hospital with an exacerbation of COPD [Abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>Suppl 48</NO>
<PG>64s</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923571"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-09-01 11:49:27 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>De Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, Van den Berg JW</AU>
<TI>Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study.[see comment]. Comment in: Chest. 2007 Dec;132(6):1728-9; PMID: 18079214</TI>
<SO>Chest</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>6</NO>
<PG>1741-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923572"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923570"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ding-2016" MODIFIED="2017-12-19 12:30:29 +1100" MODIFIED_BY="[Empty name]" NAME="Ding 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-12-19 12:30:29 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ding Z, Li X, Lu Y, Rong G, Yang R, Zhang R, Wang G, Wei X, Ye Y, Qian Z, Liu H, Zhu D, Zhou R, Zhu K, Ni R, Xia K, Luo N, Pei C</AU>
<TI>A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease</TI>
<SO>Respiratory medicine</SO>
<YR>2016</YR>
<VL>121</VL>
<PG>39-47</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7743995"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7743994"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GlaxoSmithKline-2005" MODIFIED="2011-04-29 01:47:57 +1000" MODIFIED_BY="[Empty name]" NAME="GlaxoSmithKline 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-04-29 01:47:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>GlaxoSmithKline</AU>
<TI>A single centre, randomised, double-blind, parallel group study to compare the efficacy of nebulised fluticasone propionate 2 mg twice daily (bd) with placebo in patients with moderate to severe chronic obstructive pulmonary disease</TI>
<SO>GlaxoSmithKline Clinical Trial Register</SO>
<YR>2005</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923574"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923573"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Kalkoti-2014" MODIFIED="2017-12-19 12:30:13 +1100" MODIFIED_BY="[Empty name]" NAME="Kalkoti 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-12-19 12:30:13 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalkoti V, Kanani NJ</AU>
<TI>A prospective study for evaluating the clinical efficacy of methylxanthines in patients of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) admitted in a tertiary care hospital</TI>
<SO>Indian journal of pharmacology</SO>
<YR>2014</YR>
<VL>46</VL>
<NO>7 SUPPL. 1</NO>
<PG>S25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7743997"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7743996"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2003" MODIFIED="2011-09-01 11:49:41 +1000" MODIFIED_BY="[Empty name]" NAME="Li 2003" YEAR="2000">
<REFERENCE MODIFIED="2011-03-21 10:33:57 +1100" MODIFIED_BY="Julia AE Walters" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li H, He G, Chu H, Zhao L, Yu H</AU>
<TI>A step-wise application of methylprednisolone versus dexamethasone in the treatment of acute exacerbations of COPD</TI>
<SO>Respirology</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>2</NO>
<PG>199-204</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923576"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-09-01 11:49:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li HP, He GJ, Chu HQ</AU>
<TI>The application of methylprednisolone in acute exacerbations of COPD</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl 31</NO>
<PG>50s</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923577"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923575"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Makarova-2016" MODIFIED="2017-12-19 12:29:59 +1100" MODIFIED_BY="[Empty name]" NAME="Makarova 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-12-19 12:29:59 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Makarova EV, Varvarina GN, Menkov NV, Tsapaeva MY, Lazareva ES, Kazatskaya ZhA, Novikov VV, Karaulov AV</AU>
<TI>Nebulized budesonide in the treatment of exacerbations of chronic obstructive pulmonary disease: Efficacy, safety, and effects on the serum levels of soluble differentiation molecules</TI>
<SO>Terapevticheskii arkhi</SO>
<YR>2016</YR>
<VL>88</VL>
<NO>3</NO>
<PG>24-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7743999"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7743998"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCrory-2000" MODIFIED="2011-09-01 11:49:58 +1000" MODIFIED_BY="[Empty name]" NAME="McCrory 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-09-01 11:49:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCrory DC, Hasselblad V</AU>
<TI>The results of a randomized controlled trial of hydrocortisone in acute exacerbation of COPD</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>1</NO>
<PG>122</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923579"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923578"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Odonchimeg-2015" MODIFIED="2017-12-19 12:29:33 +1100" MODIFIED_BY="[Empty name]" NAME="Odonchimeg 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-12-19 12:29:33 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Odonchimeg P, Ichinnorov D, Sarantuyaa Zh, Tumur-Ochir Ts, Choyzhamts G</AU>
<TI>Efficacy of different regimens of steroid therapy in patients with exacerbation of chronic obstructive pulmonary disease</TI>
<SO>Pulmonologiya</SO>
<YR>2015</YR>
<VL>25</VL>
<NO>1</NO>
<PG>58-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7744001"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7744000"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2014" MODIFIED="2017-12-19 12:29:23 +1100" MODIFIED_BY="[Empty name]" NAME="Sharma 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-12-19 12:29:23 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma N, Venado A, Morrison J</AU>
<TI>Protocol-based treatment of septic shock, fibrinolysis for submassive pulmonary embolism, and use of corticosteroids in acute exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation</TI>
<SO>Am J Respir Crit Care Med</SO>
<YR>2014</YR>
<VL>190</VL>
<NO>7</NO>
<PG>827-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7744003"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7744002"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2015" MODIFIED="2017-12-20 02:51:26 +1100" MODIFIED_BY="Emma J Dennett" NAME="Sun 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-12-20 02:51:26 +1100" MODIFIED_BY="Emma J Dennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun WP, Yuan GX, Hu YJ, Liao LZ, Fu L</AU>
<TI>Effect of low-dose glucocorticoid on corticosteroid insufficient patients with acute exacerbation of chronic obstructive pulmonary disease</TI>
<SO>World Journal of Emergency Medicine</SO>
<YR>2015</YR>
<VL>6</VL>
<NO>1</NO>
<PG>34-39</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7744005"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7744004"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2015a" MODIFIED="2017-12-19 12:28:24 +1100" MODIFIED_BY="[Empty name]" NAME="Sun 2015a" YEAR="2015">
<REFERENCE MODIFIED="2017-12-19 12:28:24 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun X, He Z, Zhang J, Deng J, Bai J, Li M, Zhong X</AU>
<TI>Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD</TI>
<SO>Pulmonary pharmacology &amp; therapeutics</SO>
<YR>2015</YR>
<VL>31</VL>
<PG>111-116</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7744007"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7744006"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woods-2014" MODIFIED="2017-12-19 12:28:44 +1100" MODIFIED_BY="[Empty name]" NAME="Woods 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-12-19 12:28:44 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woods JA, Wheeler JS, Finch CK, Pinner NA</AU>
<TI>Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Int J Chron Obstruct Pulmon Dis</SO>
<YR>2014</YR>
<VL>9</VL>
<PG>421-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7744009"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7744008"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yilmazel-Ucar-2014" MODIFIED="2017-12-19 12:29:04 +1100" MODIFIED_BY="[Empty name]" NAME="Yilmazel Ucar 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-12-19 12:29:04 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yilmazel Ucar E, Araz O, Meral M, Sonkaya E, Saglam L, Kaynar H, Gorguner AM, Akgun M</AU>
<TI>Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: a randomized control trial</TI>
<SO>Med Sci Monit</SO>
<YR>2014</YR>
<VL>20</VL>
<PG>513-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7744011"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7744010"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-09-07 17:01:48 +1000" MODIFIED_BY="Julia A.E. Walters"/>
<ONGOING_STUDIES MODIFIED="2017-12-20 02:51:47 +1100" MODIFIED_BY="Emma J Dennett">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Leuppi-2017" MODIFIED="2017-12-20 02:51:47 +1100" MODIFIED_BY="Emma J Dennett" NAME="Leuppi 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-12-20 02:51:47 +1100" MODIFIED_BY="Emma J Dennett" PRIMARY="NO" TYPE="OTHER">
<AU>Leuppi J</AU>
<TI>Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD (RECUT)</TI>
<SO>Clinicaltrials.gov</SO>
<YR>2015</YR>
<PG>NCT02386735</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7744013"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7744012"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Reid-2010" MODIFIED="2011-09-02 04:40:46 +1000" MODIFIED_BY="[Empty name]" NAME="Reid 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-09-02 04:40:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Reid D, Soltani A, Wood-Baker R, Walters EH</AU>
<SO>Personal correspondence</SO>
<YR>2010</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2923581"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2923580"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-11-16 15:17:47 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-12-08 21:17:11 +1100" MODIFIED_BY="Julia A.E. Walters">
<REFERENCE ID="REF-Agusti-2010" MODIFIED="2014-09-25 20:57:22 +1000" MODIFIED_BY="Emma Jackson" NAME="Agusti 2010" TYPE="JOURNAL_ARTICLE">
<AU>Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA et al</AU>
<TI>Characterisation of COPD heterogeneity in the ECLIPSE cohort</TI>
<SO>Respiratory Research</SO>
<YR>2010</YR>
<VL>11</VL>
<PG>122</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anthonisen-1987" MODIFIED="2011-09-01 11:55:43 +1000" MODIFIED_BY="[Empty name]" NAME="Anthonisen 1987" TYPE="JOURNAL_ARTICLE">
<AU>Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA</AU>
<TI>Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1987</YR>
<VL>106</VL>
<NO>2</NO>
<PG>196-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bathoorn-2008" MODIFIED="2014-03-03 13:26:14 +1100" MODIFIED_BY="[Empty name]" NAME="Bathoorn 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bathoorn E, Kerstjens H, Postma D, Timens W, MacNee W</AU>
<TI>Airways inflammation and treatment during acute exacerbations of COPD</TI>
<SO>International Journal of Chronic Obstructive Pulmonary Disease</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>2</NO>
<PG>217-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buist-2007" MODIFIED="2014-12-08 21:14:30 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Buist 2007" TYPE="JOURNAL_ARTICLE">
<AU>Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM et al</AU>
<TI>International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<NO>9589</NO>
<PG>741-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Vries-2007" MODIFIED="2014-09-25 22:29:00 +1000" MODIFIED_BY="Emma Jackson" NAME="De Vries 2007" TYPE="JOURNAL_ARTICLE">
<AU>De Vries F, Bracke M, Leufkens HGM, Lammers JWJ, Cooper C, Van Staa TP</AU>
<TI>Fracture risk with intermittent high-dose oral glucocorticoid therapy</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>1</NO>
<PG>208-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Decramer-1994" MODIFIED="2014-11-29 07:36:58 +1100" MODIFIED_BY="[Empty name]" NAME="Decramer 1994" TYPE="JOURNAL_ARTICLE">
<AU>Decramer M, Lacquet LM, Fagard R, Rogiers P</AU>
<TI>Corticosteroids contribute to muscle weakness in chronic airflow obstruction</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1994</YR>
<VL>150</VL>
<NO>1</NO>
<PG>11-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2008" MODIFIED="2014-12-08 20:51:28 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Deeks 2008" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Higgins JPT, Altman DG</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]</SO>
<YR>2008</YR>
<ED>Higgins JPT, Green S</ED>
<PB>www.cochrane-handbook.org. The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2010-10-26 17:31:02 +1100" MODIFIED_BY="Julia AE Walters" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donaldson-2002" MODIFIED="2014-03-03 12:45:16 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Donaldson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA</AU>
<TI>Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease</TI>
<SO>Thorax</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>10</NO>
<PG>847-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donaldson-2005" MODIFIED="2014-09-25 22:42:08 +1000" MODIFIED_BY="Emma Jackson" NAME="Donaldson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Donaldson GC, Wilkinson TMA, Hurst JR, Perera WR, Wedzicha JA</AU>
<TI>Exacerbations and time spent outdoors in chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2005</YR>
<VL>171</VL>
<PG>446-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donaldson-2006" MODIFIED="2008-10-01 01:14:06 +1000" MODIFIED_BY="Toby J Lasserson" NAME="Donaldson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Donaldson GC, Wedzicha JA</AU>
<TI>COPD exacerbations 1: epidemiology</TI>
<SO>Thorax</SO>
<YR>2006</YR>
<VL>61</VL>
<PG>164-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Effing-2009" MODIFIED="2014-09-25 22:42:34 +1000" MODIFIED_BY="Emma Jackson" NAME="Effing 2009" TYPE="JOURNAL_ARTICLE">
<AU>Effing TW, Kerstjens HAM, Monninkhof EM, van der Valk PDLPM, Wouters EFM, Postma DS et al</AU>
<TI>Definitions of exacerbations: does it really matter in clinical trials on COPD?</TI>
<SO>Chest</SO>
<YR>2009</YR>
<VL>136</VL>
<NO>3</NO>
<PG>918-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-2002" MODIFIED="2014-11-29 07:42:48 +1100" MODIFIED_BY="[Empty name]" NAME="Evans 2002" TYPE="JOURNAL_ARTICLE">
<AU>Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y</AU>
<TI>Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<NO>9318</NO>
<PG>1648-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Falk-2008" MODIFIED="2014-09-25 22:52:55 +1000" MODIFIED_BY="Emma Jackson" NAME="Falk 2008" TYPE="JOURNAL_ARTICLE">
<AU>Falk JA, Minai OA, Mosenifar Z</AU>
<TI>Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease</TI>
<SO>Proceedings of the American Thoracic Society</SO>
<YR>2008</YR>
<VL>5</VL>
<NO>4</NO>
<PG>506-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GOLD-2014" MODIFIED="2014-12-08 21:15:11 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="GOLD 2014" TYPE="OTHER">
<AU>GOLD</AU>
<TI>Global Strategy for the Diagnosis, Management and Prevention of COPD, 2014</TI>
<SO>http://www.goldcopd.org/</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Groenewegen-2001" MODIFIED="2014-09-25 23:05:31 +1000" MODIFIED_BY="Emma Jackson" NAME="Groenewegen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Groenewegen K, Schols A, Wouters E</AU>
<TI>Prognosis after hospitalization for acute exacerbations of COPD</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>Suppl 33</NO>
<PG>209s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hardin-2014" MODIFIED="2014-09-25 23:21:18 +1000" MODIFIED_BY="Emma Jackson" NAME="Hardin 2014" TYPE="JOURNAL_ARTICLE">
<AU>Hardin M, Cho M, McDonald ML, Beaty T, Ramsdell J, Bhatt S et al</AU>
<TI>The clinical and genetic features of COPD-asthma overlap syndrome</TI>
<SO>European Respiratory Journal</SO>
<YR>2014</YR>
<VL>44</VL>
<NO>2</NO>
<PG>341-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-10-01 01:14:07 +1000" MODIFIED_BY="Toby J Lasserson" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JD, Altman G</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-12-08 21:15:27 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins J, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hurst-2010" MODIFIED="2014-09-25 23:22:18 +1000" MODIFIED_BY="Emma Jackson" NAME="Hurst 2010" TYPE="JOURNAL_ARTICLE">
<AU>Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R et al</AU>
<TI>Susceptibility to exacerbation in chronic obstructive pulmonary disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>363</VL>
<NO>12</NO>
<PG>1128-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2014" MODIFIED="2014-12-08 21:15:38 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Jones 2014" TYPE="JOURNAL_ARTICLE">
<AU>Jones PW, Lamarca R, Chuecos F, Singh D, Agusti A, Bateman ED et al</AU>
<TI>Characterisation and impact of reported and unreported exacerbations: results from ATTAIN</TI>
<SO>European Respiratory Journal</SO>
<YR>2014</YR>
<VL>epub ahead of print</VL>
<PG>doi:10.1183/09031936.00038814</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kiser-2014" MODIFIED="2014-09-25 23:23:03 +1000" MODIFIED_BY="Emma Jackson" NAME="Kiser 2014" TYPE="JOURNAL_ARTICLE">
<AU>Kiser TH, Allen RR, Valuck RJ, Moss M, Vandivier RW</AU>
<TI>Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2014</YR>
<VL>189</VL>
<NO>9</NO>
<PG>1052-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leidy-2010" MODIFIED="2014-09-25 23:24:56 +1000" MODIFIED_BY="Emma Jackson" NAME="Leidy 2010" TYPE="JOURNAL_ARTICLE">
<AU>Leidy NK, Wilcox TK, Jones PW, Murray L, Winnette R, Howard K et al</AU>
<TI>Development of the EXAcerbations of chronic obstructive pulmonary disease Tool (EXACT): a patient-reported outcome (PRO) measure</TI>
<SO>Value in Health</SO>
<YR>2010</YR>
<VL>13</VL>
<NO>8</NO>
<PG>965-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leidy-2011" MODIFIED="2014-12-08 21:15:56 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Leidy 2011" TYPE="JOURNAL_ARTICLE">
<AU>Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S</AU>
<TI>Standardizing measurement of chronic obstructive pulmonary disease exacerbations</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2011</YR>
<VL>183</VL>
<NO>3</NO>
<PG>323-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leidy-2014" MODIFIED="2014-12-08 21:16:01 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Leidy 2014" TYPE="JOURNAL_ARTICLE">
<AU>Leidy NK, Murray LT, Jones P, Sethi S</AU>
<TI>Performance of the EXAcerbations of Chronic Pulmonary Disease Tool Patient-reported Outcome Measure in three clinical trials of chronic obstructive pulmonary disease</TI>
<SO>Annals of the American Thoracic Society</SO>
<YR>2014</YR>
<VL>11</VL>
<NO>3</NO>
<PG>316-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindenauer-2010" MODIFIED="2014-09-25 23:26:10 +1000" MODIFIED_BY="Emma Jackson" NAME="Lindenauer 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB</AU>
<TI>Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>303</VL>
<NO>23</NO>
<PG>2359-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lopez-2006" MODIFIED="2014-09-25 23:47:22 +1000" MODIFIED_BY="Emma Jackson" NAME="Lopez 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS et al</AU>
<TI>Chronic obstructive pulmonary disease: current burden and future projections</TI>
<SO>European Respiratory Journal</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>2</NO>
<PG>397-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Majumdar-2010" MODIFIED="2014-09-25 23:47:47 +1000" MODIFIED_BY="Emma Jackson" NAME="Majumdar 2010" TYPE="JOURNAL_ARTICLE">
<AU>Majumdar SR, Villa-Roel C, Lyons KJ, Rowe BH</AU>
<TI>Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease</TI>
<SO>Respiratory Medicine</SO>
<YR>2010</YR>
<VL>104</VL>
<NO>2</NO>
<PG>260-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McEvoy-1996" MODIFIED="2014-12-08 21:16:14 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="McEvoy 1996" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy CE, Niewoehner DE</AU>
<TI>Adverse effects of corticosteroid therapy for COPD</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>111</VL>
<PG>732-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKenzie-2003" MODIFIED="2011-09-02 03:49:46 +1000" MODIFIED_BY="[Empty name]" NAME="McKenzie 2003" TYPE="JOURNAL_ARTICLE">
<AU>McKenzie DK, Frith PA, Burdon JG, Town GI</AU>
<TI>The COPDX Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2003</TI>
<SO>Medical Journal of Australia</SO>
<YR>2003</YR>
<VL>178</VL>
<NO>Suppl</NO>
<PG>S7-S39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-1997" MODIFIED="2014-09-25 23:48:16 +1000" MODIFIED_BY="Emma Jackson" NAME="Murray 1997" TYPE="JOURNAL_ARTICLE">
<AU>Murray CJ, Lopez AD</AU>
<TI>Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9064</NO>
<PG>1498-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2010" MODIFIED="2014-12-08 21:16:26 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="NICE 2010" TYPE="OTHER">
<AU>National Institute for Health and Care Excellence</AU>
<TI>Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care [update 2010]</TI>
<SO>http://guidance.nice.org.uk/CG101</SO>
<YR>(accessed 18 July 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oostenbrink-2004" MODIFIED="2014-03-03 12:55:24 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Oostenbrink 2004" TYPE="JOURNAL_ARTICLE">
<AU>Oostenbrink JB, Rutten-van Molken MP</AU>
<TI>Resource use and risk factors in high-cost exacerbations of COPD</TI>
<SO>Respiratory Medicine</SO>
<YR>2004</YR>
<VL>98</VL>
<PG>883-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Papi-2006" MODIFIED="2014-09-26 00:08:32 +1000" MODIFIED_BY="Emma Jackson" NAME="Papi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G et al</AU>
<TI>Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2006</YR>
<VL>173</VL>
<NO>10</NO>
<PG>1114-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2014-09-25 14:07:25 +1000" MODIFIED_BY="Julia A.E. Walters" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodriguez_x002d_Roisin-2000" MODIFIED="2011-04-22 00:37:10 +1000" MODIFIED_BY="Emma J Welsh" NAME="Rodriguez-Roisin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez-Roisin R</AU>
<TI>Toward a consensus definition for COPD exacerbations</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>117</VL>
<NO>5 Suppl 2</NO>
<PG>398S-401S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schermer-2002" MODIFIED="2014-03-03 12:47:21 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Schermer 2002" TYPE="JOURNAL_ARTICLE">
<AU>Schermer T, Chavannes N, Saris C, Akkermans R, van Schayck C, van Weel C</AU>
<TI>Exacerbations and associated health care cost in patients with chronic obstructive pulmonary disease in general practice. Results from the COOPT trial</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>Suppl 38</NO>
<PG>398s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seemungal-2000" MODIFIED="2008-10-01 01:14:06 +1000" MODIFIED_BY="Toby J Lasserson" NAME="Seemungal 2000" TYPE="JOURNAL_ARTICLE">
<AU>Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA</AU>
<TI>Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>5</NO>
<PG>1608-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sethi-2002" MODIFIED="2014-09-26 00:14:27 +1000" MODIFIED_BY="Emma Jackson" NAME="Sethi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Sethi S, Evans N, Grant BJ, Murphy TF</AU>
<TI>New strains of bacteria and exacerbations of chronic obstructive pulmonary disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<NO>7</NO>
<PG>465-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sethi-2008" MODIFIED="2014-12-08 21:16:49 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Sethi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sethi S, Murphy TF</AU>
<TI>Infection in the pathogenesis and course of chronic obstructive pulmonary disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>359</VL>
<NO>22</NO>
<PG>2355-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sherk-2000" MODIFIED="2014-03-03 13:20:43 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Sherk 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sherk PA, Grossman RF</AU>
<TI>The chronic obstructive pulmonary disease exacerbation</TI>
<SO>Clinics in Chest Medicine</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>4</NO>
<PG>705-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soler_x002d_Cataluna-2005" MODIFIED="2014-03-03 12:45:16 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Soler-Cataluna 2005" TYPE="JOURNAL_ARTICLE">
<AU>Soler-Cataluna JJ, Martinnez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R</AU>
<TI>Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease</TI>
<SO>Thorax</SO>
<YR>2005</YR>
<VL>60</VL>
<NO>11</NO>
<PG>925-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suissa-2012" MODIFIED="2014-03-03 13:20:43 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Suissa 2012" TYPE="JOURNAL_ARTICLE">
<AU>Suissa S, Dell'Aniello S, Ernst P</AU>
<TI>Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality</TI>
<SO>Thorax</SO>
<YR>2012</YR>
<VL>67</VL>
<NO>11</NO>
<PG>957-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sullivan-2000" MODIFIED="2014-09-26 00:14:57 +1000" MODIFIED_BY="Emma Jackson" NAME="Sullivan 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan SD, Ramsey SD, Lee TA</AU>
<TI>The economic burden of COPD</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>117</VL>
<PG>5s-9s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Therapeutic-Guidelines-2009" MODIFIED="2011-05-14 17:21:48 +1000" MODIFIED_BY="Julia AE Walters" NAME="Therapeutic Guidelines 2009" TYPE="BOOK">
<AU>Therapeutic Guidelines Ltd</AU>
<SO>Therapeutic Guidelines: Respiratory. Version 4</SO>
<YR>2009</YR>
<PB>Therapeutic Guidelines Ltd</PB>
<CY>Melbourne</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vestergaard-2007" MODIFIED="2014-03-03 13:38:00 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Vestergaard 2007" TYPE="JOURNAL_ARTICLE">
<AU>Vestergaard P, Rejnmark L, Mosekilde L</AU>
<TI>Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids</TI>
<SO>Chest</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>5</NO>
<PG>1599-607</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="17890464 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walters-2011" MODIFIED="2014-11-11 20:47:57 +1100" MODIFIED_BY="Emma J Welsh" NAME="Walters 2011" TYPE="COCHRANE_REVIEW">
<AU>Walters JA, Wang W, Morley C, Soltani A, Wood-Baker R</AU>
<TI>Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2014-09-26 00:23:48 +1000" MODIFIED_BY="Emma Jackson"><IDENTIFIER MODIFIED="2014-09-26 00:23:39 +1000" MODIFIED_BY="Emma Jackson" TYPE="DOI" VALUE="10.1002/14651858.CD006897.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walters-2014" MODIFIED="2014-11-11 20:47:43 +1100" MODIFIED_BY="Emma J Welsh" NAME="Walters 2014" TYPE="COCHRANE_REVIEW">
<AU>Walters JAE, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH</AU>
<TI>Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2014-09-26 00:28:40 +1000" MODIFIED_BY="Emma Jackson"><IDENTIFIER MODIFIED="2014-09-26 00:28:40 +1000" MODIFIED_BY="Emma Jackson" TYPE="DOI" VALUE="10.1002/14651858.CD001288.pub4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weatherall-2009" MODIFIED="2014-09-26 00:28:59 +1000" MODIFIED_BY="Emma Jackson" NAME="Weatherall 2009" TYPE="JOURNAL_ARTICLE">
<AU>Weatherall M, Travers J, Shirtcliffe PM, Marsh SE, Williams MV, Nowitz MR et al</AU>
<TI>Distinct clinical phenotypes of airways disease defined by cluster analysis</TI>
<SO>European Respiratory Journal</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>4</NO>
<PG>812-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wedzicha-2000" MODIFIED="2014-03-03 13:21:49 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Wedzicha 2000" TYPE="JOURNAL_ARTICLE">
<AU>Wedzicha JA</AU>
<TI>Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Thorax</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>Suppl 1</NO>
<PG>S23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-2004" MODIFIED="2014-09-26 00:29:10 +1000" MODIFIED_BY="Emma Jackson" NAME="Wilkinson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA</AU>
<TI>Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2004</YR>
<VL>169</VL>
<NO>12</NO>
<PG>1298-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wouters-2003" MODIFIED="2014-12-08 21:17:11 +1100" MODIFIED_BY="Julia A.E. Walters" NAME="Wouters 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wouters EFM</AU>
<TI>Economic analysis of the confronting COPD survey: an overview of results</TI>
<SO>Respiratory Medicine</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>Suppl 3</NO>
<PG>S3-S14</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2017-11-16 15:17:47 +1100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES><CHARACTERISTICS_OF_STUDIES MODIFIED="2017-12-20 02:51:16 +1100" MODIFIED_BY="Emma J Dennett"><CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-11-24 15:49:25 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><INCLUDED_CHAR MODIFIED="2014-12-05 01:36:43 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Chen-2005"><CHAR_METHODS MODIFIED="2014-12-05 01:36:43 +1100" MODIFIED_BY="Emma J Welsh"><P>STUDY DESIGN: parallel group</P><P>LOCATION/NUMBER OF CENTRES: inpatients in China, unknown number of centres</P><P>DURATION OF STUDY: 14 days        </P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2014-12-05 01:36:43 +1100" MODIFIED_BY="Emma J Welsh"><P>N SCREENED = not stated</P><P>N RANDOMISED = SCS &#8804; 7 days n = 44, SCS &gt; 7 days n = 43</P><P>N COMPLETED = SCS &#8804; 7 days n = 41, SCS &gt; 7 days n = 40</P><P>M = 98</P><P>F = 32</P><P>AGE INT = 70.3, CONTROL = 71.7 (NS diff)</P><P>SMOKERS: INT = 18/44 (41%), CONTROL = 20/43 (47%) (NS diff)</P><P>BASELINE DETAILS: Baseline comparison of groups showed no significant differences in age, gender, course of disease, proportion of current smokers or the prestudy course of exacerbation</P><P>INCLUSION CRITERIA: exacerbation of COPD: type 2 AEs (i.e. at least 2/3 increased dyspnoea, increased sputum, purulent sputum); use of diagnostic criteria for COPD: 2 years of continuous productive cough, FEV<SUB>1</SUB>/FVC post bronchodilator &lt; 0.7, FEV<SUB>1</SUB> &lt; 80% predicted</P><P>EXCLUSION CRITERIA: respiratory failure, diabetes, bronchial asthma</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2014-12-05 01:36:43 +1100" MODIFIED_BY="Emma J Welsh"><P>SCS &#8804; 7 days: prednisolone 30 mg/d 7 days + placebo 7 days</P><P>SCS &gt; 7 days: prednisolone 30 mg/d 10 days + 15 mg/d 5 days</P><P>Delivery: oral</P><P>Co-interventions permitted: not stated</P><P>Co-interventions not permitted: not stated</P><P>Follow-up period: not stated</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2014-12-05 01:36:43 +1100" MODIFIED_BY="Emma J Welsh"><P>Outcomes measured: lung function, arterial blood gas measurement, days of hospitalisation</P><P>Composite symptom score: highest 18 (worse) to lowest 0 (no symptoms) for breathlessness, sputum volume, cough, amount of sleep, exercise capacity, wheezing</P><P>Treatment failure: no definition stated<BR/>Rate of relapse: no definition stated<BR/>Side effects: corticosteroids<BR/></P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2014-12-05 01:36:43 +1100" MODIFIED_BY="Emma J Welsh"><P>INVESTIGATOR-SUPPLIED DATA: outcomes reported: absolute values and change in FEV<SUB>1</SUB>, FEV<SUB>1</SUB>/FVC ratio, PEF, PaO<SUB>2</SUB><BR/> # relapse, # failed treatment, # side effect</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2014-12-05 01:37:00 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Gomaa-2008"><CHAR_METHODS MODIFIED="2014-12-05 01:37:00 +1100" MODIFIED_BY="Emma J Welsh"><P>STUDY DESIGN: parallel</P><P>LOCATION, NUMBER OF CENTRES: Cairo, Egypt</P><P>DURATION OF STUDY: 14 days</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2014-12-05 01:37:00 +1100" MODIFIED_BY="Emma J Welsh"><P>N SCREENED: not stated</P><P>N RANDOMISED: 42</P><P>N COMPLETED: not stated</P><P>M not stated/F not stated</P><P>AGE: not stated</P><P>BASELINE DETAILS: not stated<BR/>INCLUSION CRITERIA: COPD exacerbation with postbronchodilator FEV<SUB>1</SUB> less than 50% of predicted and without respiratory acidosis</P><P>EXCLUSION CRITERIA: not stated</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2014-12-05 01:37:00 +1100" MODIFIED_BY="Emma J Welsh"><P>SCS &#8804; 7 days: prednisolone 30 mg 7 days</P><P>SCS &gt; 7 days: prednisolone 30 mg 14 days</P><P>Co-interventions: not stated</P><P>FOLLOW-UP PERIOD: 30 days</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2014-12-05 01:37:00 +1100" MODIFIED_BY="Emma J Welsh"><P>FEV<SUB>1</SUB> day 1, day 7, day 14 and day 30</P><P>Symptom score evaluation (breathlessness, cough and sputum)</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2014-08-05 16:45:35 +1000" MODIFIED_BY="Julia A.E. Walters"><P>Information from abstract only</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2014-12-08 20:57:45 +1100" MODIFIED_BY="Julia A.E. Walters" STUDY_ID="STD-Leuppi-2013"><CHAR_METHODS MODIFIED="2014-12-05 01:37:05 +1100" MODIFIED_BY="Emma J Welsh"><P>STUDY DESIGN: parallel</P><P>LOCATION, NUMBER OF CENTRES: Switzerland, recruited in 5 teaching hospitals</P><P>DURATION OF STUDY: 14 days, follow-up 180 days</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2014-12-05 01:37:05 +1100" MODIFIED_BY="Emma J Welsh"><P>N SCREENED: 717</P><P>N RANDOMISED: 314</P><P>N COMPLETED: 296</P><P>M = 188, F = 123</P><P>BASELINE DETAILS:</P><P>Gender F: SCS &#8804; 7 days 33%/SCS &gt; 7 days 47% (P value 0.02)</P><P>CURRENT SMOKERS: SCS &#8804; 7 days 49%/SCS &gt; 7 days 40%</P><P>LTOT: SCS &#8804; 7 days 16%/SCS &gt; 7 days 11%</P><P>AGE: SCS &#8804; 7 days: 69.8 (11.3)/SCS &gt; 7 days 69.8 (10.6)</P><P>FEV<SUB>1</SUB> % predicted: SCS &#8804; 7 days 32 (SD 15)/SCS &gt; 7 days 31 (SD 13)</P><P>PYH SMOKING median years: SCS &#8804; 7 days 50/SCS &gt; 7 days 45</P><P><BR/>INCLUSION CRITERIA: age &gt; 40 years, smoking history &#8805; 20 pack-years</P><P>EXCLUSION CRITERIA: history of asthma, FEV<SUB>1</SUB>/FVC ratio &gt; 0.7 (post bronchodilator), radiological diagnosis of pneumonia, estimated survival &lt; 6 months (due to severe co-morbidity), pregnancy or lactation, inability to give written consent</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2014-12-05 01:37:05 +1100" MODIFIED_BY="Emma J Welsh"><P>SCS &#8804; 7 days: 5 days: day 1: IV methylprednisolone 40 mg, days 2 to 5: oral prednisolone 40 mg, days 6to 14: placebo</P><P>SCS &gt; 7 days: 14 days: day 1: IV methylprednisolone 40 mg, days 2 to 14: oral 40 mg prednisolone</P><P>Co-interventions:</P><OL><LI>Broad-spectrum antibiotics (7 days)</LI><LI>Inhaled, nebulised, short-acting bronchodilator (4 to 6 times/d prn)</LI><LI>Inhaled glucocorticoids and &#946;<SUB>2</SUB> agonist (twice daily)</LI><LI>Inhaled tiotropium 18 µg (once daily)</LI></OL><P>Physiotherapy, supplemental oxygen and ventilator support (administered according to international guidelines)<BR/>Additional glucocorticoids administered at the discretion of treating physicians</P><P>TREATMENT PERIOD: 5 days vs 14 days</P><P>TREATMENT SETTING: inpatient after presentation to ED. Treated as outpatients after discharge direct from ED; INT: 12 participants (7.7%); CONTROL: 13 participants (8.4%)</P><P>FOLLOW-UP PERIOD: 180 days</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2014-12-05 01:37:05 +1100" MODIFIED_BY="Emma J Welsh"><P>FEV<SUB>1 </SUB>% predicted</P><P>Adverse effects: (infection, hyperglycaemia, hypertension, other)</P><P>Relapse</P><P>Duration of hospital stay</P><P>Mortality</P><P>Quality of life (bronchitis-associated quality-of-life score, 0 to 6 = worst)</P><P>Patient-reported overall performance (visual analogue scale)</P><P>Dyspnoea (Medical Research Council Dyspnoea score 1 to 5 = worst)</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2014-12-08 20:57:45 +1100" MODIFIED_BY="Julia A.E. Walters"><P>More women in the short-term arm (46.5% vs 32.7%; P value 0.02). ISRCTN19646069.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2014-12-05 01:37:15 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Rahman-2004"><CHAR_METHODS MODIFIED="2014-12-05 01:37:15 +1100" MODIFIED_BY="Emma J Welsh"><P>STUDY DESIGN: parallel</P><P>LOCATION, NUMBER OF CENTRES: Bangladesh, single tertiary-care centre</P><P>DURATION OF STUDY: 14 days</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2014-08-05 16:49:13 +1000" MODIFIED_BY="Julia A.E. Walters"><P>N SCREENED: not stated</P><P>N RANDOMISED: not stated</P><P>N COMPLETED: not stated</P><P>M = not stated</P><P>F = not stated</P><P>AGE: claimed no significant difference between groups</P><P>BASELINE DETAILS: claimed no significant difference between groups<BR/>INCLUSION CRITERIA: not stated</P><P>EXCLUSION CRITERIA: not stated</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2014-12-05 01:37:15 +1100" MODIFIED_BY="Emma J Welsh"><P>SCS &#8804; 7 days: 7-day group received oral prednisolone 30 mg/d for 7 days</P><P>SCS &gt; 7 days: 14-day group administered 30 mg/d oral prednisolone for 14 days</P><P>Co-interventions: not stated</P><P>TREATMENT PERIOD: 7 days vs 14 days</P><P>FOLLOW-UP PERIOD: not stated</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2011-09-01 07:09:20 +1000" MODIFIED_BY="[Empty name]"><P>FEV<SUB>1</SUB>, FVC, symptom score (specific symptoms not stated)</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2014-12-05 01:37:15 +1100" MODIFIED_BY="Emma J Welsh"><P>No reply from study author to request for more information about study and results</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2014-12-05 01:37:26 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Salam-1998"><CHAR_METHODS MODIFIED="2014-12-05 01:37:26 +1100" MODIFIED_BY="Emma J Welsh"><P>STUDY DESIGN: parallel</P><P>LOCATION, NUMBER OF CENTRES: unclear</P><P>DURATION OF STUDY: 10 days</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2014-12-05 01:37:26 +1100" MODIFIED_BY="Emma J Welsh"><P>N SCREENED: not stated</P><P>N RANDOMISED: 21</P><P>N COMPLETED: not clear</P><P>M = no details available</P><P>F = no details available</P><P>AGE: no details available</P><P>BASELINE DETAILS: study authors stated no significant differences between groups at baseline<BR/>INCLUSION CRITERIA: patients admitted with an exacerbation of COPD who had not received steroids within the preceding month</P><P>EXCLUSION CRITERIA: not stated</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2014-12-05 01:37:26 +1100" MODIFIED_BY="Emma J Welsh"><P>SCS &#8804; 7 days: 3 days of IV CS dose not stated and 7 days of placebo</P><P>SCS &gt; 7 days: 3 days of intravenous (IV) CS and 7 days oral CS dose not stated</P><P>Co-interventions: not stated</P><P>TREATMENT PERIOD: 10 days vs 3 days</P><P>FOLLOW-UP PERIOD: not stated</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2011-09-01 07:10:39 +1000" MODIFIED_BY="[Empty name]"><P>FEV<SUB>1</SUB>, FVC, dyspnoea, cough</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2014-12-05 01:37:26 +1100" MODIFIED_BY="Emma J Welsh"><P>Request to study author for more information about the study and results&#8212;no data supplied</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2014-12-05 01:37:34 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Sayiner-2001"><CHAR_METHODS MODIFIED="2014-12-05 01:37:34 +1100" MODIFIED_BY="Emma J Welsh"><P>STUDY DESIGN: parallel</P><P>LOCATION, NUMBER OF CENTRES: Izmir, Turkey. 1 tertiary centre</P><P>DURATION OF STUDY: 6 months</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2014-12-05 01:37:34 +1100" MODIFIED_BY="Emma J Welsh"><P>N SCREENED: 198</P><P>N RANDOMISED: 36</P><P>N COMPLETED: 34 (SCS &#8804; 7 n = 17; SCS &gt; 7 n = 17)</P><P>M = SCS &#8804; 7: 16, SCS &gt; 7: 16</P><P>F = SCS &#8804; 7: 1, SCS &gt; 7: 1</P><P>AGE: SCS &#8804; 7: 67.4 SCS &gt; 7: 64.1</P><P>BASELINE DETAILS: no significant differences between the 2 groups for age, duration of COPD, smoking history, blood eosinophilia, baseline levels of FEV<SUB>1</SUB> Number of exacerbations within 12 months (31 participants): no differences between groups</P><P>LTOT SCS &#8804; 7: 5 (29%); SCS &gt; 7: 2 (12%)</P><P>Prior medication: ipratropium bromide, long-acting beta2-agonists and theophylline<BR/>INCLUSION CRITERIA: current or ex-smokers with a smoking history &gt; 20 pack-years and severe airway obstruction (FEV<SUB>1</SUB> &lt; 35% predicted), who presented with an exacerbation necessitating hospitalisation</P><P>EXCLUSION CRITERIA: personal or family history of asthma, atopy, allergic disease, presence of eosinophilia, use of systemic steroids within the preceding month, presence of severe hypertension, uncompensated congestive heart failure or uncontrolled (or difficult to control) diabetes mellitus and respiratory failure necessitating mechanical ventilation therapy</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2014-12-05 01:37:34 +1100" MODIFIED_BY="Emma J Welsh"><P>SCS &#8804; 7: methylprednisolone, 0.5 mg/kg IV 6-hourly for 3 days, followed by normal saline solution as placebo treatment IV twice daily for the following 3 days and once daily for the final 4 days</P><P>SCS &gt; 7: methylprednisolone, 0.5 mg/kg IV 6-hourly for the first 3 days, followed by 0.5 mg/kg 12-hourly for 3 days and 0.5 mg/kg once daily for 4 more days (total 10 days)</P><P>Co-interventions: all given high doses of inhaled beta2-agonists, ipratropium bromide, theophylline (dose determined according to serum level measurements), antibiotics when indicated (presence of increased dyspnoea, sputum volume and sputum purulence) for 10 days, and H2-receptor antagonists for 10 days, during which they received the study medication</P><P>TREATMENT PERIOD: 10 days. All participants remained hospitalised for at least 10 days</P><P>FOLLOW-UP PERIOD: following 6 months</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2014-12-05 01:37:34 +1100" MODIFIED_BY="Emma J Welsh"><P>FEV<SUB>1</SUB>and PaO<SUB>2</SUB> levels on day 3 and day 10, absolute group means</P><P>Arterial blood gas levels day 1, day 3, day 5, day 7 and day 10 (arterial blood gases taken on room air after cessation of supplemental oxygen 30 minutes before, if the participant was on oxygen)</P><P>Symptom scores (dyspnoea, cough)</P><P>Recurrence of exacerbation in the following 6 months (collected by review of participants' records)</P><P>Adverse events.</P><P>Symptom scores (using 7-point scale on which higher scores represented better function)</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2014-12-05 01:37:34 +1100" MODIFIED_BY="Emma J Welsh"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2014-12-05 01:38:51 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Sirichana-2008"><CHAR_METHODS MODIFIED="2014-12-05 01:38:51 +1100" MODIFIED_BY="Emma J Welsh"><P>STUDY DESIGN: parallel</P><P>LOCATION, NUMBER OF CENTRES: Thailand, single tertiary-care centre (King Chulalongkorn Memorial Hospital)</P><P>DURATION OF STUDY: 30 days</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2014-12-05 01:38:51 +1100" MODIFIED_BY="Emma J Welsh"><P>N SCREENED: 107</P><P>N RANDOMISED: 48</P><P>N COMPLETED: 42</P><P>M = SCS &#8804; 7: 22; SCS &gt; 7: 20</P><P>F = SCS &#8804; 7: 3; SCS &gt; 7: 3</P><P>AGE: SCS &#8804; 7: 72.45 ± 9.62 years; SCS &gt; 7: 73.39 ± 9.16 years</P><P>BASELINE DETAILS: not stated<BR/></P><P>INCLUSION CRITERIA: participant with COPD who presented with acute exacerbation and age &gt; 40 years</P><P>Definition of acute exacerbation of COPD: at least 2 of 3 of these symptoms: increased dyspnoea, increased sputum volume, increased purulent sputum</P><P>Persistence of symptoms at least 24 hours</P><P>EXCLUSION CRITERIA: patient with history of asthma, atopic, allergy, bronchiectasis, lung cancer, pneumonia</P><P>Respiratory failure</P><P>Previously used systemic corticosteroids within preceding 30 days</P><P>Poorly controlled DM, severe infection</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2014-12-05 01:38:51 +1100" MODIFIED_BY="Emma J Welsh"><P>SCS &#8804; 7: 5-day group received prednisolone 30 mg/d for 5 days</P><P>SCS &gt; 7: 10-day group was administered 30 mg/d prednisolone for 10 days</P><P>Co-interventions: not stated</P><P>TREATMENT PERIOD: 5 days vs 10 days</P><P>FOLLOW-UP PERIOD: 30 days</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2011-09-01 11:35:26 +1000" MODIFIED_BY="[Empty name]"><P>FEV<SUB>1</SUB>, FVC, IC, clinical symptoms, fasting plasma glucose and CRP<BR/>Recurrent exacerbation within 30 days</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2014-12-05 01:38:51 +1100" MODIFIED_BY="Emma J Welsh"><P>Investigators supplied group mean data for FEV<SUB>1 </SUB>(L), FVC (L), IC (L), fasting plasma glucose(mg/dL), CRP (mg/L) and recurrent exacerbation within 30 days</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2014-12-05 01:39:01 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Wood_x002d_Baker-1997"><CHAR_METHODS MODIFIED="2014-12-05 01:39:01 +1100" MODIFIED_BY="Emma J Welsh"><P>STUDY DESIGN: parallel 3-group design<BR/>LOCATION, NUMBER OF CENTRES: hospitalised patients, 2 centres in Australia/New Zealand</P><P>DURATION OF STUDY: 2 weeks<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2014-12-05 01:39:01 +1100" MODIFIED_BY="Emma J Welsh"><P>N SCREENED: 47</P><P>N RANDOMISED: 38</P><P>N COMPLETED: 28 (20 withdrawals, 1 death)</P><P>M = 24</P><P>F = 14</P><P>AGE: SCS &#8804; 7: 69.3, SD 5.5: SCS &gt; 7: 71.1, SD 9.7</P><P>BASELINE DETAILS: not stated<BR/></P><P>INCLUSION CRITERIA: &gt; 40 years of age; &gt; 10 pack-year smoking history; FEV<SUB>1</SUB> &lt; 50% of predicted value<BR/>EXCLUSION CRITERIA: long-term corticosteroid therapy &gt; 5 mg prednisolone per day or taking oral prednisolone for the current exacerbation; other co-existent lung disease, including pneumonia; previous adverse reaction to corticosteroids; inability to cooperate with investigators; endoscopically or radiographically proven peptic ulcer disease within the past 2 years; history of cardiac failure, current hepatic or renal failure; inadequately treated hypertension<BR/></P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2014-08-05 16:55:16 +1000" MODIFIED_BY="Julia A.E. Walters"><P>SCS &#8804; 7: prednisolone 2.5 mg/kg orally daily for 3 days followed by 11 days placebo<BR/>SCS &gt; 7: prednisolone 0.6 mg/kg orally daily for 7 days followed by prednisolone 0.3 mg/kg orally daily for 7 days<BR/>Co-interventions: inhaled bronchodilators, oral antibiotics, oral/intravenous xanthines and oxygen</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2014-12-05 01:39:01 +1100" MODIFIED_BY="Emma J Welsh"><P>Measured: spirometry, 6-minute walking distance, duration of hospitalisation, PaO<SUB>2</SUB>, PaCO<SUB>2</SUB>, visual analogue scale of breathlessness (in mm on a 100-mm scale, more breathless represented by a higher number), treatment failure (no definition), mortality, adverse events<BR/>Reported or data available: spirometry, 6-minute walking distance, duration of hospitalisation, visual analogue scale of breathlessness; mortality: 1 death in the placebo arm Morbidity: no adverse biochemical effects</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2014-12-05 01:39:01 +1100" MODIFIED_BY="Emma J Welsh"><P>Study stopped early after 36 months because of poor enrolment. Results published as abstract, and study data available to review authors. Data analysed by review authors in 3 groups. Data from 3-day and 14-day treatment groups used in the review</P></CHAR_NOTES></INCLUDED_CHAR><FOOTNOTES><P>ABG: arterial blood gas; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; CS: corticosteroid; ED: emergency department; FEV<SUB>1</SUB>: forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: Global Strategy for Diagnosis, Management, and Prevention of COPD; IC: inspiratory capacity; INT: intervention; LTOT: long-term oxygen therapy; PaCO<SUB>2</SUB>: partial pressure of carbon dioxide in arterial blood; PaO<SUB>2</SUB>: partial pressure of oxygen in arterial blood; PEF: peak expiratory flow; SCS: systemic corticosteroid; SD: standard deviation.</P></FOOTNOTES></CHARACTERISTICS_OF_INCLUDED_STUDIES><CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-12-19 12:15:01 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY"><EXCLUDED_CHAR MODIFIED="2011-09-01 11:38:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aaron-2003"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-01 11:38:37 +1000" MODIFIED_BY="[Empty name]"><P>Did not assess different durations of corticosteroid treatment</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abroug-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><P>Compared systemic corticosteroids vs placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2014-12-04 22:45:24 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Albert-1980"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-04 22:45:24 +1100" MODIFIED_BY="Emma J Welsh"><P>Compared intravenous methylprednisolone vs placebo for 3 days in exacerbations of COPD</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2014-12-04 22:45:27 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Albert-2008"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-04 22:45:27 +1100" MODIFIED_BY="Emma J Welsh"><P>Article was a comment on RCT of carbocysteine</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ardestani-2017"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><P>Compared two courses of IV steroids over the same duration</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brusse_x002d_Keizer-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><P>Compared amoxicillin/clavulanic acid vs placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ceviker-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><P>Compared oral vs parenteral steroids</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2014-12-04 22:45:28 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Cordero-1996"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-04 22:45:28 +1100" MODIFIED_BY="Emma J Welsh"><P>Compared systemic corticosteroids vs placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2014-12-04 22:45:31 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Courtney-2003"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-04 22:45:31 +1100" MODIFIED_BY="Emma J Welsh"><P>Compared oral steroid vs placebo in stable COPD</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2014-12-04 22:45:34 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Davies-1999"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-04 22:45:34 +1100" MODIFIED_BY="Emma J Welsh"><P>Compared oral steroid vs placebo in exacerbations of COPD</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2014-12-04 22:45:38 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-De-Jong-2007"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-04 22:45:38 +1100" MODIFIED_BY="Emma J Welsh"><P>Compared oral vs IV corticosteroid given for 5 days</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ding-2016"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:39 +1100" MODIFIED_BY="[Empty name]"><P>Compared neublised vs parenteral steroids</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2014-12-04 22:45:41 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-GlaxoSmithKline-2005"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-04 22:45:41 +1100" MODIFIED_BY="Emma J Welsh"><P>Study of stable COPD not exacerbation</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalkoti-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Compared Deriphyllin + standard treatment vs standard treatment.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2014-12-04 22:45:45 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Li-2003"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-04 22:45:45 +1100" MODIFIED_BY="Emma J Welsh"><P>Comparison of methylprednisolone vs dexamethasone in the treatment of patients with acute exacerbations of COPD</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Makarova-2016"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Compared neublised vs IV steroids</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2010-08-21 22:04:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCrory-2000"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-21 22:04:10 +1000" MODIFIED_BY="[Empty name]"><P>Article was a letter on a study by Bullard 1996</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Odonchimeg-2015"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Compared MDI budesonide vs nebulised budesonide vs IV prednisolone</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Commentary on a study by Abroug 2014</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2015"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Compared IV hydrocortisone vs placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2015a"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Compared inhaled budesonide vs IV methylprednisolone</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Woods-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Systematic review of systemic corticosteroids in AECOPD</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yilmazel-Ucar-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Compared IV methylprednisolone with two strengths of neublised budesonide</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_EXCLUDED_STUDIES><CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-09-07 17:01:48 +1000" MODIFIED_BY="Julia A.E. Walters" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><FOOTNOTES/></CHARACTERISTICS_OF_AWAITING_STUDIES><CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-12-20 02:51:16 +1100" MODIFIED_BY="Emma J Dennett" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><ONGOING_CHAR MODIFIED="2017-12-20 02:51:16 +1100" MODIFIED_BY="Emma J Dennett" STUDY_ID="STD-Leuppi-2017"><CHAR_STUDY_NAME MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD (RECUT)</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Prospective, randomized, double-blind, placebo-controlled, non-inferiority trial in an out-patient setting</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-12-20 02:51:16 +1100" MODIFIED_BY="Emma J Dennett"><P>Inclusion Criteria:</P><OL><LI>Informed Consent as documented by signature</LI><LI>Age &#8805;40 years</LI><LI>History of &#8805;10 pack-years of smoking (past or present smokers)</LI><LI>Airway obstruction, defined as FEV1/FVC&#8804;70%</LI><LI>Current acute exacerbation of COPD by clinical criteria, defined by the presence of at least two of the following: Change of baseline dyspneaChange of coughChange of sputum quantity or purulence</LI></OL><P>Exclusion Criteria:</P><OL><LI>Diagnosis of asthma</LI><LI>Initial necessity of hospitalisation</LI><LI>Women who are pregnant or breast feeding</LI><LI>Premenopausal women with insufficient contraception and anamnestic risk for pregnancy</LI><LI>Severe coexisting disease with life expectancy &lt;6 months</LI><LI>Diagnosis of tuberculosis</LI><LI>Known severe immunosuppression or immunosuppression after solid organ or stem cell transplantation</LI><LI>Inability to follow study procedures, e.g. due to language problems, psychological disorders, dementia, etc. of the participant</LI><LI>Participation in another study involving an investigational drug</LI><LI>Previous enrolment into the current study</LI></OL></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Intervention group 1: Three days prednisolone 40mg, two days placebo</P><P>Intervention group 2: Five days prednisolone 40mg</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Primary:</P><OL><LI>Time to next exacerbation [ Time Frame: Six month follow-up period after index exacerbation. ]</LI></OL><P>Secondary:</P><OL><LI>Cumulative glucocorticoid dose [ Time Frame: Six month follow-up period after index exacerbation. ]</LI><LI>Glucocorticoid side effects and complications [ Time Frame: Six month follow-up period after index exacerbation. ]</LI><LI>Change in FEV1 [ Time Frame: 7 days follow-up period after index exacerbation. ]</LI><LI>Hospitalization rate during index exacerbation [ Time Frame: Six month follow-up period after index exacerbation. ]</LI><LI>Overall mortality [ Time Frame: Six month follow-up period after index exacerbation. ]</LI></OL></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>March 2015 (Recruiting)</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><P>Prof. Joerg Leuppi. +41 61 925 21 80 <A HREF="mailto:joerg.leuppi%40ksbl.ch?subject=NCT02386735,%20KSBL2015-017,%20Reduction%20of%20Corticosteroid%20Use%20in%20Outpatient%20Treatment%20of%20Exacerbated%20COPD">joerg.leuppi@ksbl.ch</A></P><P>Kantonsspital Baselland, Liestal, BL, Switzerland, 4410</P></CHAR_CONTACT_INFORMATION><CHAR_NOTES MODIFIED="2017-12-01 15:18:52 +1100" MODIFIED_BY="[Empty name]"/></ONGOING_CHAR><ONGOING_CHAR MODIFIED="2014-12-04 22:46:00 +1100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Reid-2010"><CHAR_STUDY_NAME MODIFIED="2014-11-28 23:46:46 +1100" MODIFIED_BY="[Empty name]"><P>A randomised double blind study of short course systemic steroids versus conventional 14 days course in acute exacerbations of COPD</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2010-08-21 22:28:36 +1000" MODIFIED_BY="[Empty name]"><P>Randomised controlled trial, blinded, parallel</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2014-12-04 22:45:57 +1100" MODIFIED_BY="Emma J Welsh"><P>Inclusion criteria:</P><P>All patients admitted to the Royal Hobart Hospital with the primary diagnosis of acute exacerbation of COPD</P><P>No age limit, males and females</P><P>Exclusion criteria:</P><OL><LI>Patients who had already received more than 1 oral CS dose from their GP before presentation, or who have received a treatment CS course within the past 1 month, will not be eligible</LI><LI>Patients taking long-term oral CS at a dose greater than 5 mg/d</LI><LI>Significant co-morbidities such as ongoing angina or current cardiac failure</LI><LI>Pneumonic consolidation, lung cancer, fibrosis, bronchiectasis or asthma</LI><LI>Inability to comply with instructions</LI><LI>Patients with inadequate social supports: These patients often have prolonged admissions once the acute phase has resolved; ICS begun before admission will not be an exclusion criterion but will be taken into account in a subgroup analysis of exacerbations of COPD</LI></OL></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2014-12-04 22:45:57 +1100" MODIFIED_BY="Emma J Welsh"><P>Intervention group 1: prednisolone 0.5 mg/kg for 14 days</P><P>Intervention group 2: prednisolone of 1 mg/kg for 3 days (max 50 mg) + 11 days placebo</P><P>Control group: placebo</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2010-08-21 22:31:18 +1000" MODIFIED_BY="[Empty name]"><P>Length of stay in hospital, rate of treatment failure, symptom score, lung function tests, sputum cellularity</P></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2014-12-04 22:45:58 +1100" MODIFIED_BY="Emma J Welsh"><P>07/07/2007. Recruiting not completed</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2014-12-04 22:46:00 +1100" MODIFIED_BY="Emma J Welsh"><P>Dr David Reid, Prof EH Walters. Menzies Research Institute, Tasmania, Hobart TAS 7001, Australia. +61 3 62267043; D.E.C.Reid@utas.edu.au</P></CHAR_CONTACT_INFORMATION><CHAR_NOTES MODIFIED="2010-08-21 22:19:29 +1000" MODIFIED_BY="[Empty name]"/></ONGOING_CHAR><FOOTNOTES><P>COPD: chronic obstructive pulmonary disease; CS: corticosteroid; GP: general practitioner; ICS: inhaled corticosteroid.</P></FOOTNOTES></CHARACTERISTICS_OF_ONGOING_STUDIES></CHARACTERISTICS_OF_STUDIES><QUALITY_ITEMS MODIFIED="2017-11-24 15:49:25 +1100" MODIFIED_BY="[Empty name]"><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-11-24 15:49:25 +1100" MODIFIED_BY="[Empty name]" NO="1"><NAME>Random sequence generation (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-05 01:36:56 +1100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Chen-2005"><DESCRIPTION><P>Stochastic function used to create 150 numbers 0 to 1<BR/>Randomisation code prepared by an assistant not involved in other parts of the study<BR/>Sealed envelopes prepared before study initiation by assistant</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-25 16:45:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomaa-2008"><DESCRIPTION><P>Not stated</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-08 23:13:20 +1100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Leuppi-2013"><DESCRIPTION><P>Randomly assigned to one of two treatment regimens using a centralised, computerbased<BR/>randomisation procedure with fixed blocks of 6. Study subjects randomised after stratification.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-18 20:01:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2004"><DESCRIPTION><P>Not stated</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-18 19:58:32 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salam-1998"><DESCRIPTION><P>Not stated</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-05 01:38:45 +1100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Sayiner-2001"><DESCRIPTION><P>Randomisation sequence was generated before recruitment of participants. This was done by allocating study participants to odd numbers and the control group to even numbers</P><P>Randomisation code was broken only after all data were analysed and statistical analysis was performed</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-08 21:08:03 +1100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Sirichana-2008"><DESCRIPTION><P>Block randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-05 01:39:05 +1100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Wood_x002d_Baker-1997"><DESCRIPTION><P>Computer-generated random numbers table</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-11-24 15:49:25 +1100" MODIFIED_BY="[Empty name]" NO="2"><NAME>Allocation concealment (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 07:05:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2005"><DESCRIPTION><P>Sealed envelopes used and allocated by third party</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-25 16:45:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomaa-2008"><DESCRIPTION><P>Not stated</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-08 23:13:20 +1100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Leuppi-2013"><DESCRIPTION><P>Each study subject randomly assigned to receive a prepared set of study medication, consisting of two drug vials. The drugs prepared prior to the initiation of the study and packed by the Pharmacology Department, University Hospital, Basel, according to a randomisation list.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-18 20:01:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2004"><DESCRIPTION><P>Not stated</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-18 19:58:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salam-1998"><DESCRIPTION><P>Not stated</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-05 01:38:45 +1100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Sayiner-2001"><DESCRIPTION><P>Randomisation code was set up and sealed opaque envelopes were prepared before study initiation by one of the study authors (AS), who also prepared the study medications along with the head nurse</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-08 21:08:29 +1100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Sirichana-2008"><DESCRIPTION><P>Opaque envelopes used</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-27 16:17:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wood_x002d_Baker-1997"><DESCRIPTION><P>information not available</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2017-11-24 15:49:25 +1100" MODIFIED_BY="[Empty name]" NO="3"><NAME>Blinding (performance bias and detection bias)</NAME><DESCRIPTION><P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-05 01:36:56 +1100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Chen-2005"><DESCRIPTION><P>Participants: use of identical boxes and medications</P><P>Researchers: blinded to medications</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-25 16:45:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomaa-2008"><DESCRIPTION><P>States single blinded but no details on blinding provided</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-08 21:04:56 +1100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Leuppi-2013"><DESCRIPTION><P>Patients, caregivers, outcome assessors, data collectors, the biostatistician, and all other investigators remained blinded to group allocation until the primary analysis was completed.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-05 01:37:21 +1100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2004"><DESCRIPTION><P>Claimed to be single blind; however did not state whether 7-day group received placebo for the extra 7 days</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-05 01:37:29 +1100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Salam-1998"><DESCRIPTION><P>Yes, but more information required to decide if adequate</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-05 01:38:45 +1100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Sayiner-2001"><DESCRIPTION><P>Double-blind study: participants and data collectors blinded</P><P>Only the principal investigator (AS) and the head nurse were informed about the randomisation list</P><P>Participants were blinded to the nature of the IV medications. On inclusion of a participant in the study, the related envelope was opened and the drug package was given to the nurse in charge of treatment</P><P>Physician/investigator who followed the participant, recorded arterial blood gas results, performed bedside spirometry and assessed symptom scores remained blinded to the study medication<BR/></P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-08 21:09:17 +1100" MODIFIED_BY="Julia A.E. Walters" RESULT="NO" STUDY_ID="STD-Sirichana-2008"><DESCRIPTION><P>Participants, investigators, outcome assessors not blinded</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-27 16:18:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wood_x002d_Baker-1997"><DESCRIPTION><P>Participants blinded to allocation until completion</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-11-24 15:49:25 +1100" MODIFIED_BY="[Empty name]" NO="4"><NAME>Incomplete outcome data (attrition bias)</NAME><DESCRIPTION><P>Attrition bias due to amount, nature or handling of incomplete outcome data</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-05 01:36:56 +1100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Chen-2005"><DESCRIPTION><P>Numbers of failed treatment given, numbers with side effects given and information included in publication<BR/>Publication details, reasons for withdrawals as worsening disease, poor compliance, treatment failure</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-25 16:46:14 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomaa-2008"><DESCRIPTION><P>Specific data not provided</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-08 23:13:20 +1100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Leuppi-2013"><DESCRIPTION><P>Three patients excluded after randomisation in a blinded fashion because of erroneous initial COPD diagnoses. Data from remaining 311 patients were used for intention-to-treat analyses. 296 patients completed 14-day treatment<BR/>period according to study protocol and were included in the perprotocol analysis.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-05 01:37:17 +1100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2004"><DESCRIPTION><P>Not stated</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-18 19:58:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salam-1998"><DESCRIPTION><P>Not stated</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-05 01:38:45 +1100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Sayiner-2001"><DESCRIPTION><P>2 withdrawals. 1 from each group, reason given</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-05 01:38:55 +1100" MODIFIED_BY="Emma J Welsh" RESULT="NO" STUDY_ID="STD-Sirichana-2008"><DESCRIPTION><P>Number of participants in group 1 was 25, and the number completing the study was 19<BR/>1 participant was reported to withdraw<BR/>Unknown why the other 5 did not complete the study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-27 16:22:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wood_x002d_Baker-1997"><DESCRIPTION><P>Full data on outcomes listed in protocol are available</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-11-24 15:49:25 +1100" MODIFIED_BY="[Empty name]" NO="5"><NAME>Selective reporting (reporting bias)</NAME><DESCRIPTION><P>Reporting bias due to selective outcome reporting</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-05 01:36:56 +1100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2005"><DESCRIPTION><P>Results given by study author for FEV<SUB>1</SUB>, PaO<SUB>2</SUB>, symptom scores, rate of relapse, number of side effects, number with failed treatment</P><P>No information on hospital duration<BR/>Unclear what symptom score scale was used</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-25 16:46:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomaa-2008"><DESCRIPTION><P>Inadequate information to address</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-08 21:03:12 +1100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Leuppi-2013"><DESCRIPTION><P>Prior to its initiation, the study was registered (ISRCTN19646069). The protocol summary published on the<BR/>LANCET website (http://www.thelancet.com/protocol-reviews/05PRT-17), planned outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-18 20:01:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2004"><DESCRIPTION><P>Not stated</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-18 19:58:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salam-1998"><DESCRIPTION><P>Not stated</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-05 01:38:45 +1100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Sayiner-2001"><DESCRIPTION><P>Days 5 and 7 spirometry and ABG results not included. Reason:A comparison of 3 days vs 10 days of treatment was chosen for the 2 groups because these times were roughly the treatment duration in previous studies showing that steroids were effective. Both regimens were of relatively short duration, and the potential for adverse events was taken into account</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-08 21:10:22 +1100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Sirichana-2008"><DESCRIPTION><P>Protocol not available</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-27 16:18:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wood_x002d_Baker-1997"><DESCRIPTION><P>None identified</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6"><NAME>Other bias</NAME><DESCRIPTION><P>Bias due to problems not covered elsewhere in the table</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7"><NAME>Blinding of participants and personnel (performance bias)</NAME><DESCRIPTION><P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8"><NAME>Blinding of outcome assessment (detection bias)</NAME><DESCRIPTION><P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM></QUALITY_ITEMS><SOF_TABLES MODIFIED="2014-12-05 01:46:26 +1100" MODIFIED_BY="Emma J Welsh"><SOF_TABLE ID="SOF-01" MODIFIED="2014-12-05 01:46:26 +1100" MODIFIED_BY="Emma J Welsh" NO="1" READONLY="YES"><TITLE MODIFIED="2014-12-04 22:46:07 +1100" MODIFIED_BY="Emma J Welsh">SCS treatment for 7 or fewer days compared with SCS treatment for longer than 7 days for acute exacerbations of COPD</TITLE><TABLE COLS="7" ROWS="15"><TR><TD COLSPAN="7"><P><B>SCS treatment for 7 or fewer days compared with SCS treatment for longer than 7 days for acute exacerbations of COPD</B></P></TD></TR><TR><TD COLSPAN="7"><P><B>Patient or population:</B> patients with acute exacerbations of COPD<BR/><B>Settings:</B> hospital-initiated treatment<BR/><B>Intervention:</B> SCS treatment for 7 or fewer days<BR/><B>Comparison: </B>SCS treatment for longer than 7 days</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Outcomes</P></TH><TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP"><P>Illustrative comparative risks* (95% CI)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Relative effect<BR/>(95% CI)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Number of participants<BR/>(studies)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Quality of the evidence<BR/>(GRADE)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Comments</P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Assumed risk</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Corresponding risk</P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P><B>SCS treatment for longer than 7 days</B></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><B>SCS treatment for 7 or fewer days</B></P></TH></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Treatment failure</B><BR/>Need for additional treatment<BR/>Follow-up: 10 to 14 days</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>83 per 1000</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>61 per 1000</B><BR/>(32 to 117)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>OR 0.72 </B><BR/>(0.36 to 1.46)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>457<BR/>(4 studies)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Equivalent to 22 fewer (95% CI 51 fewer to 34 more)</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Relapse</B><BR/>New acute exacerbation or COPD-related admission<BR/>Follow-up: 14 to 180 days</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>295 per 1000</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>304 per 1000</B><BR/>(227 to 395)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>OR 1.04 </B><BR/>(0.7 to 1.56)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>478<BR/>(4 studies)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>In one study (<LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK>), hazard ratio for time to re-exacerbation was 0.95 (95% CI 0.66 to 1.37)</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Adverse drug effect</B>&#8212;<B>hyperglycaemia</B><BR/>Follow-up: 3 to 14 days</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>442 per 1000</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>439 per 1000</B><BR/>(336 to 548)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>OR 0.99 </B><BR/>(0.64 to 1.53)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>345<BR/>(2 studies)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate<SUP>a</SUP></B></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P/></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Adverse drug effects</B><BR/>Gastrointestinal tract bleeding, symptomatic gastrointestinal reflux, symptoms of congestive heart failure or ischaemic heart disease, sleep disturbance, fractures, depression<BR/>Follow-up: 10 to 180 days</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>84 per 1000</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>75 per 1000</B><BR/>(40 to 135)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>OR 0.88 </B><BR/>(0.46 to 1.7)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>503<BR/>(5 studies)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>Low</B><SUP>a,b</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P/></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Mortality</B><BR/>Follow-up: 14 to 180 days</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>77 per 1000</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>71 per 1000</B><BR/>(32 to 147)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>OR 0.91 </B><BR/>(0.4 to 2.06)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>336<BR/>(2 studies)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P/></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Length of hospitalisation</B><BR/>(days)<BR/>Follow-up: 3 to 14 days</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean length of hospitalisation in control groups was<BR/><B>10 days</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean length of hospitalisation in intervention groups was<BR/><B>0.61 lower </B>(1.51 lower to 0.28 higher)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>421<BR/>(3 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P/></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Lung function (end of treatment)</B><BR/>FEV<SUB>1</SUB> (L)<BR/>Follow-up: 10 to 14 days</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean FEV<SUB>1</SUB> in control groups ranged from 0.84 to 1.14 L</P></TD><TD ROWSPAN="1" VALIGN="TOP"><P>Mean lung function (end of treatment) in intervention groups was<BR/><B>0.04 lower </B>(0.19 lower to 0.10 higher)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P/></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>187<BR/>(4 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8861;&#8861;&#8861;<BR/><B>Very low</B><SUP>a,c,d,e</SUP></P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P/></TD></TR><TR><TD><P><B>Health-related quality of life (QOL)</B></P><P>Overall score (includes activity limitations, symptoms, fatigue, emotional functioning); scale 0 best to 6 worst; minimum important difference 0.5</P><P>Follow-up: 30 days</P></TD><TD><P>Mean QOL score in control groups was 1.24</P></TD><TD><P>Mean QOL score in intervention groups was <B>0.06 higher</B> (-0.16 lower to 0.28 higher)</P></TD><TD><P/></TD><TD><P>271 (1 study)</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>a</SUP></P></TD><TD><P/></TD></TR><TR><TD COLSPAN="7"><P>*The basis for the <B>assumed risk</B> (e.g. median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/><B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio.</P></TD></TR><TR><TD COLSPAN="7"><P>GRADE Working Group grades of evidence.<BR/><B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/><B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/><B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/><B>Very low quality:</B> We are very uncertain about the estimate.<BR/></P></TD></TR></TABLE><FOOTNOTES><P><SUP>a</SUP>Wide confidence intervals include significant benefit or harm (-1 for imprecision).<BR/><SUP>b</SUP>Participants and physicians not blinded to treatment in one study (-1 for risk of bias).<BR/><SUP>c</SUP>Participants and physicians not blinded to treatment in one study; however risk of bias for the outcome measurement is considered low.<BR/><SUP>d</SUP>High risk of attrition bias in one study (-1 for risk of bias).<BR/><SUP>e</SUP>Significant unexplained heterogeneity (-1 for inconsistency).</P></FOOTNOTES></SOF_TABLE></SOF_TABLES><ADDITIONAL_TABLES MODIFIED="2014-12-05 01:46:19 +1100" MODIFIED_BY="Emma J Welsh"><ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-12-05 01:46:19 +1100" MODIFIED_BY="Emma J Welsh" NO="1"><TITLE MODIFIED="2014-08-05 17:41:53 +1000" MODIFIED_BY="Julia A.E. Walters">Study characteristics</TITLE><TABLE COLS="10" ROWS="9"><TR><TH><P>Study ID/Setting</P></TH><TH><P>Inclusion criteria</P></TH><TH><P>AE definition</P></TH><TH><P>N participants included/Completing</P></TH><TH><P>Mean age, years</P></TH><TH><P>% males/ % smokers</P></TH><TH><P>Prestudy SCS use, %</P></TH><TH><P>SCS &#8804; 7 days</P></TH><TH><P>SCS &gt; 7 days</P></TH><TH><P>Definition of treatment failure</P></TH></TR><TR><TD><P><LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK> China/ inpatients</P></TD><TD><P>2 years of continuous productive cough, FEV<SUB>1</SUB>/FVC post BD &lt; 0.7, FEV<SUB>1</SUB> &lt; 80% predicted. No respiratory failure, diabetes or bronchial asthma</P></TD><TD><P>At least 2 of 3 symptoms: increased sputum or dyspnoea or purulent sputum</P></TD><TD><P>86/81</P></TD><TD><P>71</P></TD><TD><P>75/44</P></TD><TD><P>Not stated</P></TD><TD><P>Prednisolone 30 mg 7 days</P></TD><TD><P>Prednisolone 30 mg/d 10 days + 15 mg/d 5 days</P></TD><TD><P>Not known</P></TD></TR><TR><TD><P><LINK REF="STD-Gomaa-2008" TYPE="STUDY">Gomaa 2008</LINK> (abstract only)</P></TD><TD><P>FEV<SUB>1</SUB> &lt; 50% predicted, no respiratory acidosis</P></TD><TD><P>Not stated</P></TD><TD><P>42/Not known</P></TD><TD><P>Not stated</P></TD><TD><P>Not stated</P></TD><TD><P>Not stated</P></TD><TD><P>Prednisolone 30 mg 7 days</P></TD><TD><P>Prednisolone 30 mg 15 days</P></TD><TD><P>Outcome not reported</P></TD></TR><TR><TD><P><LINK REF="STD-Leuppi-2013" TYPE="STUDY">Leuppi 2013</LINK> Switzerland/5 sites</P></TD><TD><P>Age &gt; 40 years, smoking history &#8805; 20 pack-years</P></TD><TD><P>At least 2 of the following: change in baseline dyspnoea, cough or sputum quantity/purulence</P></TD><TD><P>314/296</P></TD><TD><P>69</P></TD><TD><P>60/45</P></TD><TD><P>20</P></TD><TD><P>5 days: days 1 to 4 methylprednisolone 40 mg, days 2 to 5 oral prednisolone 40 mg</P></TD><TD><P>14 days: days 1 to 4 methylprednisolone 40 mg, days 2 to 14 oral 40 mg prednisolone</P></TD><TD><P>Received open-label glucocorticoids during index exacerbation</P></TD></TR><TR><TD><P><LINK REF="STD-Rahman-2004" TYPE="STUDY">Rahman 2004</LINK> (abstract only) Bangladesh/1 site</P></TD><TD><P>Not stated</P></TD><TD><P>Not stated</P></TD><TD><P>Not stated</P></TD><TD><P>Not stated</P></TD><TD><P>Not stated</P></TD><TD><P>Not stated</P></TD><TD><P>Prednisolone 30 mg 7 days</P></TD><TD><P>Prednisolone 30 mg 14 days</P></TD><TD><P>Outcome not reported</P></TD></TR><TR><TD><P><LINK REF="STD-Salam-1998" TYPE="STUDY">Salam 1998</LINK> (abstract only) USA/Unknown sites</P></TD><TD><P>Not stated</P></TD><TD><P>Not stated</P></TD><TD><P>21/Not known</P></TD><TD><P>Not stated</P></TD><TD><P>Not stated</P></TD><TD><P>None in previous month</P></TD><TD><P>IV CS 3 days</P></TD><TD><P>IV CS 3 days + 7 days OCS</P></TD><TD><P>Outcome not reported</P></TD></TR><TR><TD><P><LINK REF="STD-Sayiner-2001" TYPE="STUDY">Sayiner 2001</LINK> Turkey/1 site</P></TD><TD><P>FEV<SUB>1</SUB> &lt; 35% predicted, PYH &gt; 20, no respiratory failure requiring ventilation</P></TD><TD><P>Not stated, requiring admission</P></TD><TD><P>36/34</P></TD><TD><P>65</P></TD><TD><P>94/Not stated</P></TD><TD><P>None in previous month</P></TD><TD><P>IV methylprednisone 0.5 mg/kg qds 3 days</P></TD><TD><P>IV methylprednisone 0.5 mg/kg qds 3 days, bd 3 days, od 4 days</P></TD><TD><P>Required open-label steroid treatment</P></TD></TR><TR><TD><P><LINK REF="STD-Sirichana-2008" TYPE="STUDY">Sirichana 2008</LINK> (abstract and author data) Thailand/1 site</P></TD><TD><P>Age &gt; 40 years, symptoms &gt; 24 hours</P></TD><TD><P>Increase in at least 2 of 3 symptoms&#8212;dyspnoea, sputum volume, sputum purulence; requiring admission</P></TD><TD><P>48/42</P></TD><TD><P>73</P></TD><TD><P>88/Not stated</P></TD><TD><P>None in previous month</P></TD><TD><P>Prednisolone 30 mg 5 days</P></TD><TD><P>Prednisolone 30 mg 10 days</P></TD><TD><P>Outcome not reported</P></TD></TR><TR><TD><P><LINK REF="STD-Wood_x002d_Baker-1997" TYPE="STUDY">Wood-Baker 1997</LINK> (abstract and author data) Australia &amp; New Zealand/2 sites</P></TD><TD><P>Age &gt; 40 years; &gt; 10 pack-year smoking history; FEV<SUB>1</SUB> &lt; 50% predicted</P></TD><TD><P>Not stated, requiring admission</P></TD><TD><P>38/28</P></TD><TD><P>71</P></TD><TD><P>63/Not stated</P></TD><TD><P>None for current AEs, no long-term OS &gt; 5 mg/d</P></TD><TD><P>Prednisolone 2.5 mg/kg orally daily for 3 days</P></TD><TD><P>Prednisolone 0.6 mg/kg orally daily for 7 days followed by prednisolone 0.3 mg/kg orally daily for 7 days</P></TD><TD><P>Lack of progress according to attending physician during treatment</P></TD></TR></TABLE><FOOTNOTES/></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-12-04 22:36:09 +1100" MODIFIED_BY="Emma J Welsh" NO="2"><TITLE MODIFIED="2014-09-01 16:27:19 +1000" MODIFIED_BY="Julia A.E. Walters">Sensitivity analyses</TITLE><TABLE COLS="3" ROWS="16"><TR><TD><P/></TD><TH><P>Excluding Sirichana (not blinded)</P></TH><TH><P>All studies</P></TH></TR><TR><TH><P>Relapse</P></TH><TD><P>1.01 (0.66 to 1.55)</P></TD><TD><P>1.04 (0.70 to 1.56)</P></TD></TR><TR><TH><P>FEV<SUB>1</SUB> early</P></TH><TD><P>-0.09 (-0.22 to 0.05)</P></TD><TD><P>-0.07 (-0.19 to 0.05)</P></TD></TR><TR><TH><P>FEV<SUB>1</SUB> end</P></TH><TD><P>-0.06 (-0.23 to 0.11)</P></TD><TD><P>-0.04 (-0.19 to 0.10)</P></TD></TR><TR><TH><P>FVC early</P></TH><TD><P>-0.00 (-0.25 to 0.25)</P></TD><TD><P>0.01 (-0.20 to 0.22)</P></TD></TR><TR><TH><P>FVC end</P></TH><TD><P>-0.14 (-0.38 to 0.09)</P></TD><TD><P>-0.12 (-0.33 to 0.09)</P></TD></TR><TR><TH><P>Adverse event&#8212;other</P></TH><TD><P>0.94 (0.48 to 1.82)</P></TD><TD><P>0.89 (0.46 to 1.69)</P></TD></TR><TR><TD><P/></TD><TH><P>Excluding Sayiner (IV SCS)</P></TH><TH><P>All studies</P></TH></TR><TR><TH><P>Treatment failure</P></TH><TD><P>0.66 (0.32 to 1.37)</P></TD><TD><P>0.72 (0.36 to 1.46)</P></TD></TR><TR><TH><P>Relapse</P></TH><TD><P>1.02 (0.67 to 1.56)</P></TD><TD><P>1.04 (0.70 to 1.56)</P></TD></TR><TR><TH><P>Adverse event&#8212;hyperglycaemia</P></TH><TD><P>0.99 (0.63 to 1.54)</P></TD><TD><P>0.99 (0.64 to 1.53)</P></TD></TR><TR><TH><P>Adverse event&#8212;other</P></TH><TD><P>0.89 (0.46 to 1.69)</P></TD><TD><P>0.89 (0.46 to 1.69)</P></TD></TR><TR><TH><P>FEV<SUB>1</SUB> early</P></TH><TD><P>-0.02 (-0.19 to 0.16)</P></TD><TD><P>-0.07 (-0.19 to 0.05)</P></TD></TR><TR><TH><P>FEV<SUB>1</SUB> end</P></TH><TD><P>0.03 (-0.06 to 0.12)</P></TD><TD><P>-0.04 (-0.19 to 0.10)</P></TD></TR><TR><TH><P>FVC early</P></TH><TD><P>0.12 (-0.18 to 0.42)</P></TD><TD><P>0.01 (-0.20 to 0.22)</P></TD></TR><TR><TH><P>FVC end</P></TH><TD><P>-0.06 (-0.34 to 0.22)</P></TD><TD><P>-0.12 (-0.33 to 0.09)</P></TD></TR></TABLE><FOOTNOTES/></ADDITIONAL_TABLE></ADDITIONAL_TABLES><ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-12-08 21:20:20 +1100" MODIFIED_BY="Julia A.E. Walters"><COMPARISON ID="CMP-001" MODIFIED="2014-12-08 21:20:20 +1100" MODIFIED_BY="Julia A.E. Walters" NO="1"><NAME>Systemic corticosteroids for 7 or fewer days vs longer than 7 days</NAME><DICH_OUTCOME CHI2="1.0144391933359038" CI_END="1.4631088010664839" CI_START="0.35714284237012467" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7228684776013057" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.1652766227390278" LOG_CI_START="-0.44715804930622494" LOG_EFFECT_SIZE="-0.14094071328359856" METHOD="MH" MODIFIED="2014-11-10 22:54:14 +1100" MODIFIED_BY="Christopher J Cates" NO="1" P_CHI2="0.7977581717288675" P_Q="1.0" P_Z="0.36700364942132035" Q="0.0" RANDOM="NO" SCALE="103.43579487037232" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="229" TOTAL_2="228" WEIGHT="100.00000000000003" Z="0.9021002062758066"><NAME>Treatment failure</NAME><GROUP_LABEL_1>seven days or less</GROUP_LABEL_1><GROUP_LABEL_2>more than seven days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &gt; 7 days</GRAPH_LABEL_2><DICH_DATA CI_END="2.4869108674789833" CI_START="0.12434884634064411" EFFECT_SIZE="0.5560975609756098" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3956602201490196" LOG_CI_START="-0.905358239587583" LOG_EFFECT_SIZE="-0.25484900971928165" MODIFIED="2010-07-26 21:56:43 +1000" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.7642246833945214" STUDY_ID="STD-Chen-2005" TOTAL_1="44" TOTAL_2="43" VAR="0.5840393667094566" WEIGHT="25.695472259696327"/><DICH_DATA CI_END="1.6133300951448948" CI_START="0.27721523758829864" EFFECT_SIZE="0.6687598116169545" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.2077232352333565" LOG_CI_START="-0.5571829016986195" LOG_EFFECT_SIZE="-0.17472983323263147" MODIFIED="2014-03-03 15:51:15 +1100" MODIFIED_BY="Julia A.E. Walters" ORDER="669" O_E="0.0" SE="0.4493096511802859" STUDY_ID="STD-Leuppi-2013" TOTAL_1="156" TOTAL_2="155" VAR="0.20187916264375017" WEIGHT="67.00732697796774"/><DICH_DATA CI_END="83.7603763141623" CI_START="0.12086821224604492" EFFECT_SIZE="3.1818181818181817" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.923038619850311" LOG_CI_START="-0.9176879014662097" LOG_EFFECT_SIZE="0.5026753591920505" MODIFIED="2014-08-07 17:57:54 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="52" O_E="0.0" SE="1.668656820444391" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" VAR="2.7844155844155845" WEIGHT="2.499041356964369"/><DICH_DATA CI_END="19.629617691588546" CI_START="0.06062688857858191" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.292911841319297" LOG_CI_START="-1.2173347195404975" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2010-07-26 21:58:08 +1000" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="1.4745312557699224" STUDY_ID="STD-Wood_x002d_Baker-1997" TOTAL_1="12" TOTAL_2="13" VAR="2.1742424242424243" WEIGHT="4.798159405371588"/></DICH_OUTCOME><DICH_OUTCOME CHI2="0.49396780494971243" CI_END="1.5617446370138495" CI_START="0.6977595312344381" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0438976031348484" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.1936100232658642" LOG_CI_START="-0.156294222436249" LOG_EFFECT_SIZE="0.01865790041480762" METHOD="MH" MODIFIED="2014-10-04 02:21:40 +1000" MODIFIED_BY="Emma J Welsh" NO="2" P_CHI2="0.9202146946603986" P_Q="1.0" P_Z="0.8344311974403947" Q="0.0" RANDOM="NO" SCALE="9.122174244420812" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="241" TOTAL_2="237" WEIGHT="100.0" Z="0.2090218297681949"><NAME>Relapse</NAME><GROUP_LABEL_1>SCS 7 days or less</GROUP_LABEL_1><GROUP_LABEL_2>SCS more than 7 days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &gt; 7 days</GRAPH_LABEL_2><DICH_DATA CI_END="6.343720113251369" CI_START="0.28024215224505017" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8023440135352833" LOG_CI_START="-0.5524665403186836" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2010-10-25 08:58:33 +1100" MODIFIED_BY="Julia AE Walters" ORDER="53" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Chen-2005" TOTAL_1="44" TOTAL_2="43" VAR="0.6333333333333334" WEIGHT="5.952292595850672"/><DICH_DATA CI_END="1.5284765749503098" CI_START="0.6064845011195794" EFFECT_SIZE="0.9628070175438597" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="57" LOG_CI_END="0.18425878722450498" LOG_CI_START="-0.21718029317209725" LOG_EFFECT_SIZE="-0.01646075297379612" MODIFIED="2014-01-13 00:13:58 +1100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.23580730298046057" STUDY_ID="STD-Leuppi-2013" TOTAL_1="156" TOTAL_2="155" VAR="0.05560508413891872" WEIGHT="79.09276254775853"/><DICH_DATA CI_END="5.53348755838761" CI_START="0.3096996225584393" EFFECT_SIZE="1.309090909090909" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.7429989378065325" LOG_CI_START="-0.5090593239324833" LOG_EFFECT_SIZE="0.1169698069370246" MODIFIED="2014-08-07 17:58:28 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="33" O_E="0.0" SE="0.7354652207338501" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" VAR="0.5409090909090909" WEIGHT="6.980813742927809"/><DICH_DATA CI_END="5.2936755218927445" CI_START="0.370253142999442" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7237573175149633" LOG_CI_START="-0.43150124615848723" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2014-09-01 17:09:02 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="34" O_E="0.0" SE="0.6786045989239038" STUDY_ID="STD-Sirichana-2008" TOTAL_1="24" TOTAL_2="22" VAR="0.4605042016806723" WEIGHT="7.974131113462992"/></DICH_OUTCOME><IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-10-04 02:21:44 +1000" MODIFIED_BY="Emma J Welsh" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.7304628173345913" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="155" WEIGHT="0.0" Z="0.0"><NAME>Time to re-exacerbation</NAME><GROUP_LABEL_1>SCS seven days or less</GROUP_LABEL_1><GROUP_LABEL_2>SCS more than seven days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours &gt;7 days</GRAPH_LABEL_2><EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE><IV_DATA CI_END="1.367331880331135" CI_START="0.6600357304856592" EFFECT_SIZE="0.9499936296895315" ESTIMABLE="YES" ESTIMATE="-0.0513" LOG_CI_END="0.13587393980768342" LOG_CI_START="-0.18043255365095703" LOG_EFFECT_SIZE="-0.022279306921636797" MODIFIED="2014-07-20 23:10:31 +1000" MODIFIED_BY="[Empty name]" ORDER="370" SE="0.1858" STUDY_ID="STD-Leuppi-2013" TOTAL_1="156" TOTAL_2="155" WEIGHT="0.0"/></IV_OUTCOME><DICH_OUTCOME CHI2="1.2706137619424197E-4" CI_END="1.5273746309270801" CI_START="0.6395295159403281" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9883325140742527" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.18394557287134689" LOG_CI_START="-0.19413940690979614" LOG_EFFECT_SIZE="-0.005096917019224632" METHOD="MH" MODIFIED="2014-12-08 21:17:44 +1100" MODIFIED_BY="Julia A.E. Walters" NO="4" P_CHI2="0.9910063156421943" P_Q="1.0" P_Z="0.9578561510313413" Q="0.0" RANDOM="NO" SCALE="35.31" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="173" TOTAL_2="172" WEIGHT="100.00000000000001" Z="0.052844065879856815"><NAME>Adverse effect&#8212;hyperglycaemia</NAME><GROUP_LABEL_1>SCS 7 days or less</GROUP_LABEL_1><GROUP_LABEL_2>More than 7 days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &gt; 7 days</GRAPH_LABEL_2><DICH_DATA CI_END="1.541582251019861" CI_START="0.6329590759438465" EFFECT_SIZE="0.9878048780487805" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="74" LOG_CI_END="0.1879667014343009" LOG_CI_START="-0.19862436844443485" LOG_EFFECT_SIZE="-0.0053288335050669456" MODIFIED="2014-01-13 00:08:45 +1100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.22708550810342834" STUDY_ID="STD-Leuppi-2013" TOTAL_1="156" TOTAL_2="155" VAR="0.051567827990592216" WEIGHT="95.6733845911279"/><DICH_DATA CI_END="8.05699772563552" CI_START="0.1241157108457694" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9061732410495242" LOG_CI_START="-0.9061732410495242" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-07 17:59:14 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="19" O_E="0.0" SE="1.0645812948447542" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" VAR="1.1333333333333333" WEIGHT="4.3266154088721125"/></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-12-08 21:17:59 +1100" MODIFIED_BY="Julia A.E. Walters" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="17.86" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="156" TOTAL_2="155" WEIGHT="0.0" Z="0.0"><NAME>Adverse effect&#8212;hypertension</NAME><GROUP_LABEL_1>SCS 7 days or less</GROUP_LABEL_1><GROUP_LABEL_2>More than 7 days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &gt; 7 days</GRAPH_LABEL_2><DICH_DATA CI_END="1.2202198957303467" CI_START="0.3054909726779206" EFFECT_SIZE="0.61054579093432" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.08643810190162353" LOG_CI_START="-0.5150016187245069" LOG_EFFECT_SIZE="-0.2142817584114417" MODIFIED="2014-01-13 00:10:31 +1100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.3532886690704214" STUDY_ID="STD-Leuppi-2013" TOTAL_1="156" TOTAL_2="155" VAR="0.12481288369354973" WEIGHT="0.0"/></DICH_OUTCOME><DICH_OUTCOME CHI2="0.7972521433534462" CI_END="1.6921873080797223" CI_START="0.46321930345803275" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8853551977422465" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" I2="0.0" I2_Q="100.0" ID="CMP-001.06" LOG_CI_END="0.2284484333857081" LOG_CI_START="-0.33421335081208614" LOG_EFFECT_SIZE="-0.05288245871318906" METHOD="MH" MODIFIED="2014-12-08 21:18:16 +1100" MODIFIED_BY="Julia A.E. Walters" NO="6" P_CHI2="0.6712418748146819" P_Q="0.0" P_Z="0.7125606513956493" Q="1.7630736046477595E-33" RANDOM="NO" SCALE="176.54" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="253" TOTAL_2="250" WEIGHT="99.99999999999999" Z="0.36841924368313356"><NAME>Other adverse effects&#8212;gastrointestinal tract bleeding, symptomatic gastrointestinal reflux, symptoms of congestive heart failure or ischaemic heart disease, sleep disturbance, fractures, depression</NAME><GROUP_LABEL_1>seven days or less</GROUP_LABEL_1><GROUP_LABEL_2>more than seven days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &gt; 7 days</GRAPH_LABEL_2><DICH_DATA CI_END="5.460316011305268" CI_START="0.041624883698776864" EFFECT_SIZE="0.47674418604651164" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7372177778685902" LOG_CI_START="-1.3806469669162544" LOG_EFFECT_SIZE="-0.3217145945238322" MODIFIED="2010-07-26 21:52:42 +1000" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="1.2440442346861817" STUDY_ID="STD-Chen-2005" TOTAL_1="44" TOTAL_2="43" VAR="1.5476460578559275" WEIGHT="10.147607524556642"/><DICH_DATA CI_END="1.9887318510272707" CI_START="0.4955719675554151" EFFECT_SIZE="0.9927536231884058" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.29857622934367695" LOG_CI_START="-0.3048932678333365" LOG_EFFECT_SIZE="-0.003158519244829757" MODIFIED="2014-03-03 16:21:37 +1100" MODIFIED_BY="Julia A.E. Walters" ORDER="670" O_E="0.0" SE="0.35448096986396604" STUDY_ID="STD-Leuppi-2013" TOTAL_1="156" TOTAL_2="155" VAR="0.125656757995698" WEIGHT="81.99279020851293"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-07 17:59:59 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="5" O_E="0.0" SE="0.0" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/><DICH_DATA CI_END="7.56369531300742" CI_START="0.01131275067646809" EFFECT_SIZE="0.2925170068027211" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8787340259180129" LOG_CI_START="-1.9464317842551917" LOG_EFFECT_SIZE="-0.5338488791685896" MODIFIED="2014-08-07 18:00:21 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="72" O_E="0.0" SE="1.6595163816920446" STUDY_ID="STD-Sirichana-2008" TOTAL_1="24" TOTAL_2="22" VAR="2.7539946211042556" WEIGHT="7.859602266930408"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-26 21:54:50 +1000" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.0" STUDY_ID="STD-Wood_x002d_Baker-1997" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="2.0628897481208837" CI_START="0.4016534248462089" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9102564102564102" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.31447601756974564" LOG_CI_START="-0.3961485255125559" LOG_EFFECT_SIZE="-0.04083625397140512" METHOD="MH" MODIFIED="2014-10-04 02:21:58 +1000" MODIFIED_BY="Emma J Welsh" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.8217771364796052" Q="0.0" RANDOM="NO" SCALE="4.056969826494393" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="168" TOTAL_2="168" WEIGHT="100.0" Z="0.22525984453147482"><NAME>Mortality</NAME><GROUP_LABEL_1>seven days or less</GROUP_LABEL_1><GROUP_LABEL_2>more than seven days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours &gt; 7 days</GRAPH_LABEL_2><DICH_DATA CI_END="2.062889748120884" CI_START="0.40165342484620886" EFFECT_SIZE="0.9102564102564102" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.31447601756974575" LOG_CI_START="-0.39614852551255597" LOG_EFFECT_SIZE="-0.04083625397140512" MODIFIED="2014-01-13 00:14:49 +1100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.4174243742547642" STUDY_ID="STD-Leuppi-2013" TOTAL_1="156" TOTAL_2="155" VAR="0.17424310822198147" WEIGHT="100.0"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-27 16:40:14 +1000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.0" STUDY_ID="STD-Wood_x002d_Baker-1997" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/></DICH_OUTCOME><CONT_OUTCOME CHI2="1.1862194845091603" CI_END="0.2830923856147457" CI_START="-1.5071164502147179" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6120120322999861" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2014-09-25 13:41:23 +1000" MODIFIED_BY="Julia A.E. Walters" NO="8" P_CHI2="0.5526063718688106" P_Q="1.0" P_Z="0.1802157011052865" Q="0.0" RANDOM="NO" SCALE="5.26" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="211" TOTAL_2="210" UNITS="" WEIGHT="99.99999999999999" Z="1.3400911864646885"><NAME>Length of hospitalisation</NAME><GROUP_LABEL_1>SCS 7 days or less</GROUP_LABEL_1><GROUP_LABEL_2>SCS more than 7 days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &gt; 7 days</GRAPH_LABEL_2><CONT_DATA CI_END="1.7035084808539773" CI_START="-1.503508480853978" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="12.4" MODIFIED="2011-07-18 11:03:51 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="151" SD_1="3.5" SD_2="4.1" SE="0.8181316052245081" STUDY_ID="STD-Chen-2005" TOTAL_1="44" TOTAL_2="43" WEIGHT="31.160533086115795"/><CONT_DATA CI_END="0.1647802803431777" CI_START="-2.1647802803431775" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="9.0" MODIFIED="2014-09-25 13:41:23 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="62" SD_1="4.4444" SD_2="5.9259" SE="0.5942865733915602" STUDY_ID="STD-Leuppi-2013" TOTAL_1="156" TOTAL_2="155" WEIGHT="59.05536830879113"/><CONT_DATA CI_END="2.3238287486760294" CI_START="-3.399428748676029" EFFECT_SIZE="-0.5377999999999998" ESTIMABLE="YES" MEAN_1="7.5455" MEAN_2="8.0833" MODIFIED="2010-10-11 12:12:40 +1100" MODIFIED_BY="[Empty name]" ORDER="45" SD_1="2.4234" SD_2="4.3788" SE="1.4600414962969686" STUDY_ID="STD-Wood_x002d_Baker-1997" TOTAL_1="11" TOTAL_2="12" WEIGHT="9.784098605093067"/></CONT_OUTCOME><CONT_OUTCOME CHI2="0.690702651823881" CI_END="0.053320140403038105" CI_START="-0.18838879701762712" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0675343283072945" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2014-11-29 07:56:59 +1100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.7079716670055618" P_Q="0.7779895611315073" P_Z="0.2734107876877192" Q="0.07949013834074563" RANDOM="NO" SCALE="0.84" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="48" UNITS="" WEIGHT="100.00000000000001" Z="1.0952416788133579"><NAME>FEV<SUB>1</SUB> (L) (early)</NAME><GROUP_LABEL_1>seven days or less</GROUP_LABEL_1><GROUP_LABEL_2>more than seven days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &gt; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &#8804;7 days</GRAPH_LABEL_2><CONT_SUBGROUP CHI2="0.6112125134831355" CI_END="0.06420326387717927" CI_START="-0.2210668185079372" DF="1" EFFECT_SIZE="-0.07843177731537897" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" MODIFIED="2014-11-29 07:56:49 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.43433182712094165" P_Z="0.2811499142389089" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="35" WEIGHT="71.79148937642512" Z="1.0777397860745925"><NAME>FEV<SUB>1</SUB> absolute</NAME><CONT_DATA CI_END="0.053610482477911475" CI_START="-0.2776104824779114" EFFECT_SIZE="-0.11199999999999999" ESTIMABLE="YES" MEAN_1="0.599" MEAN_2="0.711" MODIFIED="2014-08-07 18:02:12 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="10" SD_1="0.2226" SD_2="0.268" SE="0.08449669676801504" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" WEIGHT="53.253699359129364"/><CONT_DATA CI_END="0.29869439091278766" CI_START="-0.26269439091278807" EFFECT_SIZE="0.017999999999999794" ESTIMABLE="YES" MEAN_1="1.142" MEAN_2="1.124" MODIFIED="2014-08-07 17:41:02 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="35" SD_1="0.459" SD_2="0.452" SE="0.14321405552697367" STUDY_ID="STD-Sirichana-2008" TOTAL_1="23" TOTAL_2="18" WEIGHT="18.537790017295748"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="0.0" CI_END="0.18774779699435246" CI_START="-0.26734779699435246" DF="0" EFFECT_SIZE="-0.0398" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" MODIFIED="2014-11-29 07:56:59 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7317384065022863" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="13" WEIGHT="28.208510623574895" Z="0.3428139828865503"><NAME>FEV<SUB>1</SUB> change</NAME><CONT_DATA CI_END="0.18774779699435246" CI_START="-0.26734779699435246" EFFECT_SIZE="-0.0398" ESTIMABLE="YES" MEAN_1="0.3025" MEAN_2="0.3423" MODIFIED="2011-07-16 07:04:15 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="146" SD_1="0.2053" SD_2="0.3267" SE="0.11609794812007794" STUDY_ID="STD-Wood_x002d_Baker-1997" TOTAL_1="8" TOTAL_2="13" WEIGHT="28.208510623574895"/></CONT_SUBGROUP></CONT_OUTCOME><CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2014-11-29 07:57:44 +1100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="8.79" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="141" TOTAL_2="148" UNITS="" WEIGHT="0.0" Z="0.0"><NAME>FEV<SUB>1</SUB> % predicted (6 days)</NAME><GROUP_LABEL_1>seven days or less</GROUP_LABEL_1><GROUP_LABEL_2>more than seven days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &gt; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &#8804;7 days</GRAPH_LABEL_2><CONT_DATA CI_END="4.664566776695338" CI_START="-3.1455667766953326" EFFECT_SIZE="0.7595000000000027" ESTIMABLE="YES" MEAN_1="42.2785" MEAN_2="41.519" MODIFIED="2014-07-14 09:56:42 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="57" SD_1="16.7257" SD_2="17.143" SE="1.9924176196593426" STUDY_ID="STD-Leuppi-2013" TOTAL_1="141" TOTAL_2="148" WEIGHT="0.0"/></CONT_OUTCOME><CONT_OUTCOME CHI2="1.4216495991626716" CI_END="0.2189440449794586" CI_START="-0.2025602406155901" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.008191902181934246" ESTIMABLE="YES" I2="0.0" I2_Q="12.645069490593663" ID="CMP-001.11" MODIFIED="2014-08-07 18:03:11 +1000" MODIFIED_BY="Julia A.E. Walters" NO="11" P_CHI2="0.4912389242005326" P_Q="0.28464983769298613" P_Z="0.9392731195553589" Q="1.1447550746918864" RANDOM="NO" SCALE="1.11" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="48" UNITS="" WEIGHT="99.99999999999999" Z="0.07618348752397508"><NAME>FVC (L) (early)</NAME><GROUP_LABEL_1>seven days or less</GROUP_LABEL_1><GROUP_LABEL_2>more than seven days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &gt;7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &#8804;7 days</GRAPH_LABEL_2><CONT_SUBGROUP CHI2="0.27689452447078505" CI_END="0.1860270317570253" CI_START="-0.2878185157661827" DF="1" EFFECT_SIZE="-0.05089574200457871" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" MODIFIED="2014-08-07 18:03:11 +1000" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.5987439756966793" P_Z="0.6737263163774369" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="35" WEIGHT="79.12803500041434" Z="0.42103939486961606"><NAME>FVC measured</NAME><CONT_DATA CI_END="0.1968131228568793" CI_START="-0.39281312285687947" EFFECT_SIZE="-0.09800000000000009" ESTIMABLE="YES" MEAN_1="1.136" MEAN_2="1.234" MODIFIED="2014-08-07 18:03:11 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="53" SD_1="0.3628" SD_2="0.503" SE="0.15041762255956112" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" WEIGHT="51.103468268607905"/><CONT_DATA CI_END="0.43310950392058367" CI_START="-0.3631095039205843" EFFECT_SIZE="0.0349999999999997" ESTIMABLE="YES" MEAN_1="2.267" MEAN_2="2.232" MODIFIED="2014-08-07 17:45:35 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="70" SD_1="0.749" SD_2="0.551" SE="0.2031208262298802" STUDY_ID="STD-Sirichana-2008" TOTAL_1="23" TOTAL_2="18" WEIGHT="28.02456673180643"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="1.3906441042473954E-32" CI_END="0.6935073030287013" CI_START="-0.22910730302870133" DF="0" EFFECT_SIZE="0.2322" ESTIMABLE="YES" I2="100.0" ID="CMP-001.11.02" MODIFIED="2011-07-16 07:18:09 +1000" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="0.0" P_Z="0.32386232968818784" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="13" WEIGHT="20.871964999585646" Z="0.9865519887117097"><NAME>FVC change from baseline</NAME><CONT_DATA CI_END="0.6935073030287013" CI_START="-0.2291073030287013" EFFECT_SIZE="0.23220000000000002" ESTIMABLE="YES" MEAN_1="0.6722" MEAN_2="0.44" MODIFIED="2011-07-16 07:18:09 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="149" SD_1="0.5042" SD_2="0.5941" SE="0.23536519378286255" STUDY_ID="STD-Wood_x002d_Baker-1997" TOTAL_1="9" TOTAL_2="13" WEIGHT="20.871964999585646"/></CONT_SUBGROUP></CONT_OUTCOME><CONT_OUTCOME CHI2="7.17122537739779" CI_END="0.09663633298226626" CI_START="-0.18553903928313448" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.044451353150434116" ESTIMABLE="YES" I2="58.16614536400745" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2014-12-08 21:18:55 +1100" MODIFIED_BY="Julia A.E. Walters" NO="12" P_CHI2="0.06663604160062542" P_Q="0.964251572835865" P_Z="0.5368984180828387" Q="0.0020087447038811476" RANDOM="YES" SCALE="0.46" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.011544512640657992" TOTALS="YES" TOTAL_1="93" TOTAL_2="94" UNITS="" WEIGHT="100.0" Z="0.617509958714456"><NAME>FEV<SUB>1</SUB> (L) end of treatment</NAME><GROUP_LABEL_1>seven days or less</GROUP_LABEL_1><GROUP_LABEL_2>more than seven days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &gt;7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &#8804;7 days</GRAPH_LABEL_2><CONT_SUBGROUP CHI2="7.09011245663286" CI_END="0.1565319101634557" CI_START="-0.25435067513288884" DF="2" EFFECT_SIZE="-0.04890938248471659" ESTIMABLE="YES" I2="71.79170270946855" ID="CMP-001.12.01" MODIFIED="2014-11-29 07:58:16 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02886704256005246" P_Z="0.6407800938920878" STUDIES="3" TAU2="0.02274535001394711" TOTAL_1="82" TOTAL_2="82" WEIGHT="74.56778723137441" Z="0.46660837721803294"><NAME>FEV<SUB>1</SUB> measured</NAME><CONT_DATA CI_END="0.17486334498926306" CI_START="-0.04886334498926295" EFFECT_SIZE="0.06300000000000006" ESTIMABLE="YES" MEAN_1="0.934" MEAN_2="0.871" MODIFIED="2011-08-15 18:53:02 +1000" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="0.301" SD_2="0.227" SE="0.05707418395012704" STUDY_ID="STD-Chen-2005" TOTAL_1="44" TOTAL_2="43" WEIGHT="35.00760259504204"/><CONT_DATA CI_END="-0.044737127731824006" CI_START="-0.41326287226817593" EFFECT_SIZE="-0.22899999999999998" ESTIMABLE="YES" MEAN_1="0.606" MEAN_2="0.835" MODIFIED="2014-08-07 18:03:44 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="22" SD_1="0.2391" SD_2="0.3051" SE="0.094013397042812" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" WEIGHT="25.422207846322248"/><CONT_DATA CI_END="0.32856148807267116" CI_START="-0.2925614880726711" EFFECT_SIZE="0.018000000000000016" ESTIMABLE="YES" MEAN_1="1.153" MEAN_2="1.135" MODIFIED="2014-08-07 17:48:01 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="36" SD_1="0.539" SD_2="0.498" SE="0.1584526504172222" STUDY_ID="STD-Sirichana-2008" TOTAL_1="21" TOTAL_2="22" WEIGHT="14.137976790010132"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="0.0" CI_END="0.14157926861945758" CI_START="-0.22677926861945752" DF="0" EFFECT_SIZE="-0.04259999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" MODIFIED="2014-11-29 07:58:31 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6503092668352106" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="25.43221276862559" Z="0.4533325947445179"><NAME>FEV<SUB>1</SUB> change from baseline</NAME><CONT_DATA CI_END="0.14157926861945758" CI_START="-0.22677926861945752" EFFECT_SIZE="-0.04259999999999997" ESTIMABLE="YES" MEAN_1="0.2691" MEAN_2="0.3117" MODIFIED="2011-07-16 07:07:39 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="147" SD_1="0.2216" SD_2="0.2289" SE="0.09397074133618787" STUDY_ID="STD-Wood_x002d_Baker-1997" TOTAL_1="11" TOTAL_2="12" WEIGHT="25.43221276862559"/></CONT_SUBGROUP></CONT_OUTCOME><CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2014-11-29 07:58:54 +1100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.1" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="118" TOTAL_2="127" UNITS="" WEIGHT="0.0" Z="0.0"><NAME>FEV<SUB>1</SUB> % predicted 30 days</NAME><GROUP_LABEL_1>seven days or less</GROUP_LABEL_1><GROUP_LABEL_2>more than seven days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &gt; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &#8804;7 days</GRAPH_LABEL_2><CONT_DATA CI_END="5.700024253618708" CI_START="-3.168224253618704" EFFECT_SIZE="1.265900000000002" ESTIMABLE="YES" MEAN_1="47.3418" MEAN_2="46.0759" MODIFIED="2014-07-14 09:59:51 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="57" SD_1="18.0517" SD_2="17.3002" SE="2.262349863872251" STUDY_ID="STD-Leuppi-2013" TOTAL_1="118" TOTAL_2="127" WEIGHT="0.0"/></CONT_OUTCOME><CONT_OUTCOME CHI2="0.4251552565835612" CI_END="0.08604174522191163" CI_START="-0.3250552519322073" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.11950675335514785" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2014-12-08 21:19:05 +1100" MODIFIED_BY="Julia A.E. Walters" NO="14" P_CHI2="0.8084976584558363" P_Q="0.7698938732182801" P_Z="0.25448167111140496" Q="0.08556428473425184" RANDOM="NO" SCALE="1.11" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="51" UNITS="" WEIGHT="99.99999999999999" Z="1.1395312255107004"><NAME>FVC (L) end of treatment</NAME><GROUP_LABEL_1>seven days or less</GROUP_LABEL_1><GROUP_LABEL_2>more than seven days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &gt; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &#8804;7 days</GRAPH_LABEL_2><CONT_SUBGROUP CHI2="0.33959097184930936" CI_END="0.10859826874205511" CI_START="-0.3896177900515627" DF="1" EFFECT_SIZE="-0.1405097606547538" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" MODIFIED="2014-08-07 18:04:11 +1000" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.5600655909225731" P_Z="0.2689340695659995" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="39" WEIGHT="68.08527019298805" Z="1.105520649119584"><NAME>FVC measured</NAME><CONT_DATA CI_END="0.11232272221530903" CI_START="-0.49832272221530916" EFFECT_SIZE="-0.19300000000000006" ESTIMABLE="YES" MEAN_1="1.148" MEAN_2="1.341" MODIFIED="2014-08-07 18:04:11 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="49" SD_1="0.4782" SD_2="0.4288" SE="0.1557797615791187" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" WEIGHT="45.32213561772879"/><CONT_DATA CI_END="0.3948224001270624" CI_START="-0.46682240012706244" EFFECT_SIZE="-0.03600000000000003" ESTIMABLE="YES" MEAN_1="2.321" MEAN_2="2.357" MODIFIED="2014-08-07 17:44:23 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="71" SD_1="0.735" SD_2="0.705" SE="0.21981138608940495" STUDY_ID="STD-Sirichana-2008" TOTAL_1="21" TOTAL_2="22" WEIGHT="22.76313457525926"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="0.0" CI_END="0.2891469366776284" CI_START="-0.4385469366776284" DF="0" EFFECT_SIZE="-0.07469999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.02" MODIFIED="2011-07-16 07:20:11 +1000" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="1.0" P_Z="0.6873951267030383" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="12" WEIGHT="31.91472980701194" Z="0.40239258569012487"><NAME>FVC change from baseline</NAME><CONT_DATA CI_END="0.2891469366776284" CI_START="-0.4385469366776284" EFFECT_SIZE="-0.07469999999999999" ESTIMABLE="YES" MEAN_1="0.607" MEAN_2="0.6817" MODIFIED="2011-07-16 07:20:11 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="150" SD_1="0.4143" SD_2="0.4556" SE="0.18563960335373844" STUDY_ID="STD-Wood_x002d_Baker-1997" TOTAL_1="10" TOTAL_2="12" WEIGHT="31.91472980701194"/></CONT_SUBGROUP></CONT_OUTCOME><CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2014-11-29 07:59:10 +1100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="15.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0"><NAME>PaO<SUB>2</SUB> (mmHg) (early)</NAME><GROUP_LABEL_1>SCS 7 days or less</GROUP_LABEL_1><GROUP_LABEL_2>SCS more than 7 days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &gt; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &#8804; 7 days</GRAPH_LABEL_2><CONT_DATA CI_END="8.80941172619835" CI_START="-9.209411726198356" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" MEAN_1="52.8" MEAN_2="53.0" MODIFIED="2010-08-25 22:25:28 +1000" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="13.1939" SD_2="13.6062" SE="4.596723101681175" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/></CONT_OUTCOME><CONT_OUTCOME CHI2="1.048522234095934" CI_END="2.2056692786420697" CI_START="-4.9596714298987274" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3770010756283289" ESTIMABLE="YES" I2="4.627678128139189" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2014-12-08 21:19:17 +1100" MODIFIED_BY="Julia A.E. Walters" NO="16" P_CHI2="0.30584802938185573" P_Q="1.0" P_Z="0.4512617940024025" Q="0.0" RANDOM="NO" SCALE="16.69" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="60" UNITS="" WEIGHT="100.0" Z="0.753313101130695"><NAME>PaO<SUB>2</SUB> (mmHg) end of treatment</NAME><GROUP_LABEL_1>SCS 7 days or less</GROUP_LABEL_1><GROUP_LABEL_2>SCS more than 7 days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &gt; 7days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &#8804; 7 days</GRAPH_LABEL_2><CONT_DATA CI_END="2.8054817788112585" CI_START="-12.80548177881126" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="55.8" MEAN_2="60.8" MODIFIED="2010-09-11 17:17:16 +1000" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="12.7816" SD_2="10.3078" SE="3.982461841329689" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" WEIGHT="21.0675615605301"/><CONT_DATA CI_END="3.6225437725484264" CI_START="-4.44254377254842" EFFECT_SIZE="-0.4099999999999966" ESTIMABLE="YES" MEAN_1="79.2" MEAN_2="79.61" MODIFIED="2010-08-09 21:40:22 +1000" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="9.38" SD_2="9.8" SE="2.057458098391916" STUDY_ID="STD-Chen-2005" TOTAL_1="44" TOTAL_2="43" WEIGHT="78.9324384394699"/></CONT_OUTCOME><CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2014-12-08 21:19:47 +1100" MODIFIED_BY="Julia A.E. Walters" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="35.66" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="34" TOTAL_2="34" UNITS="" WEIGHT="0.0" Z="0.0"><NAME>PaCO<SUB>2</SUB> (mmHg)</NAME><GROUP_LABEL_1>SCS 7 days or less</GROUP_LABEL_1><GROUP_LABEL_2>SCS more than 7 days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours SCS &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours SCS &gt;7 days</GRAPH_LABEL_2><CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.01" MODIFIED="2014-12-08 21:19:37 +1100" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0"><NAME>3 days of follow-up</NAME><CONT_DATA CI_END="7.536058064083996" CI_START="-11.136058064084004" EFFECT_SIZE="-1.8000000000000043" ESTIMABLE="YES" MEAN_1="55.3" MEAN_2="57.1" MODIFIED="2010-08-24 16:21:27 +1000" MODIFIED_BY="Julia AE Walters" ORDER="57" SD_1="12.3693" SD_2="15.2554" SE="4.76338245892559" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.02" MODIFIED="2014-12-08 21:19:47 +1100" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0"><NAME>10 days of follow-up</NAME><CONT_DATA CI_END="8.204107498982172" CI_START="-5.204107498982172" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="54.9" MEAN_2="53.4" MODIFIED="2010-09-11 17:18:44 +1000" MODIFIED_BY="[Empty name]" ORDER="58" SD_1="11.1324" SD_2="8.6585" SE="3.4205258626501895" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/></CONT_SUBGROUP></CONT_OUTCOME><CONT_OUTCOME CHI2="0.246084621168011" CI_END="0.14400687539643287" CI_START="-0.29451612896229157" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.07525462678292937" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2014-12-08 21:19:56 +1100" MODIFIED_BY="Julia A.E. Walters" NO="18" P_CHI2="0.6198456410997403" P_Q="1.0" P_Z="0.5011406514215544" Q="0.0" RANDOM="NO" SCALE="1.77" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="160" UNITS="" WEIGHT="100.0" Z="0.672696103504247"><NAME>Symptoms&#8212;dyspnoea (early)</NAME><GROUP_LABEL_1>Favours &#8804; 7 days</GROUP_LABEL_1><GROUP_LABEL_2>SCS more than 7 days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours &gt; 7 days</GRAPH_LABEL_2><CONT_DATA CI_END="0.17564467272731382" CI_START="-0.2880284813914418" EFFECT_SIZE="-0.056191904332064" ESTIMABLE="YES" MEAN_1="2.9776" MEAN_2="3.0434" MODIFIED="2014-07-14 12:09:22 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="671" SD_1="1.2074" SD_2="1.127" SE="0.11828614142304407" STUDY_ID="STD-Leuppi-2013" TOTAL_1="143" TOTAL_2="143" WEIGHT="89.44598649458986"/><CONT_DATA CI_END="0.4381094614699227" CI_START="-0.9117344688703145" EFFECT_SIZE="-0.23681250370019594" ESTIMABLE="YES" MEAN_1="-5.4" MEAN_2="-5.1" MODIFIED="2014-03-03 17:27:56 +1100" MODIFIED_BY="Julia A.E. Walters" ORDER="27" SD_1="1.2369" SD_2="1.2369" SE="0.34435426900382704" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" WEIGHT="10.554013505410134"/></CONT_OUTCOME><CONT_OUTCOME CHI2="5.891305721486763" CI_END="0.36069152893370626" CI_START="-0.031849827294244404" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.16442085081973093" ESTIMABLE="YES" I2="49.07750264837888" I2_Q="0.0" ID="CMP-001.19" MODIFIED="2014-12-08 21:20:03 +1100" MODIFIED_BY="Julia A.E. Walters" NO="19" P_CHI2="0.11702009533655289" P_Q="0.5343448103242495" P_Z="0.1006084915390224" Q="0.38612286345856134" RANDOM="NO" SCALE="2.84" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="200" TOTAL_2="204" UNITS="" WEIGHT="99.99999999999999" Z="1.6419107989577961"><NAME>Symptoms&#8212;dyspnoea (15 days)</NAME><GROUP_LABEL_1>SCS 7 days or less</GROUP_LABEL_1><GROUP_LABEL_2>SCS more than 7 days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours &gt;7 days</GRAPH_LABEL_2><CONT_SUBGROUP CHI2="5.505182858028201" CI_END="0.600628740102101" CI_START="-0.09118166593636179" DF="2" EFFECT_SIZE="0.2547235370828696" ESTIMABLE="YES" I2="63.67059820577254" ID="CMP-001.19.01" MODIFIED="2014-03-03 17:23:56 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06376245057619534" P_Z="0.14893274065153475" STUDIES="3" TAU2="0.0" TOTAL_1="66" TOTAL_2="67" WEIGHT="32.195609907309915" Z="1.4433115036703292"><NAME>Change</NAME><CONT_DATA CI_END="0.39553434090754025" CI_START="-0.47571913019905543" EFFECT_SIZE="-0.04009239464575759" ESTIMABLE="YES" MEAN_1="-5.1" MEAN_2="-5.0" MODIFIED="2014-03-03 17:23:56 +1100" MODIFIED_BY="Julia A.E. Walters" ORDER="153" SD_1="2.1" SD_2="2.8" SE="0.22226262267545013" STUDY_ID="STD-Chen-2005" TOTAL_1="41" TOTAL_2="40" WEIGHT="20.299334240245702"/><CONT_DATA CI_END="1.6608812693083164" CI_START="0.23361876029324624" EFFECT_SIZE="0.9472500148007813" ESTIMABLE="YES" MEAN_1="-5.5" MEAN_2="-6.3" MODIFIED="2010-09-28 16:38:08 +1000" MODIFIED_BY="Julia AE Walters" ORDER="170" SD_1="0.8246" SD_2="0.8246" SE="0.364104269331767" STUDY_ID="STD-Sayiner-2001" TOTAL_1="17" TOTAL_2="17" WEIGHT="7.564202055746758"/><CONT_DATA CI_END="1.3699545852484285" CI_START="-0.5160272468754279" EFFECT_SIZE="0.42696366918650036" ESTIMABLE="YES" MEAN_1="-0.775" MEAN_2="-2.4" MODIFIED="2014-03-03 17:19:41 +1100" MODIFIED_BY="Julia AE Walters" ORDER="173" SD_1="3.2006" SD_2="3.923" SE="0.4811266551325025" STUDY_ID="STD-Wood_x002d_Baker-1997" TOTAL_1="8" TOTAL_2="10" WEIGHT="4.332073611317454"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="0.0" CI_END="0.35989859247899764" CI_START="-0.11681387667882424" DF="0" EFFECT_SIZE="0.1215423579000867" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.02" MODIFIED="2014-07-14 12:22:29 +1000" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="1.0" P_Z="0.3175899557750006" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="137" WEIGHT="67.80439009269007" Z="0.9994227526756045"><NAME>Absolute</NAME><CONT_DATA CI_END="0.35989859247899764" CI_START="-0.11681387667882424" EFFECT_SIZE="0.1215423579000867" ESTIMABLE="YES" MEAN_1="2.6859" MEAN_2="2.5333" MODIFIED="2014-07-14 12:22:29 +1000" MODIFIED_BY="Julia A.E. Walters" ORDER="672" SD_1="1.3101" SD_2="1.1925" SE="0.12161255842404987" STUDY_ID="STD-Leuppi-2013" TOTAL_1="134" TOTAL_2="137" WEIGHT="67.80439009269007"/></CONT_SUBGROUP></CONT_OUTCOME><CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.20" MODIFIED="2014-12-08 21:20:11 +1100" MODIFIED_BY="Julia A.E. Walters" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.94" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="145" TOTAL_2="145" UNITS="" WEIGHT="0.0" Z="0.0"><NAME>Quality of life&#8212;overall (6 days)</NAME><GROUP_LABEL_1>SCS &#8804; 7 days</GROUP_LABEL_1><GROUP_LABEL_2>SCS more than 7 days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours &gt; 7 days</GRAPH_LABEL_2><CONT_DATA CI_END="0.20691180313091187" CI_START="-0.14691180313091182" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="1.68" MEAN_2="1.65" MODIFIED="2014-09-22 12:17:04 +1000" MODIFIED_BY="[Empty name]" ORDER="671" SD_1="0.806" SD_2="0.7292" SE="0.09026278264619635" STUDY_ID="STD-Leuppi-2013" TOTAL_1="145" TOTAL_2="145" WEIGHT="0.0"/></CONT_OUTCOME><CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.21" MODIFIED="2014-12-08 21:20:20 +1100" MODIFIED_BY="Julia A.E. Walters" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.59" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="131" UNITS="" WEIGHT="0.0" Z="0.0"><NAME>Quality of life&#8212;overall (30 days)</NAME><GROUP_LABEL_1>SCS 7 days or less</GROUP_LABEL_1><GROUP_LABEL_2>SCS more than 7 days</GROUP_LABEL_2><GRAPH_LABEL_1>Favours &#8804; 7 days</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours &gt;7 days</GRAPH_LABEL_2><CONT_DATA CI_END="0.24883560097237165" CI_START="-0.11403560097237184" EFFECT_SIZE="0.0673999999999999" ESTIMABLE="YES" MEAN_1="1.2887" MEAN_2="1.2213" MODIFIED="2014-07-20 22:35:41 +1000" MODIFIED_BY="[Empty name]" ORDER="55" SD_1="0.83" SD_2="0.6625" SE="0.09257088518131588" STUDY_ID="STD-Leuppi-2013" TOTAL_1="132" TOTAL_2="131" WEIGHT="0.0"/></CONT_OUTCOME></COMPARISON></ANALYSES_AND_DATA><FIGURES MODIFIED="2017-12-19 12:16:43 +1100" MODIFIED_BY="[Empty name]"><FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-12-19 12:16:43 +1100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>1 Study flow diagram.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-11-24 15:49:26 +1100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT"><CAPTION><P>Risk of bias summary: review authors' judgements about each item for each included study.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-11-24 15:49:26 +1100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT"><CAPTION><P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P></CAPTION><FILE>iVBORw0KGgoAAAANSUhEUgAAAjAAAADOCAMAAAAXKMgdAAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///9BjlLGAAAgSUlEQVR42u19C5Qb1ZnmXy+VSo9uSS3ZbfvgxbExkzQ5nIBp8LS9jLFJ4MDAkDPLZA9ZdrLJmt1MzmbIMEnO7mYnwIDTxB7jGSATDHiSzYPwmMSPHBvjdQxNwHSAhOOxEz/aDm7c7X7oVuvRUkklVe29t0rdUlvdltrdtuz8P7Sluvf+//2r6qt7/yrdr34AFJQ6RIAwHgSUmkUX8Rig1CMIGBQEDAoCBgUBg4KAQUHAoKAgYFCmLTIegrOJjoeg7OkuAuYiGIUvuAMFnJJQMIZBQcCgIGBQ/pAA09TVmHsRq9x8IFrr/lRvaCIu6gKMLElKc9XWudsvsLsdVVfvBE5Wbj9uVdmpSBXF7PPOp7KnojgaQmDUNcIEhwK/r3qV2cIFdFWlp3FjT5WKZkurLBBemKBJ4T94rIqmdbfzmbmmojiRjSAy6gHMS5FB2E/hocg+Qg935EuSnw77HskL9NI1VWkVvc7Xhr3SJvq9yVEJK5KPtlkrraUa/aroW8va0BlsbRZMj+gdt2N6pY5mWiaxMn49qx2aN1TSpXYv2wSlejW0VnP9CJxOFchKrax/1o6Pe/EJ/Wf/Q0k/5u2QmuxlozL5+hIw10pyaMwPjqyit0OjzYJLYJNH8pOSHV8WkVEHYOyeWHNsJUAok83Ra7eY+L/7sl2QVIzvFAQgPsn4TaILdqU2Nd/r9wdH+WknyaeH6ElIPm/0LAL4rDysPkuxtW0ZwK75EPgfOVhUskN89r6Nw7TMsBc53aXEjZpplXR3JdUj90dL9VbqxaTrhz7H/17EmjfWv9OO9d1/YEL/HwFXnySsI0Z8oNeXjeyyie+HRuBEtLQ/ztDi/YJJFQo2fLPZyG4t2ZEwiqkHMMLdR/KDbGRWlM+3AlzvT6wU/5QUjimfUwAODvYouvIp6AvcR1oC5PhwkKlExC/BEJiFw/PfNoG89IuILtPZa+gdgFOCad4JnWbJjjboW9musLLHnLNCTifbiSSYhYH5bxcA+vwJTSqU6tsDuuL6oYDYDu3CWP+8HR9gou2V/UOf4OovHUgMKUprv6jQMtqzMtKadf1w9nTnyOe8Ofr5Iui04V+7duDIECJmEqm2CFwOCMnwMB1hclY4k4SFKR1UrX/NLwE8vpHwx+in78adin8EpGZChCuGmU7XTVZai/S02iAakUSRDvxqktVTY2LPXFsUs64d4fjRdgowt4xNZknW2is5usDsejSpTKfkh6qN0G0o69+jJdgtUtyq7J/acPsMJYdZNMLaKX4hQdv5i4bjxwjrmznYnM2zz5Cx6pVgwrFDp72cMnY4dPxpoBCe+mC8pKvLCHQlj+d0Ok70sVkKRnbQi06wQdhBIwbrNVhBa27YSqv6ucrKAb+fnIJ0Pm+ANEyc+PiGU0CuF7a2fGDmsiU7ffBx+lkqozI4TMckS3B1uV27Qqfkhw1su7x/JwY/LMQr+6d1rv72+MFSrL5C6IvTdkXR9cM5E/SzKLPPaFtwp8d27cA8UcGxpJ4YBvbtfhTuEHqjxRGOElo2L9pCQhQzu6KLyBt5Fdjtyv5lEHRUSFckDsFsjLYwYeijl5MmOmzAO3PJgregTbyClbp2DsQ+bRKTlhH3cYcyN7hlgWUdmBPiJT3cqbF6qlPyYzXfLu/fcT4iX1nZP61z9dtiN3cTE9YUWFk2uo5E80+6fjh7+p9Id34j2yr0HI6aa107UES81DcljUDoxNLD80z521/Zt7LjkM4mitCJFq3gpYP2nwhDIQHkJgJiZJgIbIYBU7PFvAAx3RZkA5rSy9836aDfnL7h39LNJDZi3fCuAa6d2NK3IJCMJloX0jIm/YtsXzqgu7rMLm3l1jMd4vqx5xbBpNtl/bNpCdiUla3sn9a5+tmmwaiWDidFk5Z1/YnY/oZQ8oODVS4U1aQCys5rWueeVjORfseOd8cawCmp6pQkgXbm0wl6Ig0t01nMw67896DX4EXGgSeLRRogbrFzucdoCZ0w7Ax0apt5MGDlCS3MWHn9ERqG5n/6pCzl6OeBh+wsK/3pd6BkJ9ObH3mIlsVZGZMNhWJK3L3F1WV2WSunnumU/Pj+8EMS3S7r33IQZ6jBfEX/Vrakr1iy/jAY8bs207Itdsubj435wePl4b/96iMS3fx+ZzEO+XzO2Y8wPFN2OAzhwl/VF1jGH3QZs8Z8dALSWsQnPPo3/+2Jc+mLHFw5o75HSPkWjjDlI8ysAWbLV4dqbBkzbYk08KyNgDkvgLl0BJdoli3R1HGJZu0HCwVwPQwKAgYFAYOCgEG5OAWDXrxLqivwR8BcBKMwEtlQ8OpBQcCgoCBgUBoAMHZsMkrYOUttds0z/KnRen/V4hjiYrYAc6vIfmf2/BgyxUnbLDyXH2OmsFsGkDmV29SfM0SpRk4bbXM+pUoektmEwJgdwJBXhPeA84CEF6s2WEtP0697zqGHSexyUV16Zsg34VEJ9acSQNSLzPFq1l2K5FAly20kjz84zg5gLv+UugE4D8juZQwzxhOLecXWJggslBj57JnUQrJgMStbSKtWhzUx4I76t4pS04Ryt2y1fiudYh5QJEYxo3a9oVulgOlllLnYapHVOe0DpzWZr6PJ+iloVNE3Vv8Rxo4Tvac5605q8hdSMrllCatl44x3z60lIhsFHee7zVtS6s+xoxmIjFkBjPE3r/yI84BAuJ9okhFsi5KEFemNg5Id+sRBOCkGeiLXAkkKuWQqC6+llNd6eYBAEntbjHhluVMGqT2BvXSKeSZj5DU6BtwP16b37+sNaE0fJ7RueC/Vd9rrczNvsqmEFPqBpP3DdCBz66k/aXX43j8CosG+ocO9UqA38hrt863hnckuuPaWX4Y/dMIUIe1rKlwOYL3g9ufaka9BZEw25J/Lco+oPhRR8gJbUi0H+4ylQ+CVdl31s885tV414XKJpKNH28HjSbO2ztLN6FGvxv4tL1d4GRGW2kMOVVX1JkAO6gsTCZCadDO99LBb59pxV3JzXpKsjihjuop/9w0RyJvZrLGYx1iclyQfDSigyqMLPxAYwYrHLk06+P/9Ts5PcvtjdpCXNEHOxkuqVb4hXhYAD+cSCS/ObxmiZ6CYgzt5XPElL2eF/APjEj0fbadRZwFWREpcokILg0RleQFY2XuQSFKTsEfzFmwew/RRH+1tkIK+f2tJLGN1rh3B5Yowi6F2LQxj9cKnqBU6rcyHY6UWK4RClIJAvgf6IhVnQt7D+Uluf9wOpOIpHEtmHrxkXV4SvzzYxThCdm9f3GQ8sc8A4451ndhoyOx83s/4SL3DrEoq4xJtjzMOXGX5dmBln4FROjRA9pMBg7FtaQzDccEYUPN74qO7aF3Jju3YOmJ3Awx3mgkyXr8t/st8PgvbHE4Ea9cD/cO0XeGHFbwk+sc4SPZYf9wOLI3h6xtmATCL40IyuX7ep5wYJhuNkti13iNX32wSMxdLxZYx8/SuuF24MyaTqLmVtXPPVNucLxJiVpa3zfnvtOzIXDo9EFggHO63RngM005rl7/DRpg7WV03lOzIeW4r4skBibYXlsN4fducVcxK2+0Rk/SDoLOybGwN6S94uD33vSVCnpj5bWwcc/tz7ICFRLbZiGEYfRqgWTs0d+caGmt0rQLGMMte+X5UO9laFPPyvpWRhJRfmNIjSbC0UVB2rinRT7puGvxoOl1Z7pR1rS6IUo60DrQq2bTGYpiUDlJaozHMEK2TxFypPeOnMVvNZqZ7uWDfvx7G67tWD1w9kIPoiAWBZGREydGAJxu0QUs7HG8v90JS87bc1U5jmGNOfwccO6q/jMaAMcyssQb6VT6Smyn6YdIYlH6QoHOx8rLKp2O8pLLc2XJ0qLZ55oVesudsgKPse2VlydB4vVsZF5gXdktVL9irYcbaO/2xJntWl1PHEDCXHM2EaNqM2uuq4MUhYJCXVJcgYMoBgyvuzi7WH7wDZYKAOavgENxQox0KAgYFAYOCgoBBwaB3Vm6r8RAgke0iG4Vn24OzrYO1cUpCwRgGBQGDgoBBueQAc0Y+synysFXP4UCafdNk9jxQFx+uOVL9e80yCeMNiWy1AUbukNiClseLIFewvnK3nZGzrHTA51Y1+l42/vPpufO4G6/LNf2Aky1W/15NVlWzqLiAr9xf+HEzAqMWwNj3Dt2XIHyFawXri62dzVQbMkK+6u/XvVPRpvmmZXddN7xZE/lNqP7dMxEbLJdbZ88UFir3F9bkcElvLYARvhb5nhiB6wW4YzGoEa/s5GHT2M/rwVt4DjYfz5Wm3eqMN4xBpoZVzgBjedXo9eoNeb1NWaPDjHk7OGuMbjNbkt9cKzexLG+8tWurW5WkZoipY9nZ2l1m2TMaNDn54EKeDp9T5+ZM8+7RGA+N9uez3PMdc7/HuA+bCkmFxJyMbP1eUWqyT6c7nFxul3WEx/rme2x5ReY13d8A7YdlZGP7ixnZaoxhdNsIAvQC7BbASnhTTh42rSDwnGW7Umo6F4WAYpBX/pyHKoV+ljPN12ReDpA2Nlp07i+kva/HVXVjKiFs9CezfJva0po/9G0KjBIIZ4xmekaYLSNK/ljYZ3ggqRqr3OxsvWlfU3ERz+MmZLK5JYxZtt2lKbKcaUsBrr3Fs+/DGKSljarlLhRJud9T3IflUiAUSXoNWATkejti7CnM9W3kudzk44eOR0v7wcTKaqF8jO+v3LTROAgklRhKAmzFKKYmwKgKDPAcRaINK/wjmvSnxDymEMXlB/kSmliIn/YpmsJnjitvUABWBHV9gwnk2thlBstt5htpZ7nTlg4E2ke+EOXbsCKgk9sDGsveNqIoeitwW1JBG/KtVIZI4efzu9xgoi+g654894HlYStCxDDBfQc9y5lGm73tS6ycY5JrE+265Iww/PvnBebDbdSHdgG4TdmEg++PDCvtii1SH4SDg8do399w98PZe59OtM/y/R0Zbldug4jwNNCdanufIDSqS3k2E+HJbf6hA5slxRBVwzINUJR/MtbTNkoOxBu3SqoBsrzo1VGnhA7cxyhurLwB+3PWd3vMx6WbjoH41FaAm0/mPXIa4HCxwLeZrb648vf5yzOhVR8WmDlu65nnSSfA06f+1Si6r1ETPQb4DYt9hgTppJmDOektisN0DsHNRz1UlY4dsvKPPRQssszcgM3se6gv9/QxM8d9UA3X5s90s5PFttSClf+xSPfFax5z9oNrMje0/Rb7/O4e2VRzMHrkG+Es/H1+gzR2WC58NpNZT2din63BeDaTyhgG4i2fZFcoG08EtjTwYNzNjOXyg2zhs/Sm0738jtjE4QiZHtgeH82bO3k7gH0p2M6yspmSs815RJcxZlE2+SuDjgUsTqK2PgNLWK2bR40JKzdV9tmVcvKwDQ+mE7y/6IngTjayzWfvc7Blxkpz2UU8A9wbAmwr+WCVbEqcVceXOPYJAmfavVbBS6K2RmT2Gb07ZbCMbNpv7v8ogfm3IzGppucwpCU+xGIY627+JgzBycN22jnCvaw5DVqXhRdcx493RGFs+RwxTQXa5jR3g5u5D4QAtMXCJFpQ3O0X3DdrDC8QjnTtGgHHFmSj15skVsqjxmOYPDGpFq2/E3qjxSKQaGRvnFcVrj4cZa1O9bL7tqHodaS54MQwQ9EwaTatMR/EIrg2OauumyeJFaxddF9iea+7H04M82fE9HjZ/hajECvwzHLf2x8E89eIjBqmJPET93hjJoyqBp2Vbhww2MTQ9METok/KgbT1+7QcJI8ROWzu+LYzSwRUE27s7ZT/y/bOzlP/8LQcf5e1o0alfGeo8Fh248+c7fzPDfjjZ7d87cHHT298bV3eyijclvJgyyG567ePtaRlSXOmpFHpl6ekk53Uh56NT5vrf/76nIekZ2MP8fDmm515b6YlI+9lU5IRHHjir97hMyO9hRt4QgIl13lqw2bmQ9NVA4+2jErUZueOf+n48neFXf+iFG8c+KfXD/x1L+3X3Q++98JjHQMfdFJXjpMD+fx1P1r8w+XH/NQVb9n7PnBKKp+Szkoz6f7EmaNz9xVOKlnw71q5MNVT4qpBZcszuWtct72Cn2b+ur28KYFjY/25LcfN0K3u9qrmS4w211v+r1vfvYQR2Y61V3XJTMGx9krrrP2Wv2wsItuFX95wLrwkvyUZivucgiwhLPfipSbZCl4cAqYcMPW7onmlVOm5VoRA08FLb57WAGXy2RFpN2cRXKKJGdmmd7BQANfDoCBgUBAwKAgYlItTMOjFu6S6An8EzMUwCiORDQWvHhQEDAoKAgalgQEz83namqdYz2/OlH/9iIsZBYz03Vpb1pRPrS7Jtk4eys+p/uDAuSWsmhcuU50391Ekss0oYISv1dxyLJ+aGpqi2ZSVEyyO3+F5KrVCml5ub8zm4CD/3tMzhX+DlZUjuT2IjJmdkm51cqhF3bxqHSyvmjfsFR8wVbHZYbd5u/naYIdRZp9OSSSq8lxrTLpViXHKPHRKULsCZmohMdVWqblUrm7xSn76vQlcfS5Rj8j5agGP6CfgL6QU0uTw4vjYE2BrRnkeOGovYCYXEm/Iq8HXf8DtBxeP+zmWF876c8fPeVvBVmSNE9k6/LTJHYiMmQTMS/Cqk0MtyfOqJYTtLK9aIbVj9H8FXm1OEbDSvl8U1vC11nd5B+E90Of6jUjasPc6DDHSIQ8eSkSh2AtQvOOkFOgBHxSGflcqt/6r9osPV/hfGSWuPpe0PKxaLIvJB8PGQeiVAqcjYmYw7yx3IiaNPOTfD31CA2bvpBjsiSxP70jCc/ez7chyGPeT+v62s/ejjp/WV+D/hQacjGzbfQBKHpEx2RA/jeUe0lP3yaYAik85yhKedV3l5lXTkiDuXsOyjsiBEZ7pTA7+dkFYyK7cCcoT9xHhCmHQIaF2XbV0iCVHk9Iay7mmaiNO7rRSuexPgNisd18RiLv6DBIC68dJpcYSqbh5UdzEJDwvG5XVv0ryPHA8F1yCVjn2YWFq21Xj+d8UH1ca95NNZ8ygpOlsPXA60EgZ2S7uJZo8hrmeLaYWCi0D9CPH8qp5CtAuASxXGfsIhJfoVfoqixE+NpwcMX/Bdd5rSSY8joU7bmfZ2+gZXsDjCKuUO61ULrxMywVYAsMlfSqLWT+MrRL2epcJzjsC3Dxq4PJbaM0+weEhcS4SY6PNf9HlJY35yX139mTMTwjdqhappbDBM7IBZmSbQezaJV7R9vh+domzvGqmxMv288xpLHbhfDTr7lPQbOYMrvOZOM+1xk/UDqpyowD2BiDFu1kk28c5baVypj/MXOst6bPhYNjhPUWPB413bT7fZT/p53nUqBwZ7qY1KZ4HTij9vQCcx8S/W+V+lnhJY352JX+V4xnZBr1JAgevxtc3zORd0kuM+8xyqMV+QojZxvKqFbY6Ze84I8zfcXYbPUvZT2cIe0AiPQhH5jxFXNLksdtbSOwVL8hfJgviNvxlEbKfzpqkv1TOxpGWXoq920r64PLV6ChQjPZFGYtJ0GG+cKS/yOcoiLTm4Hk3Dxy1x/94/mrxfv59hVDhpzvCjPl55/IjUeshILGITrF0xxAiY2ZjGJbQleVQWzXE8qoF+lheNRYQiKM8c5p886u20hdhsUFsxIJP7oSwSvJd93woSjn3lmbB+5elIZSE4GhQ3/IFKc9yp31lvVvOYgrxtZU0hlFcff6YLQ2aqSVIa1HyZCLD4YTS31pQWN42/kjPzHSvcPLAMXvsj+VeY7bc72V+uvGP7Mm7fvbMM+Vvr3uxLbagz5cEr1a2pgFjmHPjJU14ulolrxqNC3ZeM545zU2zBpGKfGoVirzcyec2Weo2gHG+Gh0U2LjAtMrytvG8bON54Mpzt02WF657SdWMbCErCQiY2QHMJGNQ8wVgt81cXrZGy8h26QMmMnAJvf0AAVMOmNlZcUcuqbdlWOjBuOASzbMKEtnO52CHgoBBQcCgoCBgUDDovTC31XgIkMjWWKNwww/zBZySUDCGQUHAoCBgUPAuaaKQQx8bW0Vgz5n1tUix6ffQ5BmuVmzii+PP5wizae7qq8d4PZ4qdEQlND3D1fWaCrVdGdUWXWafdy1X8pCiIQTG+QNM17qB3Ptj+dvsCW89Z5yyzPH6rU6qFzLP/pxEbabYOFalgq3pZZK5pqI4kd2CyDhvgLnrtwch0g79qug1+Xr8frWDUcRMr9TRHDDbZBJcrIVYChRC22hO5gnw7lG94G5793j5p7lWkjmHca3m6oEa+ZLk5Inzas4wcPdulmNN1SC2Vlrr5nrjudhUkY0bzK69bFQmf7WkLJeb5nWUxaKX+xZcUsr3FlFYtjbfFxEZk4g046+9zkQ6v7GjE34z8PpzzQbLs/Sk8fJzTxlkk7D3to1D60eS6+HJ3UYRwvYjrM1TbhqIvZYulbZ/5NMy38mRTYfS4ROXZcRcD3H1tgrG73Zvfn1LUR597qcetjyY/Md/lmAo/sQLUvF3qZav5WCI+NVIZ44sM974yTOvb2F2LamYXD+UM+AH2u5vvftcUXz+JxknrYVY8P3Pnz1Fv3qMu97c+89XbiUPb3727yQIZMpWoMx+cgqh0VFijSenmHnAQGHuv27OJr4Y/Pq3xAJIe/v2ZX8o5Aq3f3vOU5ulTpkGNdLeYSJLtq/vL+byNhy4xYRE3G3JP5L1FwrfTLQaRsgyl4+MlPSM5Xpyi/RySvhg41YPz5H1bJaOkaOBlyRTPPGD31smjAZ1o1AoPHvIfs7w/MhkdqWMSsu9WcnMbWl+8fV19nNZxQGMtPPprUWhwHKu7Mhs9rya65Rf+cp6gA+/KksImKqAmZUlml1ff19JSKItZUEO2kkZbCUTPn6U5Q1hdAM5qHtVDxla7LbhMWlQh/CYjg7NGTOcoJe5v2jwtf+uHvuuamIP42VzDmRUL7I152sg0tNqg2jwhqF0IZyk5f5CjnMaGUeAlrPvil9gNS5dkq09bjLy7DNkrNodSEDXTdYznwNTzZ1P5mPj/zQQnt2DsfKN/LZ4JpfPshiG52rLQB98nF9MTv5I1fjfWkRy2/DyF+npG9MBKMrQF6dxTFHkPKKSnsOHOgomEJtz0Y7cQBz+0Sk3r9sKerk+6IFtjLV2j+S8n4FF3it4njlqZ5DWEHfGYfwni2Vks6JtTr63lQP+zxOYJ+KN9XkDdzQKRJParg4RYFn2et08adnYp81uE8T/TE9RL7x6et1OOOK24XdTvTC2bf0Z6c55IRtdxzOo8Xc4unr8bR92y5xg6B7nnEfePQjwEXaH7OZ168kT86seaIu1kK5nVW4X1tBpr4frgy0qc4Nb5lvuW0PupT0x+q5Q6DkcNdeyjGxxCEIR8TL59DnTU1LoRAzkE/O6Vl/3tpRjM0H/vytIYg6iV74l+JORhJRns4a3SE9uNHldt+gw21hZaVuRrOveOxVhbLfL3hCg4xCdVVw99p1+xJKgZRwuWlNxFHjOpphuCzJL1pZSGTctkrz+LV/asRtOiiZt47Lv+hfZvnSA34wrcqHoSSmMR9VaFNVsuF+zxbwA3h1rAKekqlPSzAe9RnbzyUc2wJbiy+sepVe1ARuKeZNe0JnevP4QZOMPSrQMeLrGjNOGh1XG+Lbo723/Tic9nbbnzccAelmVq8e+049MsZjSYxmmmFOaMxab1zJWXn+Ezmva6Ydtqpy1Xv7Ww65dI37XZtqGfS/mYEOhmBJ38yctueG/fdim4a31/c5iHvL5nGTlyWP0GnoG8C7pPAa95ygshp1afDB60/5SVrhK/tqq35ztQZ5PePSB+56YqkWkgoaHI8ysB73nKIGms7Xwb2y+dywrXOUQee/gWZWV/xOcEi+AWc7PZwxzyQku0cSMbNM7WCiA62FQEDAoCBgUBAwKAgYFAYOCgoBBQcCgIGAaRvQLrN9YBhAwKDjCoCBgUBpE8Nfq2Y8ALgHBX6undbSmCbhzvSQbwABOSSgYw6AgYFAw6L1I497w+L/hGlXAVXK+1KUMZYrT6n0s7gjX6oDuAqHy8wwlDHprDBrL/685UuZtw5Um6o+1p9P7ONZqdEAP62XNpugUp6TabjLc43luNxzTUj6X3ie2n1w/XNnZ5J3iCFP7JUvH52mccmdUn4ayXhEtTKd3PXxODlRVQsDUM0fUd8RLM5L7WefpCk+4tsPTHN2m7UD1TnFKqvOi1eu8vmF8bK9HuVIRpmXg3B2oooSAqesM6OGwXu/pmo7yOfc+U/pnKCFgarvQ9XCdIWf5rWidN9QT5rTp9F7pQe0OlAe81TvF5zA1x596+IxItIbHKHrZHbZez8HWx29d6u+9DDC1OTD21KfiOcyZSjoCBqWuSwenJJS6BAGDgoBBQcCgIGBQEDAoCBgUlHIp+/ERV8ejTCrhKoDBR3gok4mOUxIKxjAoCBgUBAwKAgblD/K2eoob7Ea+f0JnLzxgJo471sW0C4WGdnZCphsbpyQUjGEmGU0nqa7Szl13rtdmacaGfv0i2YMx2/qkrjbO0Z0xXtIUk/HElcQNOm9f+D0IXwRHt+4pSdfdS0EvuzZomV6qq0C701ivUC5vquv6LI80E/qp6FcfvzobYg9cs3rZuNFwR7feEaYq90APV2JdD5c3DleUu/TNMNRNTp/eOaikk5f1W7EnDbMHetg95eEKHxrn6E5vSgrr7n9VR8FJHQ2f/1kpPGVpeJJm53kP9Cn9bqyjO5Pc6rA+/kaU2o5RWD/fAY0+ZWR4gfYgXEuw2iBHV57Zy5mz5moYC0sj7/mYlapchqXuL6o9aAzfxOkOJuEp3h4xGYP34lmidSH3QG9g3+oaYThmwzpMRbcMj+PJ3bUJ7zhxt8NOYKfP1nwb1isn9VJHbrnbfQPuAX8jSyMf3TKqrD5pNmuroX+emfjTQEM7O/GngXANT1Yawe/wJEcb5UKfGWjwHyQRMA0WPDW6g/jjI8oMjDDWxbQLhYvJWfuSBMxFtaoHncUpCQUBg4KAQUHAoKAgYFAQMCgNcVuN7/tAqQcw+LYPFJySUBAwKAgYFAQMCgIGBQUBg4KAQUFBaRT5/4ttlg6kvXWjAAAAAElFTkSuQmCC</FILE></FIGURE><FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2017-11-24 15:49:26 +1100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT"><CAPTION><P>Forest plot outcome: treatment failure comparing systemic corticosteroids for &#8804; 7 days vs &gt; 7 days.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2017-11-24 15:49:26 +1100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT"><CAPTION><P>Forest plot of comparison: 1 Systemic corticosteroids for 7 or fewer days vs longer than seven days, outcome: 1.2 Relapse.</P></CAPTION><FILE>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</FILE></FIGURE></FIGURES><FEEDBACK/><APPENDICES MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><APPENDIX ID="APP-01" MODIFIED="2014-12-04 22:42:22 +1100" MODIFIED_BY="Emma J Welsh" NO="1"><TITLE MODIFIED="2014-10-09 00:32:24 +1100" MODIFIED_BY="[Empty name]">Sources and search methods for the Cochrane Airways Group Specialised Register (CAGR)</TITLE><APPENDIX_BODY MODIFIED="2014-12-04 22:42:22 +1100" MODIFIED_BY="Emma J Welsh"><SUBSECTION><HEADING LEVEL="3">Electronic searches: core databases</HEADING><TABLE COLS="2" ROWS="7"><TR><TD VALIGN="TOP"><P><B>Database</B></P></TD><TD VALIGN="TOP"><P><B>Frequency of search</B></P></TD></TR><TR><TD VALIGN="TOP"><P>CENTRAL</P></TD><TD VALIGN="TOP"><P>Monthly</P></TD></TR><TR><TD VALIGN="TOP"><P>MEDLINE (Ovid)</P></TD><TD VALIGN="TOP"><P>Weekly</P></TD></TR><TR><TD VALIGN="TOP"><P>Embase (Ovid)</P></TD><TD VALIGN="TOP"><P>Weekly</P></TD></TR><TR><TD VALIGN="TOP"><P>PsycINFO (Ovid)</P></TD><TD VALIGN="TOP"><P>Monthly</P></TD></TR><TR><TD VALIGN="TOP"><P>CINAHL (EBSCO)</P></TD><TD VALIGN="TOP"><P>Monthly</P></TD></TR><TR><TD VALIGN="TOP"><P>AMED (EBSCO)</P></TD><TD VALIGN="TOP"><P>Monthly</P></TD></TR></TABLE><P/></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Handsearches: core respiratory conference abstracts</HEADING><TABLE COLS="2" ROWS="9"><TR><TD VALIGN="TOP"><P><B>Conference</B></P></TD><TD VALIGN="TOP"><P><B>Years searched</B></P></TD></TR><TR><TD VALIGN="TOP"><P>American Academy of Allergy, Asthma and Immunology (AAAAI)</P></TD><TD VALIGN="TOP"><P>2001 onwards</P></TD></TR><TR><TD VALIGN="TOP"><P>American Thoracic Society (ATS)</P></TD><TD VALIGN="TOP"><P>2001 onwards</P></TD></TR><TR><TD VALIGN="TOP"><P>Asia Pacific Society of Respirology (APSR)</P></TD><TD VALIGN="TOP"><P>2004 onwards</P></TD></TR><TR><TD VALIGN="TOP"><P>British Thoracic Society Winter Meeting (BTS)</P></TD><TD VALIGN="TOP"><P>2000 onwards</P></TD></TR><TR><TD VALIGN="TOP"><P>Chest Meeting</P></TD><TD VALIGN="TOP"><P>2003 onwards</P></TD></TR><TR><TD VALIGN="TOP"><P>European Respiratory Society (ERS)</P></TD><TD VALIGN="TOP"><P>1992, 1994, 2000 onwards</P></TD></TR><TR><TD VALIGN="TOP"><P>International Primary Care Respiratory Group Congress (IPCRG)</P></TD><TD VALIGN="TOP"><P>2002 onwards</P></TD></TR><TR><TD VALIGN="TOP"><P>Thoracic Society of Australia and New Zealand (TSANZ)</P></TD><TD VALIGN="TOP"><P>1999 onwards</P></TD></TR></TABLE><P/></SUBSECTION><SUBSECTION><HEADING LEVEL="3">MEDLINE search strategy used to identify trials for the CAGR</HEADING></SUBSECTION><SUBSECTION><HEADING LEVEL="3">COPD search</HEADING><P>1. Lung Diseases, Obstructive/</P><P>2. exp Pulmonary Disease, Chronic Obstructive/</P><P>3. emphysema$.mp.</P><P>4. (chronic$ adj3 bronchiti$).mp.</P><P>5. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.</P><P>6. COPD.mp.</P><P>7. COAD.mp.</P><P>8. COBD.mp.</P><P>9. AECB.mp.</P><P>10. or/1-9</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Filter to identify RCTs</HEADING><P>1. exp "clinical trial [publication type]"/</P><P>2. (randomised or randomised).ab,ti.</P><P>3. placebo.ab,ti.</P><P>4. dt.fs.</P><P>5. randomly.ab,ti.</P><P>6. trial.ab,ti.</P><P>7. groups.ab,ti.</P><P>8. or/1-7</P><P>9. Animals/</P><P>10. Humans/</P><P>11. 9 not (9 and 10)</P><P>12. 8 not 11</P><P>The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases</P></SUBSECTION></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-02" MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]" NO="2"><TITLE MODIFIED="2010-08-03 14:18:27 +1000" MODIFIED_BY="[Empty name]">Database search strategies</TITLE><APPENDIX_BODY MODIFIED="2017-12-19 12:04:40 +1100" MODIFIED_BY="[Empty name]"><TABLE COLS="2" ROWS="9"><TR><TD><P>Database</P></TD><TD><P>Search</P></TD></TR><TR><TD VALIGN="TOP"><P>EMBASE.com</P><P>(with RCT and humans as limits)</P></TD><TD VALIGN="TOP"><P>*steroid* or *corticoid* or "adrenal cortex hormone*" or<BR/>beclomethasone or  betamethasone or cortisone or deflazacort or<BR/>dexamethasone or fluticasone or hydrocortisone or methylprednisolone<BR/>or methylprednisolone or prednis* or pregnenediones or sterapred or<BR/>triamcinolone AND exacerb* or acute* or status* or sever* or wors* or<BR/>emergenc* or attack* or crisis</P></TD></TR><TR><TD><P>Medline via PubMed</P></TD><TD><P>#1 COPD[MeSH Terms]<BR/>#2 "adrenal cortex hormone*"<BR/>#3 steroid<BR/>#4 steroids<BR/>#5 glucocorticoid*<BR/>#6 corticoid*<BR/>#7 corticosteroid*<BR/>#8 beclomethasone<BR/>#9 betamethasone<BR/>#10 fluticasone<BR/>#11 cortisone<BR/>#12 dexamethasone<BR/>#13 hydrocortisone<BR/>#14 prednisolone<BR/>#15 prednisone<BR/>#16 methylprednisolone<BR/>#17 methylprednisone<BR/>#18 triamcinolone<BR/>#19 (#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)<BR/>#20 randomised controlled trial [pt]<BR/>#21 controlled clinical trial [pt]<BR/>#22 randomised [tiab]<BR/>#23 placebo [tiab]<BR/>#24 clinical trials as topic [mesh: noexp]<BR/>#25 randomly [tiab]<BR/>#26 trial [ti]<BR/>#27 (#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26)<BR/>#28 (animals [mh] NOT humans [mh])<BR/>#29 (#27 NOT #28)<BR/>#30 ("2012/01/01"[Date - Publication] : "3000"[Date - Publication])<BR/>#31 (#1 AND #19 AND #29 AND #30)</P></TD></TR><TR><TD><P>ClinicalTrials.gov</P></TD><TD><P>steroid AND exacerbation AND COPD</P></TD></TR><TR><TD><P>Current controlled trials</P></TD><TD><P>steroid* AND exacerb* AND COPD</P></TD></TR><TR><TD><P>CINAHL (with RCTs and humans as limits)</P></TD><TD><P>COPD or COAD or emphysema* or chronic bronchitis*</P><P>AND</P><P>*steroid* or corticosteroid* or glucocorticoid* or corticoid* or</P><P>"adrenal cortex hormone*" or beclomethasone or  betamethasone or</P><P>cortisone or deflazacort or dexamethasone or fluticasone or</P><P>hydrocortisone or methylprednisolone or methylprednisolone or prednis*</P><P>or pregnenediones or sterapred or triamcinolone</P><P>AND (exacerb* or</P><P>acute* or status* or sever* or wors* or emergenc* or attack* or</P><P>crisis)</P><P>AND date restriction 2009-2010 </P></TD></TR><TR><TD><P>Australia New Zealand Clinical Trials Registry</P></TD><TD><P>COPD AND exacerb*</P></TD></TR><TR><TD><P>CENTRAL (<I>the Cochrane Library)</I></P></TD><TD><P>*steroid* or corticosteroid* or glucocorticoid* or corticoid* or<BR/>"adrenal cortex hormone*" or beclomethasone or betamethasone or<BR/>cortisone or deflazacort or dexamethasone or fluticasone or<BR/>hydrocortisone or methylprednisolone or methylprednisolone or prednis*<BR/>or pregnenediones or sterapred or triamcinolone AND (exacerb* or<BR/>acute* or status* or sever* or wors* or emergenc* or attack* or<BR/>crisis)</P></TD></TR><TR><TD><P>Cochrane Airways Group Register of Trials (via CRS Web)</P></TD><TD><P>#1 MeSH DESCRIPTOR Pulmonary Disease, Chronic Obstructive Explode All <BR/>#2 MeSH DESCRIPTOR Bronchitis, Chronic <BR/>#3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*) <BR/>#4 COPD:MISC1 <BR/>#5 (COPD OR COAD OR COBD):TI,AB,KW <BR/>#6 #1 OR #2 OR #3 OR #4 OR #5 <BR/>#7 MeSH DESCRIPTOR Adrenal Cortex Hormones Explode All <BR/>#8 MeSH DESCRIPTOR Adrenal Cortex Hormones Explode All <BR/>#9 steroid* or corticosteroid* or corticoid* <BR/>#10 beclomethasone <BR/>#11 betamethasone <BR/>#12 cortisone <BR/>#13 deflazacort <BR/>#14 dexamethasone <BR/>#15 fluticasone <BR/>#16 hydrocortisone <BR/>#17 methylprednisolone <BR/>#18 methylprednisone <BR/>#19 prednis* <BR/>#20 pregnenediones <BR/>#21 sterapred <BR/>#22 triamcinolone <BR/>#23 MeSH DESCRIPTOR Acute Disease <BR/>#24 exacerb* or acute* or sever* or wors* or emergenc* or attack* or crisis <BR/>#25 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 <BR/>#26 #23 or #24 <BR/>#27 #6 and #25 and #26</P></TD></TR></TABLE><P/></APPENDIX_BODY></APPENDIX></APPENDICES><EXTENSIONS><EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART"><ALIAS ALIAS_ID="1"><FLOWCHARTBOX TEXT="&lt;p&gt;5 studies included in quantitative synthesis (meta-analysis).&lt;br&gt;Reason for exclusion: no data n=3&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;8 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;8 studies included in previous version of review&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/><FLOWCHARTBOX TEXT="&lt;p&gt;0 new studies included&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;14 studies assessed for eligibility&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;390 records screened&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;390 records after duplicates removed&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;417 records identified through database searching (2014-2017)&lt;/p&gt;" WIDTH="120"/><FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;376 records excluded&lt;/p&gt;" WIDTH="120"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;13 full-text articles to excluded:&lt;br&gt;7 wrong intervention,&lt;br&gt;4 wrong comparator,&lt;br&gt;2 wrong study design&lt;br&gt;1 post-hoc analysis of&lt;span modified=&quot;2017-12-01 15:24:00 +1100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; &lt;/span&gt;already included study (Leuppi 2013)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/></FLOWCHARTBOX></FLOWCHARTBOX></FLOWCHARTBOX></FLOWCHARTBOX></ALIAS></EXTENSION></EXTENSIONS></COCHRANE_REVIEW>